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Life is like a weird clinical study: we are not sure if it is controlled or 
observational; it is single-blind; the primary endpoint is poorly defined; the 
methodology is complicated with significant variability among individuals and 
countries; the mortality is 100%; and the principal investigator, if there is one, 
is surely laughing…  
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ABSTRACT 
 
The landscape of RA treatment has unquestionably changed dramatically during 
the last decade. A deeper understanding of the pathophysiological and 
immunological mechanisms in RA, earlier and more aggressive treatment, and 
the development and introduction to daily clinical practice of a new class of anti-
rheumatic drugs, the so-called biologic therapies, has contributed to this 
‘revolution’. To date, nine biologic agents have been approved for the treatment 
for RA and more molecules with distinct mechanisms of action are currently 
being tested in laboratories and in clinical trials. In all cases, very good clinical 
efficacy and safety were documented in large, randomized, controlled clinical 
trials that led to regulatory approval.  
 
However, not all questions regarding the optimal use of these agents can be 
addressed in randomized trials. Observational studies based on registries can 
provide important information about the effectiveness and safety of biologics in 
real-life RA populations as well as better insight of different treatment strategies. 
Thus they are important ‘pieces of the puzzle’ and can help complete the picture 
of RA treatment. 
  
This thesis comprises of two parts: part I is based on four studies about several 
aspects of rituximab use in RA which are based on a large international cohort. 
The second part is based on four studies about the use of TNF inhibitors in RA 
(cycling, switching and discontinuation) which are based on local and national 
registers and a pilot clinical trial.  
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1 INTRODUCTION 
1.1 RHEUMATOID ARTHRITIS 
Hermagoras (Ερμαγόρας, fl. 1st century BC), of Temnos, was an Ancient 
Greek rhetorician of the Rhodian school and a famous teacher of rhetoric 
in Rome. He introduced the method of dividing a topic under study into its 
‘seven circumstances’: what, who, when, where, why, in what way, by what 
means (Quis, quid, quando, ubi, cur, quem ad modum, quibus adminiculis), 
which provided the roots of the ‘5W’s’ used widely today in several 
investigatory processes
1
.  
Here I will briefly describe the disease of interest of this thesis based on these 
‘seven circumstances’.  
 
 
 
 
 
1.1.1 ‘What’ – definition, classification criteria of RA 
Rheumatoid Arthritis (RA) is a chronic, systemic, inflammatory disease of 
unknown etiology which is generally thought to be autoimmune in nature. It 
typically affects the small and medium joints and causes synovial inflammation 
which can lead to cartilage and bone destruction if untreated.  
To classify RA different sets of criteria have been used over the last years. Until 
recently the 1987 revised ACR criteria were used
2
 (table 1A), but the last 3 years 
new criteria have been proposed and accepted for clinical use (table 1B)
3
. The 
new criteria aim to earlier diagnosis, since they focus more on the presence of 
auto-antibodies (rheumatoid factor and anti-citrullinated peptide antibodies) and 
they do not include radiological changes. These classification criteria are mainly 
Quis, quid, quando, ubi, 
cur, quem ad modum, quibus 
adminiculis 
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used in research and as a support for clinicians, but they are not diagnostic 
criteria, and the clinicians should never forget that they cannot be used as such.  
 
 
Criterion Definition 
1. Morning stiffness 
Morning stiffness in and around the joints, lasting at least 
1 hour before maximal improvement. 
2. Arthritis of 3 or 
more joint areas 
At least 3 joint areas simultaneously have had soft tissue 
swelling or fluid (not body overgrow alone) observed by 
a physician. The 14 possible areas are right or left PIP, 
MCP, wrist, elbow, knee, ankle and MTP joints. 
3. Arthritis of hand 
joints 
At least 1 area swollen (as defined above) in a wrist, 
MCP or PIP joint 
4. Symmetric 
arthritis 
Simultaneous involvement of the same joint areas (as 
defined in 2) on both sides of the body (bilateral 
involvement of PIPs, MCPs or MTPs is acceptable 
without absolute symmetry). 
5. Rheumatoid 
nodules 
Subcutaneous nodules over bony prominences or 
extensor surfaces, or in juxtaarticular regions, observed 
by a physician 
6. Serum 
rheumatoid factor 
Demonstration of abnormal amounts of serum 
rheumatoid factor by any method for which the result has 
been positive in <5% of normal control subjects 
7. Radiographic 
changes 
Radiographic changes typical of rheumatoid arthritis on 
posteroanterior hand and wrist radiographs, which must 
include erosions or unequivocal bony decalcification 
localized in or most marked adjacent to the involved 
joints (osteoarthritic changes alone do not qualify) 
Table 1A. The 1987 RA classification criteria. At least 4 of these 7 criteria had to 
be satisfied for classification of a patient as having RA. Criteria 1-4 had to be 
present for at least 6 weeks.  
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Is RA an autoimmune disease? According to Witebsky a disease must fulfill 
three criteria to be considered autoimmune: 1) autoantibodies or a cell-mediated 
immune response against an autoantigen has to be present; 2) the respective 
autoantigen is known and 3) a similar disease can be imitated in animal models 
                  Criterion                                                                                              Score 
A. Joint involvement 
1. 1 large joint                                                                                            0 
2. 2-10 large joints                                                                                     1 
3. 1-3 small joints (with or without large joint involvement)                 2 
4. 4-10 small joints (with or without large joint involvement)               3 
5. >10 joints (at least 1 small joint)                                                           5 
B. Serology 
1. Negative RF and negative ACPA                                                          0 
2. Low-positive RF or low-positive ACPA                                               2 
3. High-positive RF or high-positive ACPA                                             3 
C. Acute-phase reactants  
1. Normal CRP and normal ESR                                                               0 
2. Abnormal CRP or abnormal ESR                                                          1 
D. Duration of symptoms 
1. < 6 weeks                                                                                               0 
2. ≥ 6 weeks                                                                                               1 
Target population: patients who  
1. Have at least 1 joint with definite clinical synovitis 
2. Patients symptoms and findings cannot be better explained by another disease 
Table 1B. The 2010 ACR-EULAR classification criteria for RA. A score of 
≥6/10 is needed for classification of a patient as having definite RA.  
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based on an analogous immune response
4
. Based on these three requirements, 
the classification of RA as an autoimmune disease remains today somewhat 
controversial. Although several autoantibodies have been identified, the identity 
of a dominant arthritogenic autoantigen remains unclear. Moreover, while 
inflammatory arthritis can be induced in animal models, such as collagen 
induced arthritis, its direct relevance to human disease has been difficult to 
prove.  
Two of the most well studied and described autoantibodies in RA are rheumatoid 
factor (RF) and anti-citrullinated protein antibodies (ACPA). RF is an 
autoantibody against the Fc part of human IgG (figure 3). RF is most often an 
IgM molecule, but it can also be found as IgA or IgG. They can create immune 
complexes activating complement in the joint of RA patients which can in its 
turn increase vascular permeability, increase chemotactic factors and attract 
immune cells to the joint
5
. RF has a relatively low specificity for RA since it can 
be present in other systemic autoimmune diseases, for example systemic lupus 
erythematosus, but also in infections as well as in healthy, elderly individuals. 
Anti-citrullinated protein antibodies are more recently discovered and in contrast 
to RF they have much higher specificity for RA, more than 95%
6-8
. Citrullination 
is a process by which arginine residues are modified (“deiminated”) to citrulline  
in the presence of high calcium concentrations by an enzyme called PAD 
(peptidyl arginine deiminase). It is a physiologic enzymatic process important for 
the degradation of intracellular proteins during apoptosis.  ACPAs are important 
both for the initiation of disease but also for diagnosis
9
. They have also been 
shown to be associated with higher risk for erosive disease and thus poorer 
prognosis
10
. Several citrullinated antigens have been described in RA, with 
citrullinated fibrinogen, alpha-enolase, vimentin and collagen type II having 
been studied better. There is also some evidence that ACPA are involved in the 
etiopathogenesis of RA
11
. ACPA can be measured by generic tests, which use 
synthetic peptides or mutated recombinant proteins. The test most commonly 
used is anti-CCP.  
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1.1.2 Who’ and ‘When’ – epidemiology of RA  
RA is a common disease with a prevalence of 0.5% - 1%. It is associated with 
considerable regional variation. Prevalence estimates for Southern European 
countries are lower than for Northern Europe, while highest rates are found in 
North America
12
. In some Native American tribes up to 5% of individuals are 
affected, while in certain parts of rural Africa the disease is said to be absent. 
Women are predominantly affected in a ratio of 3:1. The mean age of patients at 
the time of diagnosis is the fifth decade. It has long been documented that RA 
clusters in families: the likelihood that a first-degree relative of a patient will 
share the diagnosis is 2–10 times the population prevalence of the disease, and 
recurrence risks are highest for relatives of the most severely affected index 
cases.  
1.1.3 ‘Where’ – clinical presentation of RA 
The mode of onset, clinical presentation and course of the disease is highly 
variable. Some patients may have an acute onset with dramatic and systemic 
symptoms, such as fever, weight loss, polyarthritis and extra-articular 
manifestations, while other may have a more insidious onset, which is more 
common. RA affects predominantly the small to medium size joints of the body 
in a symmetrical manner. Inflammation in the joints leads to swelling, pain, 
limited movement and stiffness. Besides the joints, RA affects other organs as 
well, such as the lungs (interstitial lung disease, pulmonary nodules, pleural 
effusions), the heart (such as myocarditis and pericarditis) and mucosal glands 
(secondary Sjögren’s syndrome)13,14. Neurological and hematological 
manifestations are also seen. Rheumatoid nodules, both in juxtaarticular regions 
and in the lungs are the most common extra-articular manifestation of RA. 
Rheumatoid vasculitis is also an uncommon but well-described RA 
manifestation. RA increases the risk of cardiovascular events and certain 
malignancies, such as lymphoma
15-17
. The life span of RA patients is reduced by 
approximately 7 years. For these reasons RA should be considered a systemic 
disease (figure 1).  
  6 
A characteristic feature of RA is its heterogeneity. Both in a genetic and clinical 
lever it can differ substantially among patients. Additionally the severity and 
prognosis can also vary significantly among individuals with RA. This 
heterogeneity makes the disease both challenging and interesting to investigate.   
 
 
 
 
Figure 1. RA is a systemic disease, affecting several organs and having many systemic 
manifestations.  
Picture: Statue of Asclepius (museum of Epidaurus Theatre). Modified from Wikimedia 
Commons (http://commons.wikimedia.org/wiki/File:Asklepios_-_Epidauros.jpg ) 
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1.1.4 ‘Why’ – etiology of RA, risk factors for RA 
The etiology of RA remains hitherto unclear. We know however that 
environmental, immunological and genetic factors interact for the development 
of RA
18
. In genetically susceptible individuals, specific environmental factors 
can activate potentially pathogenic immune reactions, including antibody 
formation. It has been shown that autoantibodies are present years before the 
development of symptoms
19
. Later a stochastic factor like trauma or infection 
can trigger the abnormal inflammatory process. The most well-known genetic 
risk factors are the presence of certain HLA DR alleles (which have a common 
aminoacid motif, the ‘shared epitope’)20 and PTPN22 gene21. These however are 
associated only with seropositive RA, with the presence of RF and ACPA 
antibodies in RA patients, proving how heterogeneous RA is not only on a 
clinical level but also on a genetic one
22,23
.  
The most well established environmental risk factor for the development of RA 
is smoking
24,25
. Smoking has been shown to be a strong risk factor only for RF or 
ACPA positive RA, while the association is weak for seronegative disease
23
. 
Studies have shown significant interaction between HLA-DR risk alleles and 
smoking in RF and ACPA positive RA patients
26-28
. It is also known today that 
RA patients who continue to smoke after the diagnosis of RA have a worse 
prognosis with higher risk for radiographic progression and worse response to 
anti-rheumatic therapy
29,30
.  
1.1.5 ‘In what way’ and ‘by what means’ – immunopathogenesis 
of RA31 
The primary lesion of RA is synovitis, inflammation of the synovium in the 
affected joints. Immune cells ‘invade’ the normally relatively acellular synovium 
leading to the formation of ‘pannus’, a hyperplastic, and inflammatory tissue that 
resembles cancer tissue. Over time, this process creates a cytokine milieu in the 
joint that activates synovial fibroblasts and osteoclasts, which in turn degrade 
cartilage and bone. Key cellular mediators as well as important cytokines support 
this process and have been targets for the biological agents developed for the 
treatment of RA.  
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1.1.5.1 T-cells 
T-cells are one of the most abundant cells in the rheumatoid synovium. The 
majority are CD4+ helper cells (Th). RA has traditionally been considered to be 
associated with an ‘immunological shift’ from Th2 to Th1, leading to a 
disturbance in the healthy balance between the Th derived cytokines (INF-γ from 
Th1 and IL-4 from Th2). Newer data however suggest that other types of Th 
cells could play a critical role in the pathogenesis of RA, such as the Th17 cells. 
Th17 cells can produce IL-17, IL-10, INF-γ, TNF, IL-6, GM-CSF. IL-17 is a 
highly pleiotropic cytokine which can perpetuate inflammation, promote 
angiogenesis and osteoclastogenesis. T regulatory cells, the so-called T-regs, are 
also highly represented in RA synovium and are thought to play an important 
role as well in the immunopathogenesis of RA.  
1.1.5.2 B-cells 
Special emphasis will be given on B-cells, since they are the target of rituximab, 
one of the biologic agents under study in this thesis.  
A B-cell is a subset of lymphocytes belonging to the adaptive immune system. 
Their name comes from the bursa of Fabricius, the organ of maturation of B-cell 
in birds. In mammals the early stages of B-cell maturation takes place in the 
bone marrow. The major subsets of B-cells are follicular B-cells, marginal zone 
B-cells and B-1 B-cells, each of which is found in different anatomic locations 
within lymphoid tissues. Development of B-cell takes place both in the bone 
marrow and in peripheral lymphoid organs and involves several stages (figure 
2)
32
. B-cells have clonally distributed antigen receptors in their surface, the B-
cell receptors (BCR), which are actually membrane bound antibodies. B-cells 
from one clone express antigen receptors of the same specificity that are 
different from other clones. These antibodies, or immunoglobulins, consist of a 
fixed and a variable portion.  There are 10
10 
different combinations of the 
variable portions of these immunoglobulins!  
In figure 3 the structure of an immunoglobulin is shown. It comprises of two 
identical heavy chains (CH) and two identical light chains (CL). It has a 
  9 
symmetric core structure. Both heavy and light chains consist of aminoterminal 
variable (V) regions that participate in antigen recognition. The other ‘end’ of the 
molecule is a carboxy-terminal constant (C) region that mediates effector 
functions.  
 
 
 
 
The activation and differentiation of B cells is a long and complicated process. It 
starts by recognition of an antigen by the B-cell receptor. The activation of other 
co-receptors such as CD19 and CD21 (CD=cluster of differentiation, cell surface 
proteins that play role in cell signaling and sometimes in cell adhesion) is 
required for the transmission of the first signal. In contrast to T-cells, which can 
only recognize small polypeptides, B-cells can recognize larger proteins. T-
independent activation of B-cells occurs classically flowing stimulation with 
polyvalent antigens. Some antigens however demand cooperation with T-cells 
(T-dependent activation of B-cells). In this process co-stimulation pathways, 
Figure 2. Stages of B-cell maturation are indicated by their anatomical site and 
the expression of cell-surface markers, including CD20.  Copyright ©, Nature 
Publishing Group.  
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such as CD40 and CD40-ligand, as well as CD28 and CD80/CD86 (also known 
as B7.1/B7.2) are crucial for the initiation of the immune response. Cytokines 
play also a very important role in the T-cell dependent activation of B-cells, such 
as IL-4 and IFNγ. The type of cytokine involved in this process will influence 
the type of antibody isotype that will be produced by the particular B-cell. An 
additional cytokine required for the activation of B-cells is the BLyS (B-
lymphocyte stimulator) or BAFF (B-cell activator factor of the TNF family). 
BAFF is produced mainly by dendritic cells and has a major role in the 
activation and survival of normal as well as self-reactive B-cells. After activation 
B-cells can differentiate into antibody-producing plasma cells or memory cells.  
The multifaceted role of B-cells in the pathogenesis of RA has only recently 
been fully recognized. B-cells can differentiate to plasma cells and produce 
autoantibodies such as RF and ACPA. B cells are also highly capable 
antigen-presenting cells and can contribute to autoreactive T cell activation. 
They also produce several cytokines, like IL-4 and IL-10 that can promote 
leukocyte infiltration in the joint, angiogenesis and synovial hyperplasia. B 
cells can sustain immunologic memory by differentiating to memory B-cells. 
B-cells express several toll-like receptors (TLRs) on their cell surface which 
transmit “danger signals” by binding bacterial cell wall components or DNA 
(pathogen associated molecular patterns; PAMPs). Hence, hypomethylated 
mitochondrial DNA released from dead cells (which are abundant in RA-
synovium) could conceivably activate autoreactive B-cells, driving 
autoantibody production and immune complex formation.  
1.1.5.3 Cytokines of inflammation – the role of TNF 
Cytokines in a general term are molecules involved in signaling between cells 
during immune response. Pro-inflammatory cytokines are important mediators of 
active RA promoting the activation of the adaptive immune system and the 
‘communication’ between cells. T-cells, macrophages and stromal cells are the 
main source of cytokines in early and established RA. Interestingly, the synovial 
cytokine profile in patients with RA differs between those patients who will 
subsequently develop RA (predominance of T-cell derived cytokines such as IL-
2, IL-4, IL-13, IL-17 and of stromal and macrophage derived cytokines such as 
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IL-1, IL-15 and EGF) and those who will go into remission or progress to a 
different arthritic disease. TNF (initially named TNF-α in order to be 
differentiated from TNF-β, now known as lymphotoxin) is produced primarily 
by macrophages and has many functions in the development of inflammation 
and the activation of other leukocytes. It is prothrombotic and promotes 
leukocyte adhesion and migration. It has an important role in macrophage 
activation and differentiation, it regulates hematopoiesis, it regulates lymphocyte 
development and it induces other cytokines as well. It is therefore a perfect target 
for RA, as it has been proven also in clinical practice.  
Several other cells and mediators of both the innate and adaptive immune system 
are involved in the immunopathogenesis of RA, but will not be described here in 
more detail.  
 
 
Figure 3. Molecular structure of immunoglobulin.  (figure 
made by the author) 
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1.2 TREATMENT OF RHEUMATOID ARTHRITIS 
1.2.1 Synthetic DMARDs33 
For an anti-rheumatic agent to be qualified as ‘disease modifying’ it needs to be 
able to impact the radiological progression which leads to functional decline. A 
DMARD should be introduced from the time of RA diagnosis, as early as 
possible, aiming the lowest level of disease activity. DMARDs comprise a 
heterogeneous group of compounds with different biochemical and 
pharmacokinetic properties, affecting a range of cellular targets. The discovery 
of synthetic DMARDs has traditionally been based on empirical data, in contrast 
with recently introduced biological DMARDs agents that were developed from 
bench to bedside. The most commonly used synthetic DMARDs in clinical 
practice are methotrexate, leflunomide, hydroxychloroquine, sulfasalazine and 
glucocorticoids. Other ones, like cyclosporine A, gold, azathioprine, D-
penicillamine, are rarely used today in clinical practice.  
For the purpose of this thesis, and particularly for paper II, I will go further into 
detail for two of the most commonly used synthetic (or conventional) DMARDs, 
methotrexate and leflunomide.  
1.2.1.1 Methotrexate 
Methotrexate (MTX) is a purine synthesis antagonist. It resembles folic acid 
(figure 4) and inhibits folate-dependent enzymes, such as dihydrofolate reductase 
(DHFR). DHFR inhibition leads to depletion of tetrahydrofolates that are 
essential for DNA, RNA and protein synthesis. MTX’s exact mechanism of 
action remains today, however, somewhat elusive.  
MTX is an antimetabolite used in oncology and rheumatology. It was one of the 
first DMARDs with proven efficacy on radiographic progression. It is the 
cornerstone of RA treatment, even when used alone in monotherapy, but also in 
combination with other conventional DMARDs (leflunomide, antimalarial, 
corticosteroids) and biologic DMARDs (TNFis, rituximab, etc). MTX is used 
both orally and as an intramuscular injection once weekly in a dose ranging from 
15 to 20mg in the majority of patients. Folic acid supplementation is 
recommended in order to reduce the risk for side effects. The latter include 
mainly gastrointestinal complaints and mild transaminase elevation. More rare 
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side effects include hematological toxicity (leucopenia, thrombocytopenia, 
pancytopenia), hypersensitivity pneumonitis, liver fibrosis. MTX is teratogenic 
and should be stopped at least 3 months before contraception.  
1.2.1.2 Leflunomide 
Leflunomide (figure 5) is a pyrimidine synthesis antagonist and thus multiple 
antiproliferative and anti-inflammatory functions. It is associated with a long 
half-life of about 15 days. The dose of leflunomide in RA is 10 to 20mg/day per 
os. Leflunomide is at least as effective as methotrexate in reducing disease 
burden in both early and established RA as well as in slowing radiographic 
progression. There are some studies that have examined the efficacy and safety 
of leflunomide in combination with methotrexate and with TNFis, suggesting 
that rheumatologists should consider these combinations. Side effects include 
gastrointestinal complains including diarrhea, hypertension, rash, alopecia, 
leucopenia. Leflunomide is also teratogenic and is strongly contraindicated in 
pregnant women. Due to its long half-life elimination of the drug can take up to 
2 years. Washout with cholestyramine is indicated in order to facilitate clearance.  
 
 
 
 
 
 
Figure 4. Chemical structure of 
methotrexate (source: Wikipedia, the 
free encyclopedia) 
Figure 5. Chemical structure of 
leflunomide (source: Wikipedia, 
the free encyclopedia) 
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1.2.2 Biological DMARDs 
 
 
The landscape of RA treatment has unquestionably changed dramatically 
during the last decade. A deeper understanding of the pathophysiological and 
immunological mechanisms in RA as it was presented earlier has led to the 
development and introduction into daily clinical practice of biologic disease-
modifying agents with, in some cases, tremendous effects in patients with 
severe RA whose disease was difficult to control with conventional DMARDs. 
To date, nine biologic agents have been approved for the treatment for RA: five 
inhibitors of tumour necrosis factor (TNF: i.e. infliximab, etanercept, 
adalimumab, golimumab and certolizumab pegol), the interleukin (IL)-1 
blocker anakinra, the IL-6 blocker tocilizumab, the B-cell depleting agent 
rituximab and the T-cell co-stimulation inhibitor abatacept
34
. In addition, more 
molecules with distinct mechanisms of action are currently being tested in 
laboratories and in clinical trials. In all cases, very good clinical efficacy and 
safety were documented in trials that led to regulatory approval. Some of these 
data will be discussed below. The biologic agents approved today for the 
treatment of RA are presented in table 2.  
 
1.2.2.1 TNF inhibitors 
There are five TNF inhibitors available today for the treatment of RA. Although 
they all target the same cytokine there are important differences in their 
molecular structure, pharmacodynamics and pharmacokinetics that differentiate 
them (table 3).  
The first three TNFis that received approval for the treatment of RA were 
infliximab, etanercept and adalimumab. Infliximab is a human murine chimeric 
monoclonal antibody that binds both soluble and membrane bound TNF. It is 
approved at a dose of 3mg/kg given at week 0, 2, 6 and thereafter every 8 weeks 
intravenously. Etanercept is a recombinant TNF receptor that is fused to a human 
Fc molecule. It is administered as a subcutaneous injection once a week. 
Adalimumab is a fully human monoclonal antibody against TNF. The approved 
dose is 40mg once every other week. 
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Table 2. Biological DMARDs approved for the treatment of RA 
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The newer TNFis are golimumab and certolizumab pegol. Golimumab is a fully 
human IgG1 monoclonal antibody specific for both circulating and bound TNF. 
It is given subcutaneously once every month at a dose of 50mg and in 
combination with methotrexate (or another synthetic DMARD). Certolizumab 
pegol differs from the other antibodies as it comprises of a recombinant antigen-
binding fragment (Fab´) of a humanized antibody against TNF, conjugated to a 
polyethylene glycol (PEG) moiety. It is approved at a dose of 200mg 
subcutaneous injection every 2 weeks both in combination with synthetic disease 
modifying antirheumatic drugs (DMARDs) and as monotherapy.  
 
Several studies have demonstrated the efficacy and safety of these TNF 
inhibitors in RA patients naïve to synthetic DMARDs who in practical terms 
often equate to newly diagnosed patients. These trials have generally provided 
clear evidence of the superiority of the combination of biologics with MTX over 
MTX alone in such patients. In a small (20 patients), randomized, double-blind, 
placebo-controlled trial, Quinn et al. showed significantly greater clinical, 
functional and radiological benefit of combination treatment with MTX plus 
infliximab in early RA compared to MTX alone
35
. It is interesting that 1 year 
after stopping induction therapy with infliximab, 70% of patients had a sustained 
response. In a much larger study by St. Clairet al. patients with RA of ≤3 years 
of duration achieved significantly better clinical efficacy with infliximab plus 
MTX than with MTX monotherapy
36
. Similar results were shown in large, 
randomized, controlled trials for etanercept and adalimumab, as well as for the 
newer TNFi golimumab (the data are summarized in figure 6)
37-39
. All of the 
above-mentioned studies were based on a population of patients with early RA 
(disease duration from 6.5 to 10.8 months) who had not received prior MTX, and 
they all demonstrated that the combination of a biologic agent and MTX can 
yield better clinical, functional and radiographic outcome than MTX alone. 
However, it is worth noting that a substantial proportion of patients in these trials 
responded well to MTX monotherapy. Thus, one should keep in mind that in the 
combination groups, there are patients who would have responded to MTX 
monotherapy as well
40
. 
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The most clearly established and best documented role for biologics in the 
treatment for RA however is in those patients who have failed to respond 
adequately to one or more conventional DMARD, usually including MTX. 
Double-blind, placebo-controlled, randomized trials for all nine biologic agents 
available today have been conducted and have established the efficacy of these 
drugs in patients with RA with inadequate response to MTX. In figure 7 the 
clinical responses after 6 months of therapy with all five TNFis plus MTX versus 
placebo plus MTX are summarized
1,41-44
. All these biologic agents seem to have 
comparable efficacy in the MTX non-responder population and significantly 
greater efficacy than placebo. 
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Figure 6. Efficacy of various TNFis [infliximab (INF), etanercept (ETA), 
adalimumab (ADA) and golimumab (GMB)] in combination with 
methotrexate (MTX) vs. MTX alone assessed by ACR responses in RA 
patients who are DMARD-naïve. Common for all TNFis was that the 
combination yielded significantly greater ACR responses compared to MTX 
monotherapy. 
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1.2.2.2 Rituximab 
 
B cells play a key role in RA pathogenesis as it was shown before in detail. Their 
multifaceted role made them a very promising target for the treatment of RA. 
Today only one B-cell depleting agent is approved for the treatment of RA, 
rituximab. Rituximab is a genetically engineered, chimeric anti-CD20 
monoclonal antibody. It comprises human IgG1Fck constant regions and small 
variable light and heavy chain regions from the anti-CD20 murine antibody 
fragment, which is reactive to human CD20. CD20 is a membrane-associated 
phosphoprotein that regulates the early steps in B cell activation. Its expression 
is restricted to B cells. Binding of CD20 by rituximab neither modulates 
expression nor causing substantial internalization of CD20. Treatment with 
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Figure 7. Efficacy of all available TNFis [infliximab (INF), etanercept (ETA), 
adalimumab (ADA), golimumab (GMB) and certolizumab pegol (CZP)] in 
combination with methotrexate (MTX) vs. MTX alone assessed by ACR 
responses in RA patients who were MTX non-responders. The addition of a 
TNFi in the treatment of these patients led to significant clinical improvement.  
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rituximab causes rapid depletion of certain B cells within the first treatment 
infusions and the effects can last for 6 to 9 months. CD20 positive B cell 
precursors, transitional B cells and naïve B cells are most susceptible to 
deletion by rituximab, while B1, marginal zone and germinal center B cells are 
more resistant.   
 
Mechanism of action 
 
It is hypothesized that rituximab works through numerous candidate 
mechanisms. These mechanisms vary depending on how the disease is 
expressed in each patient. The first mechanism of B cell deletion is antibody 
dependent cell-mediated cytotoxicity (ADCC), where an antibody coated 
target cell is directly killed by an effector cell expressing Fc receptors. A 
second mechanism occurs via complement activation through the classical 
pathway which leads to the formation of the membrane attach complex 
(MAC) and consequently cell lysis. The third mechanism is the induction of 
apoptosis
45
. Which mechanism of action takes place is influenced by host 
factors, such as genetic background and disease specific factors such as the 
availability of an intact complement pathway and the magnitude of B cell 
survival signals. One other possible mechanism through which rituximab might 
work is the immune complex decoy hypothesis, whereby the binding of 
rituximab-IgG molecules to B cells forms immune complexes that efficiently 
attract and find Fc gamma  receptor-expressing effector cells, which diminishes 
recruitment of these effector cells at sites of immune complex deposition and, 
therefore, reduces inflammation and tissue damage
46
. 
 
By depleting B cells and modulating the immune system, rituximab leads to 
reduced antigen presentation, proinflammatory cytokine production and 
autoantibody production, thus efficiently reducing the severity of B-cell 
medicated autoimmune diseases, like RA.  
 
 
 
 
  20 
Pharmacokinetics of rituximab, relationship between B cell depletion and 
clinical response 
 
Rituximab has a mean terminal half-life of 19 to 22 days after the second 
infusion. Systemic clearance of rituximab is around 220 mL/d. The volume of 
distribution is slow at 4.3 to 4.7 L and similar to normal plasma volume. The 
serum concentration of rituximab appears to be inversely related to recovery of 
peripheral B cells.  
Initially it was shown that although depletion of B cells in periphery was 
observed in all rituximab treated patients, not all of them responded to therapy
47
. 
A possible explanation could be the presence of residual B cells in lymph nodes 
and in the synovium. Another explanation might be the sensitivity of 
measurement of B cells in periphery.  Indeed, more recent studies have shown a 
correlation between the depth of B cell depletion both in the circulation and in 
the synovium and clinical response
48,49
. Persistence of B cells is associated with 
poorer response
50
.  
 
 
Efficacy and safety of rituximab in RA 
 
Rituximab is shown to be more efficacious than placebo in randomized 
controlled trials with an acceptable safety profile. In the SERENE trial both RTX 
doses (1000mg x 2 and 500mg x 2) achieved significantly greater results 
compared to placebo in RA patients with background MTX who had not 
responded adequately to MTX. No significant differences in efficacy or safety 
between the two doses groups were observed. The objective of the MIRROR 
study was to assess the efficacy of repeated treatment regimens with RTX at the 
same dose, 500mg x 2 and 1000mg x 2 both at baseline and after 24 weeks and 
at a dose-escalation, 500mg x 2 at baseline followed by 1000mg x 2 after 24 
weeks again in MTX non-responders RA population. Similarly to the SERENE 
trial, no significant differences in response rates were shown. In the IMAGE 
trial, which was conducted in DMARD-naïve RA patients, both doses of 
rituximab were associated with significant clinical improvement (in some 
comparisons the improvement was slightly higher numerically for the 1000mg x 
2 group but not significantly higher), but only the higher dose of rituximab was 
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proven effective in inhibiting progression of joint damage as assessed by the 
change in total Genant-modified Sharp score (mTSS) from baseline to week 52. 
The lower dose of rituximab could also slower the progression but the change in 
score compared to MTX monotherapy did not achieve the level of statistical 
significance.  
 
 
 
 
 
 
 
 
 
In the DANCER trial rituximab proved to be effective in patients who had not 
previously responded to DMARD treatment, including biologic DMARDs. Both 
rituximab dosages were effective, with 54–55% of patients achieving an ACR20 
response by week 24, and a high proportion achieving ACR50 or ACR70 
responses. No dose-response relationship was established, based on the ACR20 
RCT RA population Groups under 
comparison 
N. 
patients 
‘SERENE’ 
Biologic-naïve, 
MTX-non-
responders 
RTX 500mg x 2, RTX 
1000mg x 2, PLC 509 
‘MIRROR’ 
Biologic-naïve, 
MTX-non-
responders 
RTX 500mg x 2 at baseline 
and week 24 
RTX 1000mg x 2 at 
baseline and week 24 
RTX 500mg x 2 at baseline 
and 1000mg x 2 at week 24 
314 
‘IMAGE’ 
Early RA, MTX-
naive 
MTX alone 
MTX + RTX 1000mg x 2  
MTX + RTX 500mg x 2  
755 
‘DANCER’ 
MTX and 
biologic non-
responders 
Placebo * 
RTX 1000mg x 2 * 
RTX 500mg x 2 * 
465 
‘REFLEX’ 
TNFi non-
responders 
Placebo 
RTX 
520 
Table 3. Five large RCTs conducted during the last years with the aim to 
assess the efficacy and safety of RTX in RA.  
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criteria, for the 2 rituximab doses studied. There were, however, trends to 
indicate that the dose may influence the achievement of high-level response (i.e., 
ACR70 response and good EULAR response). Similarly, in the REFLEX study 
RTX yielded significant ACR responses compared to placebo in patients with 
longstanding disease who did not respond to TNFis. The above trials are 
summarized in table 3 and figure 8. In an indirect comparison one could observe 
that the efficacy of rituximab is best in DMARD-naïve patients and reduced in 
patients who have already failed at least one biologic agent.  
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Figure 8. Efficacy of rituximab as assessed by ACR responses in several RA 
populations and in different doses in five large RCTs.  
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All the above studies assessed the safety of rituximab in a systematic way. The 
most common adverse effects of rituximab are infusion reactions (common with 
the first infusion), increased risk for infections (upper respiratory tract infection, 
urinary tract infection, nasopharyngitis), reactivation of viral infections. Hitherto 
few cases of progressive multifocal leukoencephalopathy (PML) have been 
reported in RA. In a pooled analysis of safety data from patients treated with 
rituximab in combination with methotrexate in a global clinical trial program, the 
overall rate of adverse events was 357 events per 100 patient-years (95% CI 
354.4; 364.9). The rate of adverse events seems to decline with time. 
Hypoglobulinemia is an expected finding in rituximab treated patients. IgM 
levels decrease with multiple courses of rituximab, but this does not appear to be 
associated with increased risk for serious infections. IgG is the most important 
among serum immunoglobulins for protective immunity. In some rituximab 
treated patients levels of IgG can also be decreased but to a minimal degree 
compared to IgM. No obvious differences in the rate of adverse events have been 
observed between the higher and the lower dose rituximab.  
 
1.2.3 Treatment strategies 
 
1.2.3.1 When should a biologic agent be introduced? 
The main conclusion from the above studies was that TNF inhibition can lead to 
significant clinical and functional improvement as well as inhibit radiographic 
progression in RA patients both before the introduction of a synthetic DMARD, 
like methotrexate, and after the inadequate response to at least one synthetic 
DMARD. These results do not, however, answer the question of whether a 
combination of biologic drugs with MTX is also superior to a combination of 
synthetic DMARDs. So far, only a few clinical trials have made a direct 
comparison of these two treatment options, by adding a biologic agent or 
adding/switching to another synthetic DMARD. In the SWEFOT trial, patients 
with early RA with an inadequate response to MTX after 3 months, defined as 
lack of achievement of low disease activity, were randomly allocated to addition 
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of either sulfasalazine and hydroxychloroquine or infliximab
51
. The latter group 
had significantly greater responses after 12 months of therapy, with 39% of 
patients achieving the primary end-point EULAR good response compared to 
25% in the former group (P = 0.016). However, after 2 years the clinical 
difference was smaller and no longer statistically significant
52
. Radiological 
progression was, however, greater with conventional therapy than with the 
biologic agent. In the BeSt trial it was shown that initial combination therapy 
with initial high-dose prednisone followed by a gradual prednisone-dose 
reduction or with infliximab provided earlier clinical improvement than 
sequential monotherapy and conventional combination therapy
53
. After 2 years, 
patients in all four treatment groups had approximately the same improvement in 
disease activity and functional status irrespective of initial treatment, probably 
because of tight control and frequent treatment adjustments. However, the more 
aggressively treated patients had less radiological progression of joint damage, 
and during the second year, more of them could be treated successfully with 
monotherapy, suggesting that the initial aggressive therapy did result in some 
long-term gains. 
In the Treatment of Early Aggressive RA (TEAR) trial, patients with early RA 
were randomized to one of four groups: methotrexate monotherapy followed by 
triple therapy in case of insufficient response (n = 124); methotrexate followed 
by the addition of etanercept (n = 255); immediate triple therapy (n = 132); or 
immediate methotrexate plus etanercept (n = 244)
54
.
 
Rather surprisingly, at 1 
year follow-up none of the four strategies was superior clinically, and only small 
differences were observed in radiographic progression. In a recently published 
double-blinded, randomized clinical trial, patients with established RA with an 
average disease duration of 5 years who had been receiving methotrexate in at 
least one year but despite that had still active disease, were randomized to 
receive either triple therapy (methotrexate, sulphasalazine and 
hydroxychloroquine) or methotrexate + etanercept
55
. The main result was that 
triple therapy was non-inferior to the addition of a biologic agent to 
methotrexate. The difference in average 28-joint disease activity score (DAS28) 
at 24 weeks almost achieved significance (P = 0.06), but was smaller than the 
non-inferiority margin. Thus, one could summarize the result by saying that 
triple therapy might be a little bit less effective than the addition of an anti-TNF 
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agent in the event of inadequate response to traditional DMARD therapy, but the 
difference is not clinically relevant
56
. 
 
1.2.3.2 What happens after the failure of the first TNFi? 
 
Data from randomized trials and cohort studies suggest that about one-third of 
patients discontinue therapy with a first biologic within a year because of 
primary ineffectiveness, loss of efficacy after a period of time or intolerance. 
The goal of treatment for these patients remains remission. Even patients with 
moderate responses (‘partial responders’) should eventually be candidates for 
an alternative treatment, taking into account that even ‘smoldering’ disease 
activity might lead to structural damage. 
After the failure of one biologic agent for the reasons described above, and 
after having perhaps tried to modify the dose of the concomitant DMARDs 
with no effect, three main treatment options are available: (i) optimize the dose 
of biologic drug; (ii) switch between TNF inhibitors; or (iii) switch to a 
biologic agent with a different mechanism of action (figure 9). 
Optimizing the dose 
Controversial data are available concerning the optimization of the infliximab 
dose. In the ATTRACT trial, four different treatment regimens (i.e. infliximab 
3 mg/kg every 4 and 8 weeks, and 10 mg/kg every 4 and 8 weeks) yielded 
similar American College of Rheumatology (ACR) responses at 24 weeks
41
. At 
48 weeks, however, there was a tendency for the lowest dosage of infliximab to 
be less effective than the higher ones, but this difference was only significant 
with respect to the ACR50 responses
57
. Results from uncontrolled 
observational studies have suggested that in patients with secondary loss of 
efficacy to infliximab, a higher dosage of infliximab could provide better 
efficacy
58
. On the other hand, in a double-blind randomized trial, 
Pavelka et al. showed no significant difference in efficacy of two dosages of 
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infliximab (3 and 5 mg/kg ) after initial failure of the lower dosage to lead to 
remission
59
. Moreover, the higher dosage had a poorer safety profile. Another 
large trial of infliximab showed similar results, with no significant superiority 
of the higher dosage of 6 mg/kg
36
. In an observational study conducted in our 
centre, patients in whom the dose of infliximab was increased in clinical 
practice appeared to have a benefit, as defined by reduction in the disease 
activity score (DAS28)
60
. However, patients in the control groups (i.e. patients 
with no change in infliximab dose and those receiving a stable dose of 
etanercept) also showed an improvement in DAS28. This observation suggests 
that the improvements were most probably attributable to regression to the 
mean and that no important benefit is gained from dose increases of infliximab. 
Finally, van den Bemt et al.  found that 17 of 18 patients who were in clinical 
practice treated with infliximab at dosages higher than 3 mg/kg showed no 
deterioration of their RA if the dosage was reduced to 3 mg/kg
61
. In 
conclusion, the evidence suggests that increasing the dose of infliximab might 
result in loss of time, higher cost and potentially more side effects with no 
significant efficacy gain in most patients. Therefore, it would clearly be useful 
to be able to identify, using relevant biomarkers, a smaller subset of patients 
who might truly benefit from dose increases. Studies to investigate this 
possibility are currently underway. 
 
Switching between TNF inhibitors 
 
Different TNF inhibitors might target the same cytokine but differ substantially 
in their molecular structure and immunological actions. This is the rationale 
behind switching between different TNF inhibitors. Because of differences in 
pharmacokinetics between these inhibitors, it is possible that a patient will 
respond to an alternative agent after the failure of the first. This issue was 
investigated in the randomized double-blinded GO-AFTER study, in which 
after failure of a prior TNF inhibitor, patients who received golimumab showed 
significantly greater responses than those who received placebo
62
. In addition, 
results from many observational studies support switching between TNF 
inhibitors, as a substantial proportion of patients can benefit from this 
strategy
63-69
. Cohort study data also suggest a gradual loss of efficacy after a 
greater number of switches. Thus, a first switch might provide significant 
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improvement, whereas the effect is much less profound at the second or third 
switch. 
 
 
Switching mechanism of action 
 
After the failure of TNF inhibition (with a single or multiple agents), the next 
step is change of mechanism, which might be more logical than trying different 
regimens of the same drug class. Large trials have proved the efficacy of 
rituximab, abatacept and tocilizumab versus placebo after TNF treatment
70-72
. 
Superiority of rituximab over placebo was observed in the REFLEX trial. 
Abatacept demonstrated acceptable safety and clinically meaningful efficacy in 
patients who failed TNF inhibitor treatment in the ATTAIN trial. Additionally, 
in the RADIATE trial, tocilizumab-treated patients achieved significantly 
better results than those who received placebo during the first 6 months of 
therapy. But are these biologic agents with a different mechanism of action 
better than an alternative TNF inhibitor? Again, no randomized clinical trial 
has provided us with hard evidence to answer this question. On the other hand, 
observational studies have compared the two treatment options. In the Swiss 
Clinical Quality Management program for RA (SCQM-RA) registry, patients 
with inadequate response to TNF inhibitor treatment achieved greater 
Figure 9. Treatment options after the failure of the 1
st
 TNFi.  
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reductions in DAS28 when switching to rituximab than to an alternative TNF 
blocker
73
. In a sub-analysis of the same population, it was shown that the 
superiority of rituximab over an alternative TNF inhibitor was observed for the 
subgroup of patients who discontinued previous TNF inhibitor therapy because 
of primary or secondary inefficacy
74
. Newer data from the British Society for 
Rheumatology Biologics Register suggest that switching to RTX may be of 
more benefit than switching to an alternative anti-TNF therapy after failing the 
first anti-TNF therapy in RA patients
75
. In a prospective observational study 
from Spain no difference in the reduction of DAS28 was observed during the 
first year of treatment between RTX and TNFi groups, but in a sub-analysis the 
difference was different between adalimumab/infliximab and RTX
76
.  
 
1.2.3.3 When can a biologic treatment be discontinued? 
 
After the achievement of low disease activity or remission, the next goal is the 
‘biologic-free remission’, which is important with respect to long-term safety 
issues, patient comfort and health economics. In various settings, the possibility 
has been investigated of discontinuing the biologic agent whilst maintaining the 
patient in remission on a conventional DMARD. As part of the ATTRACT 
study
57
, 17 patients in a single center in the United Kingdom received infliximab 
and all 17 experienced flare-ups after discontinuation of the biologic therapy 
after 2 years, with a mean time of 13.5–15.0 weeks after the end of therapy. Of 
importance, reintroduction of infliximab after disease flare was associated with 
comparable responses without any safety issues. Whereas patients included in 
the ATTRACT study had longstanding disease (mean disease duration, 
11 years), Quinn et al. addressed the same question in a randomized, double-
blind, placebo-controlled trial in a population of patients with early RA, with 
symptom duration of <12 months
35
. These authors showed that induction of 
remission with infliximab plus MTX in early, poor prognosis RA provided not 
only significant reduction in synovitis and erosions at 1 year (shown by magnetic 
resonance imaging) but also sustained functional and quality-of-life benefits for 
70% of the patients at 2 years despite infliximab withdrawal. More recently, 
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Tanaka et al. determined the possibility of discontinuing infliximab after 
attaining DAS-guided low disease activity in patients with RA in the remission 
induction by infliximab in RA (RRR) study
77
. Of 102 patients, 56 (55%) 
maintained DAS28 < 3.2 and 44 (43%) reached remission (DAS28 < 2.6) 1 year 
after the discontinuation of infliximab. The mean disease duration in this study 
was 5.9 years, which suggests that discontinuation of infliximab would be 
possible not only in patients with early RA but also in patients with more 
established disease. In a post hoc analysis from the BeSt study, it was shown that 
significantly more patients who received initial combination therapy with 
infliximab and MTX achieved sustained DAS ≤ 2.4 and were able to discontinue 
infliximab, compared with those with delayed introduction of the biologic agent 
(56% vs. 29%, p = 0.008)
78
. It was also shown in the BeSt study that the shorter 
the symptom duration, the higher the likelihood of a biologic-free, and even a 
drug-free, remission
79
. In the OPTIMA trial RA patients with early RA who 
achieved stable low disease activity on adalimumab plus methotrexate who 
withdrew adalimumab mostly maintained their good responses
80
. Even in more 
established RA, discontinuation of adalimumab can be feasible but mainly for 
patients on deep remission, as shown in the HONOR study
81
.  
 
 
The results of a systematic review and meta-analysis showed that patients with 
established RA who stopped treatment with synthetic DMARDs had a 
significantly higher risk of disease flare or deterioration than those who 
continued treatment
82
. In this analysis, however, patients had RA of more than 
2 years of duration. 
From the results of the above studies, one can draw several conclusions. First, 
biologic-free remission might be possible after achieving remission or low 
disease activity in a considerable proportion of patients. Second, the duration 
of disease until the introduction of the biologic treatment might be negatively 
associated with the risk of deterioration after discontinuation of treatment, thus 
suggesting that earlier initiation of biologic treatment not only leads to better 
results but also increases the possibility of withdrawal of biologic agents with 
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maintenance of remission. Third, if a patient has had a remission for a long 
time, it is more likely that the patient will remain in remission.  
 
In figure 10 an algorithm for biologic treatment of RA is shown below.  
 
 
 
 
 
 
Figure 10. Algorithm for biologic treatment of RA.  
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1.3 ASSESSMENT OF THERAPY IN RHEUMATOID ARTHRITIS 
1.3.1 General rules 
Clinicians use both implicit and explicit criteria for the assessment of a therapy 
and follow-up of patients. An example of an implicit criterion is ‘the patient feels 
better’, while an explicit criterion will be more precise and would be comparable 
between different subjects, for example visual analogue scale (VAS) for pain (0 
to 10). It is obvious that for research purposes but also for the clinical practice 
good explicit criteria are needed for the monitoring of therapy outcomes.  
The general acceptable goal of RA treatment today is remission or low disease 
activity for patients for whom remission is not possible
83
. Tight control with 
regular disease assessments and treatment to target are crucial in order to follow 
treatment results and if the goal is not achieved to take further actions. This 
strategy can lead to better results, as it has been shown in studies such as the Best 
trial and the TICORA trial
84,85
. Of vital importance is however the definition of 
the goal, and in this case remission. 
There are three important aspects of response to therapy in RA today: disease 
activity, function and damage. All three must be taken into consideration when 
assessing a treatment. Consequently, we need assessment measures for disease 
activity, function and damage.  
 
1.3.2 Tools 
1.3.2.1 Assessment tools for disease activity 
RA’s heterogeneity makes no single instrument able to describe the disease 
activity equally well for each patient. And this is obvious from the clinical 
reality, where some patients have many swollen and tender joints with no or 
minimal elevation of acute-phase reactants (ESR and CRP), while for other 
patients it is the other way around. For this reason composite measures are to 
prefer from single ones. A composite score is a combination of various single 
measurements but with minimum overlap.  Composite scores used in RA are 
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shown in table 4. The most widely used of them is the DAS28 (disease activity 
score based on 28 joints)
86
. There are two separate formulas for ESR and CRP
87
. 
Another composite score commonly used is the Simplified Disease Activity 
Index (SDAI), which is the sum of the 28-SJC, the 28-TJC, and the patient and 
investigator global assessments of disease activity on a 10 cm VAS and CRP in 
mg/dl
88
. The Clinical Disease Activity Index (CDAI) is a modification of the 
SDAI without the laboratory parameter CRP to allow immediate clinical 
assessment
89,90
. According to the level of DAS28, disease activity can be 
categorized to high, moderate, low or remission (figure 11).  
 
Composite scores used for the assessment of RA disease activity 
DAS28 0.56√TJC28 + 0.28 √ SJC28 + 0.70*Ln(ESR) + 0.014*VAS GH 
(Pat) 
DAS28 
(CRP) 
0.56√TJC28 + 0.28 √ SJC28 + 0.36*Ln(CRP + 1) + 0.014*VAS 
GH (Phy) + 0.96 
SDAI SJC28 + TJC28 + VAS GH (Pat) + VAS GH (Phy) + CRP 
CDAI SJC28 + TJC28 + VAS GH (Pat) + VAS GH (Phy) 
 
 
To better describe the effectiveness of a treatment it is important to have 
information not only about the level of disease activity achieved (at several time 
points after baseline), but also about the degree of improvement, the response. 
The two most widely accepted measures of response are the EULAR response 
criteria (table 5A) and the ACR response criteria (table 5B)
91-94
. 
 
 
Table 4. Composite scores for the assessment  of disease activity in RA.  
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 Improvement in DAS28 from baseline 
DAS28 at endpoint ≥1.2 >0.6 and <1.2 ≤0.6 
≤3.2 GOOD MODERATE NO 
5.1≤ and <3.2 MODERATE MODERATE NO 
>5.1 MODERATE NO NO 
 
 
 
0          1          2          3          4          5          6          7          8          9         10 
Remission              Low      Moderate            High 
2.6     3.2                 5.1 
Figure 11. Disease activity state based on DAS28.  
Table 5A. EULAR response criteria based on DAS28 status and DAS28 
improvement from baseline.  
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ACR 20 ACR 50 ACR 70 
20% improvement in  
 TJC AND 
 SJC 
and 20% improvement 
in 3 of the following: 
 VAS pain 
 VAS GH (Pat) 
 VAS GH (Phy) 
 ESR or CRP 
 HAQ 
50% improvement in  
 TJC AND 
 SJC 
And 50% improvement  
in 3 of the following: 
 VAS pain 
 VAS GH (Pat) 
 VAS GH (Phy) 
 ESR or CRP 
 HAQ 
70% improvement in  
 TJC AND 
 SJC 
And 70% improvement  
in 3 of the following: 
 VAS pain 
 VAS GH (Pat) 
 VAS GH (Phy) 
 ESR or CRP 
 HAQ 
 
 
1.3.2.2 Assessment tools for function 
The main assessment tool for the evaluation of function in RA is the Health 
Assessment Questionnaire (HAQ)
95,96
. This disability index comprises of 20 
questions regarding the ability of patients to perform 20 every-day activities. The 
score ranges from 0 to 3.  
1.3.2.3 Assessment tools for damage 
Several imaging techniques are available today in research and in clinical 
practice for diagnosis and treatment follow-up. Conventional radiography 
remains today the most widely implemented imaging tool for the evaluation of 
damage caused by inflammation in RA. Damage is closely related both to 
activity and function.  
The information from radiographs has to be quantified in order to be able to be 
comparable both between different subjects but also for the individual patient 
Table 5B. ACR response criteria.  
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over time. Several scoring methods have been developed. In this thesis (paper 
VIII) the Shard/van der Heijde scroring method was used for the evaluation of 
radiographical progression
97
.  
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2 OBJECTIVES 
2.1 OVERALL OBJECTIVE 
RCTs led to the approval of several biological agents for the treatment of RA. 
Most of these agents have been used by rheumatologist in an increasing rate the 
last years. However the use of biological agents is far from being optimized, 
since there are still many unanswered questions, for example: 
1) When should a biologic agent be introduced? 
2) After the failure of a TNF inhibitor (which is usually the first line 
biologic unless contraindicated) what is the best second-line biologic? 
Can an alternative TNF inhibitor be used, and in that case plays the type 
of TNF inhibitor any role? Or would switching of mechanism of action 
lead to better results? 
3) Could a biologic be discontinued after achieving the goal (remission or 
low disease activity)?  
4) Are there ‘target groups’ of patients who have a higher chance to respond 
to a specific biologic? Are there predictors of response to specific agents? 
Guidelines and protocols are needed for a better utilization of these highly potent 
and expensive treatments. But while RCTs remain the ‘gold standard’ today and 
provide the most reliable answers to specific questions the more complex 
questions that govern clinical decision making can rarely be addressed 
adequately using RCTs. But even if some of these questions could be addressed 
through RCTs it would demand a lot of time and money.  
Additionally, RCTs usually have strict inclusion and exclusion criteria, and thus 
they examine aspects of treatment in a very specific RA population that do not 
represent reality. This is the so called external validity of RCTs that is low 
compared to observational studies. Today we have at our disposal a well-
structured follow-up system, the registries, which when properly used can 
provide us with very useful and important information that RCTs cannot do, for 
the reasons stated above, and thus completing the puzzle.  
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2.2 SPECIFIC OBJECTIVES 
2.2.1 Part I: Studies of the treatment of RA with rituximab (papers 
I-IV) 
As it was presented earlier, the efficacy and safety of rituximab has been well 
demonstrated in RCTs. However, several important questions that relate to the 
practical use of rituximab in RA need to be further elucidated, and they were the 
objectives in the first four papers: 
I) Paper I 
a. Characterization of a large international cohort of RA patients 
treated with rituximab. 
b. Effectivess of treatment in a real-life RA population. 
c. Possible predictors of response to therapy with rituximab. 
d. Off-label use of rituximab, for example as first line biological 
treatment. 
II) Paper II 
a. Description and comparison of the effectivess and safety of 
rituximab as monotherapy or in combination with synthetic 
DMARDs such as methotrexate and leflunomide. 
III)  Paper III 
a. Comparison of the effectiveness of two different doses of 
rituximab, the approved dose rituximab (1000mg x 2) and a lower 
dose (500mg x 2) in practice. 
IV)  Paper IV 
a. Characterization of the rate of retreatment with rituximab in 
every day clinical practice. 
b. Assessment of the feasibility of achieving further clinical 
improvement with repeated treatment cycles.   
c. Comparison of the effectiveness of two retreatment strategies: on-
flare and fixed.  
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2.2.2 Part II: Studies on switching between biologics, on TNF 
inhibition and discontinuation of TNFis (papers V-VIII) 
The specific aims of the studies were: 
V)           Paper V 
a. Assessment of switching from first to second TNFi under 
different circumstances (according to the reason for 
discontinuation and the type of the first TNFi) trying to identify 
an optimal switching strategy. 
b. Description and comparison of the drug survival of adalimumab, 
etanercept and infliximab as 2
nd
 TNFis after switching from a 1
st
 
TNFi in patients with RA.  
 
VI)           Paper VI 
a. Description and comparison of the effectiveness of an 
alternativeTNFi or RTX  for patients who failed one TNFi.  
b. Whether the type of switch (type of first TNFi) and reason for 
discontinuation of the previous agent can affect the results.  
 
VII) Paper VII 
a. Description of the use of certolizumab pegol in RA in a real-life 
setting. 
b. Assessment of  the effectiveness of treatment both in a biologic 
naïve population and in patients who have previously failed at 
least one biologic agent.  
c. Assessment of  drug survival.  
 
VIII) Paper VIII 
a. Assessment of the feasibility of discontinuing adalimumab 
treatment while maintaining remission in RA patients with 
established disease who are in stable remission (defined as 
DAS28<2.6 for ≥3 months) on combination therapy with 
adalimumab + methotrexate (MTX). 
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3 MATERIALS AND METHODS 
 
This thesis is based on eight epidemiological studies. The term epidemiological 
is to characterize the type of research performed on human subjects (etymology: 
‘epi’ = upon and ‘demos’ = people and ‘logos’ = study) in contrast to 
experimental studies. Epidemiological studies can be further categorized to 
observational studies and clinical trials. In observational studies there is no 
intervention and the subjects are observed prospectively or retrospectively.  
The first seven papers are cohort observational studies. The definition of a 
cohort study is the analytic method of epidemiological study in which subsets of 
a defined population are identified who are, have been, or in the future may be 
exposed or not exposed, or exposed in different degrees, to a factor or factors 
hypothesized to influence the probability of occurrence of a given disease or 
other outcome.  The cohort studies presented here are based on large regional, 
national and international registers of RA patients treated with biologic 
DMARDs.  
3.1 REGISTERS USED 
3.1.1 The CERERRA cohort (papers I-IV) 
In 2010 a European collaboration between registries from 10 different European 
countries, the European Collaborative Registries for the Evaluation of Rituximab 
in RA (CERERRA) initiative, was initiated. This is a collaboration between 
European registries from the Czech republic, Denmark, Finland, the Netherlands, 
Norway, Portugal, Russia, Slovenia, Spain, Sweden, and Switzerland. Romania 
joined the collaboration 2 years ago (figure 12).  
Approximately once per year each of the participating countries contribute fully 
anonymized data of RA patients who are or have been treated with rituximab. 
The type of information collected is based on predefined specific objectives for 
specific projects.  
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The datasets from each country were collected and after a second quality control 
(the first being conducted by the responsible person in each country) they were 
organized in a central dataset which was the cohort.  
The main data that were collected were: 
1) Demographic information: age, sex 
2) Disease-specific information: disease duration, RF and anti-CCP status 
(defined as positive or negative according to each laboratory). 
3) Effectiveness data: SJC, TJC, ESR, CRP, VAS pain, VAS generall 
health (patient), VAS generall physician, DAS28-ESR, DAS28-CRP, 
HAQ for baseline and for each follow-up visit. 
4) Treatment information: rituximab dose, date of rituximab initiation, date 
of rituximab discontinuation (if available), date and dose of rituximab 
retreatment and when available even reason for retreatment, number of 
prior synthetic and biologic DMARDs used, concomitant synthetic 
DMARD and corticosteroids used as well as dose. 
 
 
 
 
Figure 12. Countries (in yellow) participating 
in the CERERRA collaboration 
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3.1.2 The STURE register (paper VI) 
The Stockholm TNF follow-up registry (STURE) database collects efficacy 
data for all patients starting biological treatments at the major hospitals in 
Stockholm, as part of the nationwide registry of Anti-Rheumatic Therapy in 
Sweden (ARTIS). The design of the study was approved by local ethical 
committees. The assessments are performed at baseline, 3, 6, and 12 months, 
and annually thereafter, and include the American College of Rheumatology 
(ACR) core outcomes [the 28 swollen (SJC) and tender joint count (TJC), 
visual analogue scales (VAS) for global health and for pain, the Health 
Assessment Questionnaire (HAQ) disability index, erythrocyte sedimentation 
rate (ESR), C-reactive protein], the DAS28 score and record of concurrent 
medications.  
3.1.3 The ARTIS register (papers V and VII) 
The ARTIS register is the nationwide Swedish Biologics Register (Anti-
Rheumatic Therapy in Sweden (ARTIS)). To this register, data on adult 
patients prescribed biologic agents for the treatment of rheumatic diseases in 
Sweden have been collected since 1999. The coverage of the ARTIS database 
has been estimated to be nearly 90% of all eligible patients with RA
98,99
.  
3.2 A PILOT CLINICAL TRIAL (PAPER VIII) 
The last study is based on a multi-center, randomized, controlled, open-label, 
pilot study. The main inclusion criteria were: age ≥18; diagnosis of RA based on 
1987 ACR classification criteria and positive RF or at least one erosion on the 
radiograph of hands or feet; treatment with adalimumab in the approved dose of 
40mg every other week for at least 6 months; concomitant treatment with MTX  
in a dose of at least 10mg per week for a minimum of 6 months (stable dose for a 
minimum of 3 months); stable DAS28 remission (DAS28-ESR≤2.8) for at least 
3 months based on assessments at baseline and on at least one more occasion 3-6 
months prior to baseline, documented in patient record or registry. Concomitant 
corticosteroids were allowed if the dose was 10mg per day or less (prednisolone 
or equivalent) and has been stable for at least 3 months at study entry.  
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3.3 STATISTICAL ANALYSIS 
3.3.1 Descriptive statistics 
Appropriate parametric and non-parametric statistical tests were used for the 
description of normally and non-normally distributed continuous numerical 
variables. The normality of variables was tested by skewness and by 
Kolmogorov-Smirnov test at certain studies. Variables which were similar to 
normal distribution were presented as mean±SD, while non-normally 
distributed variables were presented as median with interquartile range (IQR). 
Student t-test was used to compare two normally distributed continuous 
variables, while one-way analysis of variance was used to compare three or 
more groups, followed by Bonferroni test for post hoc comparisons between 
the groups. Chi square (χ2) test was used to compare nominal variables. 
Kruskal–Wallis test was used to compare non-normally distributed variables. 
The level of statistical significance was set to 5%. 
3.3.2 Logistic regression analysis 
Logistic regression analysis is a type of statistical model used to predict a 
binary response (for example good response to therapy or not). Univariate is 
when one independent variable is used, while multivariate when many 
independent factors are tested at the same time. In order to know which 
variables to include in the multivariate model, we started with univariate 
analysis separately for several demographic and disease variables. The results 
from these analyses (p<0.25 as the criterion) and correlation analyses (Pearson 
and Spearman correlations) guided the selection of variables for the 
multivariate logistic regression analyses with dichotomized responses as the 
dependent variables. Age and sex were usually included in the multivariate 
analyses. The non-significant variables were removed by stepwise backward 
selection. We then added back into the models, one at a time, any variable not 
originally selected from the univariate analyses. The variables were kept in the 
models if significant. Appropriate tests for linearity, interactions and goodness 
of fi t were performed. 
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3.3.3 Mixed model analysis 
A mixed effects model is a type of regression model that takes into consideration 
variation that is not generalisable to the independent variables. Such variables 
might include variation across different countries, different centers, different 
assessors, etc. These individual differences can be modeled by assuming 
different random intercepts for each subject. In the mixed model one or more 
random effects are added in the fixed effects. The mixture of random and fixed 
effects is what makes the mixed model a ‘mixed’ model.  
Mixed effects model allows continuous dependent and independent variables as 
well as interactions between any combination of discrete and continuous 
variables. They are particularly useful in settings where repeated measurements 
are made on the same statistical unit, as in longitudinal studies. Because of their 
advantage to deal with missing values, mixed effects models are often preferred 
over more traditional approaches such as repeated measures ANOVA. 
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4 RESULTS 
4.1 PAPERS I-IV: ASPECTS OF RITUXIMAB USE IN RHEUMATOID 
ARTHRITIS 
4.1.1 Paper I 
Characterization of the cohort  
Patients included in this analysis reflected a typical RA population with 
established disease. The total number of patients was 2019. The mean (SD) age 
and RA disease duration was 53.8 (13.3) and 12.1 (8.9) years, respectively. 
86% of patients were RF positive and 77% were anti-CCP positive. Patients 
had failed a mean of 2.7 prior synthetic DMARDs and 1.1 prior biologic 
DMARDs. Interestingly more than one third of patients were biologic-naïve. 
This is off-label, since rituximab is approved for patients that do not respond to 
TNF inhibition.  Concomitant synthetic DMARDs were used by 76.7% of the 
patients. There was significant heterogeneity between the countries for several 
baseline characteristics.  
Effectiveness of treatment and predictors of response 
Disease activity based on DAS28 decreased significantly during the first 6 
months of treatment. EULAR good/moderate responses at 3 months were 
achieved by 195/483 out of 1087 patients (17.9%/44.4%) and by 210/402 out of 
945 patients (22.2%/42.5%) after 6 months. DAS28 improvement of >1.2 was 
observed in 62.5% of patients. Seropositive patients (based on RF and/or anti-
CCP status) achieved significantly greater clinical responses at 3 and 6 months 
compared to seronegative patients. Patients who received rituximab as first 
biologic or after the failure of 1 TNFi responded significantly better compared to 
those who had failed two or more prior TNFis. In a multivariate logistic 
regression analysis model anti-CCP positivity, lower number of prior DMARDs 
and lower DAS28 at baseline were independently associated with EULAR good 
response to rituximab therapy after 6 months from baseline (table 6).  
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Variable OR (95% CI) p-value 
Univariate adjusted analysis 
N. prior synthetic DMARDs 0.84 (0.75-0.94) 0.002 
N. prior biologic DMARDs (0-1 vs. ≥2) 1.73 (1.25-2.38) 0.001 
Baseline HAQ 1.20 (0.80-1.70) 0.30 
Baseline DAS28 0.90 (0.87-1.02) 0.11 
Disease Duration 0.99 (0.98-1.01) 0.48 
RF (pos vs. neg) 1.50 (1.01-2.36) 0.04 
Anti-CCP (pos vs. neg) 3.00 (1.56-5.77) 0.001 
Conc. DMARDs 0.95 (0.67-1.33) 0.75 
Conc. glucocorticoids 0.77 (0.57-1.04) 0.09 
Multivariate adjusted analysis 
Anti-CCP (pos vs. neg) 2.86 (1.43-5.71) 0.003 
N. prior synthetic DMARDs 0.84 (0.70-1.01) 0.06 
N. prior biologic DMARDs (0-1 vs. ≥2) 1.89 (1.02-3.51) 0.04 
Baseline DAS28 0.74 (0.61-0.91) 0.003 
 
 
 
 
 
Table 6. Adjusted (for age and sex) univariate and multivariate logistic 
regression analysis with EULAR good response at 6 months as dependent 
variable and several baseline disease and treatment characteristics as 
independent variables. .  
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4.1.2 Paper II 
In this study 2265 RA patients who started treatment with rituximab were 
included. The majority, 1195 patients, received concomitant methotrexate, while 
177 were treated with with rituximab plus leflunomide and 505 with rituximab 
alone. The mean dose (±SD) of methotrexate was 14.4±5.4 mg a week. The 
majority of patients on rituximab plus leflunomide (95.1%) were treated with 20 
mg leflunomide a day (mean±SD daily dosage 17.6±3.6 mg). Patients on 
rituximab plus leflunomide achieved a greater reduction in disease activity score 
in 28 joints (DAS28) values from baseline to the 6 and 12-month assessments 
compared with rituximab plus methotrexate and rituximab alone.  Significantly 
more patients achieved a EULAR good response at 6 and 12 months when 
treated with rituximab plus leflunomide compared with rituximab plus 
methotrexate and rituximab alone (figure 13). Additionally, fewer patients in the 
leflunomide group required retreatment during the observational period. No 
difference in the reported rate of adverse events was observed across the 
treatment groups.  
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Figure 13. Effectiveness of RTX+MTX, RTX+LEF and RTX monotherapy 
based on EULAR response at 6 and 12 months.   
  47 
4.1.3 Paper III 
The total number of patients who fulfilled the inclusion criteria for this study was 
2873. The vast majority (91.4%) received treatment with the approved dose 
rituximab, namely 1000mg x 2, while a small number of patients (248) received 
a lower dose of 500mg x 2. These two groups were not balanced for baseline 
characteristics. Patients treated with the lower dose regimen were older, had 
longer disease duration, a lower number of prior biologic DMARDs and lower 
baseline DAS28.  
After adjustment for age, sex, disease duration, number of prior biologics, 
baseline DAS28, concomitant DMARDs and glucocorticoids, the mean 
DeltaDAS28 at 3 months was greater for the higher dose of rituximab, but at 6 
months the difference disappeared and the mean DeltaDAS28 was similar 
between the two different RTX doses. Similarly, no difference was observed 
regarding EULAR responses and proportion of patients on remission between 
the groups. Effectiveness outcomes in TNFi-naïve RTX treated patients and in 
those who received rituximab after the failure of at least one TNFi did not differ 
significantly between the two treatment groups (table 7). 
 
4.1.4 Paper IV 
Analysis of repeated retreatments 
777 patients received at least 4 cycles of rituximab during the observational 
period. Of those 81.6% were female, 83.8% were RF positive and 78.1% were 
anti-CCP positive. The mean ± SD age was 55.7 ± 12.1 years and median 
disease duration 11 years (IQR=6-18). Patients had failed a mean of 3.0 
(SD=1.6) prior synthetic DMARDs and 1.3 (SD=1.1) prior biological DMARDs. 
Mean baseline (=time of 1
st
 rituximab cycle) DAS28-ESR and HAQ was 5.7 
(SD=1.4) and 1.6 (SD=0.7), respectively. The majority (80.3%) of all patients 
received concomitant synthetic DMARD treatment, while 66% received 
concomitant glucocorticoids.  
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Table 7. Effectiveness of two doses of RTX (500mg x 2 and 1000mg x 2) for 
TNFi-naïve RA patients and for those who have previously failed treatment with 
TNFi.   
 anti-TNF naive anti-TNF failure 
 500mg x 2 1000mg x 2 p-value 500mg x 
2 
1000mg x 
2 
p-value 
Baseline DAS28 5.4±1.4 5.9±1.4 0.008 6.0±1.2 6.0±1.3 NS 
DAS28 3 months 4.4±1.3 4.3±1.3 NS 4.3±1.1 4.2±1.3 NS 
DAS28 6 months 4.1±1.3 4.3±1.2 NS 4.3±1.4 4.1±1.3 NS 
DeltaDAS28 3 
months 
0.9±1.3 1.6±1.5 0.08* 1.7±1.1 2.0±13 0.08 
DeltaDAS28 6 
months 
1.4±1.3 1.8±1.4 NS 1.9±1.6 2.2±1.4 NS 
EULAR Good 
Response 
18.6% 14.7% NS 19.4% 23.0% NS 
EULAR 
Moderate 
Response 
62.8% 70.4% NS 62.9% 64.7% NS 
EULAR No 
Response 
18.6% 15.0% NS 17.7% 12.4% NS 
Remission 
(DAS28<2.6) 
14.0% 8.8% NS 9.7% 13.7% NS 
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By using mixed effect models analysis we observed significant further DAS28 
decline with each treatment cycle. Comparison between curves revealed 
significant difference between all cycles. The percentage of patients in remission 
and with EULAR good response was higher at the beginning of every cycle 
compared to the previous one. These findings suggest that for patients that 
continue with rituximab a further improvement in clinical assessments can be 
expected and support multiple treatments with rituximab.  
Retreat on-flare or before a flare (fixed)? 
A total of 800 patients were retreated at least 2 times and the reason for 
retreatment was stated: for 616 of them the reason was flare (442 at 1
st
 and 174 
at 2
nd
 retreatment) and for 184 of them it was a fixed retreatment (128 at 1
st
 and 
56 at 2
nd
 retreatment). Patients receiving fixed retreatment had a significantly 
higher (in absolute number) DeltaDAS28 (p<0.0001) at the start of each cycle, 
compared to those retreated on-flare (figure 14). In the adjusted mixed model 
analysis, we compared the two retreatment groups for the 1
st
 and the 2
nd
 
retreatment separately using estimated marginal means.  
Figure 14. DeltaDAS28(ESR) at the start of each retreatment from 
baseline DAS28 (start of 1
st
 cycle with RTX) for patients treated in a 
fixed schedule and those treated on-flare.  
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4.2 PAPERS V-VIII: ASPECTS OF TNF INHIBITOR USE IN 
RHEUMATOID ARTHRITIS: SWITCHING, CYCLING AND 
DISCONTINUING  
4.2.1 Paper V 
 
For this analysis we identified patients from ARTIS register who switched 
within 2 months to a second TNFi after the failure of a 1
st
 TNF. After applying 
the inclusion criteria 952 patients were identified and included in the analysis. 
Regarding the effectiveness in the total groups of patients, significant 
reductions in DAS28 were observed for all 3 TNFis at 6 months: ΔDAS28 0–6 
months=−1.1±1.5 [n=38] for INF, −1.4±1.6 [n=275] for ETA and −0.8±1.5 
[n=244] for ADA. The inter-drug difference was statistically significant 
between ETA and ADA (p<0.0001). After adjustment for baseline DAS28, this 
difference remained significant (p=0.04). The percentage of patients who 
achieved ΔDAS28≥1.2 was also significantly higher for ETA compared to 
ADA. When the effectiveness of switching was assessed as a function of the 1
st
 
TNFi, overall better results were observed when patients were switched from a 
monoclonal antibody (adalimumab or infliximab) to etanercept while worse 
results were observed for those switching from etanercept to adalimumab.  
When the reason for discontinuation of the 1
st
 TNFi was taken into 
consideration, better results (rate of low disease activity/remission) at 6 months 
were observed with the 2
nd
 TNFi when the reason for switch was loss of 
efficacy or intolerance. The best responses were observed when switching to 
ETA after losing efficacy of ADA or INF as the 1
st
 TNFi (table 8). 
 
During the first 24 months after switching to the 2
nd
 TNFi, 567 patients (60%) 
discontinued their second TNFi: 46 out of 74 in the INF group (62%), 257 out 
of 448 (57%) in the ETA group and 264 out of 430 (61%) in the ADA group. 
The median (95% CI) survival time for INF, ETA and ADA was 14 (7–21), 24 
(16–32) and 16 (9–23) months, respectively. Significant differences were 
observed in drug-survival between infliximab and the other two TNFis.  
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 Primary inefficacy 
 INF  
ETA 
N=65 
INF  
ADA 
N=15 
ETA  
INF 
N=18 
ETA  
ADA 
N=115 
ADA  
INF 
N=5 
ADA  
ETA 
N=68 
DAS28 baseline 5.7±1.2 
[52] 
5.6±0.7 
[11] 
5.3±1.2 
[15] 
5.1±1.3 
[92] 
4.9±2.1 
[3] 
5.2±1.1 
[57] 
DAS28 6 months  4.3±1.5 
[52] 
4.5±1.2 
[10] 
4.0±1.2 
[13] 
4.3±1.5 
[82] 
3.9±2.0 
[4] 
3.9±1.5 
[47] 
DeltaDAS28 6 
months* 
-1.7±1.5 
[43] 
-1.3±1.3 
[8] 
-1.1±1.3 
[11] 
-0.7±1.3 
[71] 
-0.6±0.7 
[2] 
-1.3±1.5 
[42] 
 
Secondary inefficacy 
 INF  
ETA 
N=90 
INF  
ADA 
N=42 
ETA  
INF 
N=22 
ETA  
ADA 
N=101 
ADA  
INF 
N=7 
ADA  
ETA 
N=75 
DAS28 baseline 5.2±1.3 
[76] 
5.2±1.3 
[32] 
4.9±1.0 
[16] 
4.7±1.3 
[78] 
5.0±1.6 
[7] 
5.0±1.1 
[67] 
DAS28 6 months  3.5±1.5 
[70] 
3.3±1.4 
[25] 
3.2±1.7 
[15] 
4.0±1.5 
[71] 
2.9±0.3 
[3] 
3.7±1.5 
[53] 
DeltaDAS28 6 
months** 
-1.7±1.5 
[59] 
-1.3±1.6 
[17] 
-1.6±1.2 
[11] 
-0.9±1.6 
[62] 
-0.5±0.6 
[3] 
-1.4±1.6 
[50] 
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Intolerance 
 INF  
ETA 
N=57 
INF  
ADA 
N=23 
ETA  
INF 
N=5 
ETA  
ADA 
N=51 
ADA  
INF 
N=2 
ADA  
ETA 
N=30 
DAS28 baseline* 5.1±1.7 
[47] 
4.0±1.6 
[18] 
4.9±1.5 
[5] 
4.6±1.4 
[38] 
4.1±2.0 
[2] 
4.9±1.6 
[23] 
DAS28 6 months 
** 
3.8±1.6 
[36] 
3.0±1.9 
[17] 
4.2 [1] 
3.6±1.4 
[33] 
2.9±0.3 
[2] 
4.2±1.7 
[21] 
DeltaDAS28 6 
months*** 
-1.5±1.5 
[32] 
-1.0±2.2 
[14] 
-1.5 [1] 
-0.9±1.4 
[27] 
-1.3±1.7 
[2] 
-0.7±1.8 
[18] 
 
Other 
 INF  
ETA 
N=30 
INF  
ADA 
N=21 
ETA  
INF 
N=13 
ETA  
ADA 
N=58 
ADA  
INF 
N=2 
ADA  
ETA 
N=31 
DAS28 baseline* 4.8±1.7 
[22] 
4.0±1.3 
[17] 
4.9±1.7 
[9] 
4.0±1.5 
[46] 
4.8±0.9 
[2] 
4.2±1.3 
[27] 
DAS28 6 months 
** 
3.5±1.1 
[20] 
2.8±0.6 
[12] 
4.1±1.5 
[9] 
3.7±1.2 
[37] 
5.9 [1] 
3.6±1.2 
[18] 
DeltaDAS28 6 
months*** 
-1.5±1.5 
[14] 
-1.2±0.9 
[9] 
-0.7±2.4 
[7] 
-0.3±1.7 
[34] 
0.5 [1] 
-0.2±1.4 
[14] 
 
 
 
 
Table 8. Effectiveness of switching split by type of 1
st
 TNFi and reason for 
discontinuation of 1
st
 TNFi  
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4.2.2 Paper VI 
We identified 259 patients who switched to a 2
nd
 TNFi and 69 who switched to 
RTX after the failure of a 1
st
 TNFi. Both treatments yielded significant results 
during the first 6 months of therapy. The mean (SD) DAS28 improvement was 
significantly lower for infliximab and adalimumab (group of TNFi monoclonal 
antibodies) compared to RTX and etanercept. The difference remained 
statistically significant after adjustment for baseline differences (age, RF, 
baseline DAS28, HAQ). When the effectiveness of switch was examined as a 
function of the type of the 1
st
 TNFi, we observed significantly greater EULAR 
Good response rate for RTX (36.9%) compared to mAb (11.1%) (p= 0.001) 
after the failure of etanercept. After the failure of mAb, RTX and ETA yielded 
similar EULAR Good/Moderate response rates (no statistical difference was 
observed) that were numerically higher than mAb (figure 15). 
 
 
 
 
 
 
When the cause for switching was intolerance, RTX achieved significantly 
greater improvement in DAS28 (p=0.02, 95% CI 0.08–0.89) and significantly 
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Figure 15. EULAR responses at 6 months for patients switching to 
RTX or a TNFi (ETA or mAb) after the failure of a 1
st
 TNFi according 
to the type of the 1
st
 TNFi.  
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greater EULAR Good/Moderate response rates (p=0.04) compared to anti-TNF 
mAb. When the cause for switching was ineffectiveness, the improvement in 
DAS28 was similar for RTX, ETA, and mAb. The EULAR Good/Moderate 
responders were 60, 70, and 40.4% for RTX, ETA, and mAb, respectively 
(p=0.05 between RTX and mAb, p= 0.02 between mAb and ETA). The 
number of patients however was quite small to draw any safe conclusions.  
 
4.2.3 Paper VII 
During the period 01 October 2009 – 31 June 2013, 945 patients with a diagnosis 
of RA who started treatment with certolizumab pegol were identified and 
selected. 540 patients (57.1%) received certolizumab as 1
st
 biologic treatment, 
215 patients (23%) had tested 1 previous TNFi and 190 (20%) had tested at least 
2 TNFis. Patients who had failed at least 2 prior TNFis had significantly longer 
disease duration, higher disease activity and more functional disability at 
baseline compared to TNFi-naïve patients. Out of 753 patients with available 
DAS28 information at baseline, 292 (39%) had high disease activity 
(DAS28>5.1) while 461 (61%) had non-high activity in their disease 
(DAS28≤5.1). The proportion of patients in remission at 6 months for patients 
with 0, 1 and ≥2 prior TNFis was 42%, 26% and 18%, respectively (the 
difference being strongly significant between all three groups, p<0.0001), (figure 
16). Overall 38%/33%/29% achieved EULAR good/moderate/no response at 6 
months from baseline. The proportion of EULAR good responders was 
significantly greater for patients with 0 prior TNFis compared to those with 1 
and ≥2 prior TNFis at 3 and 6 months. At 6 months patients with high disease 
activity at baseline achieved significantly greater DeltaDAS28 compared to 
those with non-high disease activity at baseline, but patients with non-high 
disease activity achieved remission to a significantly greater extent compared to 
those with high disease activity initially (43% vs. 21%, p<0.0001). EULAR 
Good response rates were similar between the two groups (39% and 36%, 
p=0.6).   
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Figure 16. Proportion of patients in DAS28 disease activity state (high, 
moderate, low and remission) at baseline, 3 and 6 months for RA patients treated 
with certolizumab pegol according to the number of prior TNFis used (0, 1 or 
≥2).  
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4.2.4 Paper VIII 
A total of 237 patients with adalimumab + methotrexate were screened. Only 
33 patients were eligible and included in the study, 17 were randomized to arm 
AM and 16 to arm M. One patient was excluded in each arm due to protocol 
violation.  
At week 28 the vast majority of patients in AM group were still on remission 
(15/16) while only 1/3 of patients in M group were on remission (5/15), 
(p=0.001). The proportion of patients with at least one flare during the first 28 
weeks was 50% (8/8) in AM group and 80% (12/15) in M group (p=0.08). 
Interestingly, analysis on the subgroups of flares showed significant difference 
in the proportion of patients with at least one ΔDAS28>1.2 but no difference in 
the proportion of patients with at least one DAS28≥2.6 (p=0.2). When different 
definitions of flare were tested the difference between AM and M group 
became clearer.  
Patients who flared had longer disease duration and started treatment with 
ADA later than those who did not flare in both M and AM groups during the 
study period. There was also a tendency for lower baseline DAS28 in the non-
flared patients. A total of 9 patients entered the rescue arm during the first 28 
weeks. Remission was restored in 8 of them within 12 weeks (the one patient 
achieved again remission at the end, DAS28=2.5 at the observational follow-up 
visit). No unexpected safety signals were reported after reinstitution of ADA. 
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5 DISCUSSION 
5.1 PAPERS I-IV 
All about rituximab - Interpretation of findings 
The four studies provided new information about the every-day use of rituximab 
in RA. In the first study the clinical effectiveness of RTX during the first 6 
months after a first treatment course was confirmed in a real-life setting and was 
in agreement with the RCTs.  
Several previous studies have indicated that RF seropositivity is a predictor of 
response to treatment, which is expected since patients with RA most likely to 
respond to treatment with RTX are those in whom B cells play a more important 
role in the pathogenesis of their disease. Such patients could potentially be 
identified by analyses of serum autoantibodies, including RF and anti-CCP. The 
study confirmed this observation, as significantly better results were seen after 6 
months for RF-positive patients than for RF-negative patients, but also for anti-
CCP-positive versus negative individuals and double-positive versus double-
negative subjects. Based on figure 17,  four interesting observations could be 
made  which concluded the efficacy of rituximab with regard to RF and anti-
CCP status.  
1) Seropositive patients achieved generally significantly better results 
compared to seronegative patients (same trend for RF positive vs. RF 
negative, anti-CCP positive vs. anti-CCP negative and double 
seropositive vs. double seronegative). That was also confirmed in the 
multivariate logistic regression analysis. 
2) The difference between autoantibody positive vs. negative was more 
striking at 3 months than 6 months. There are two possible 
explanations:the difference might indeed decline, suggesting that 
seropositive patients respond quicker than seronegative, but the latter 
group continue to improve from 3 to 6 months in a slower rate. However, 
one should not forget that this is an observational study and the risk for 
selection bias is present. There is a possibility that only those 
seronegative patients who show some response at 3 months will continue 
at 6 months (the number of observations is lower at 6 compared to 3 
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Figure 17. Mean DeltaDAS28 (bars: SEM) during the first 6 months of therapy 
with rituximab for seropositive and seronegative patients according to RF and 
anti-CCP status.  
months) while those who do not respond adequately will ‘discontinue’ 
treatment. It is however common in the clinical practice to wait at least 6 
months to assess the treatment effectiveness, so it is less likely that a 
patient will start another treatment before the 6 month visit.  
3) Seronegative patients also showed significant improvement both at 3 and 
at 6 months. Immunologically this is explainable, as B cells are not only 
antibody producing cells, but also, as it is explained in detail in the 
introduction, also potent antigen-presenting cells and even responsible 
for cytokine production. In a seronegative population it might be these 
aspects of B cells that are affected. This could perhaps support the 
hypothesis of a ‘slower effect’ of rituximab in seronegative patients. 
Finally, what we call seronegative might not be really seronegative, as 
there can be autoantibodies that we do not screen for or even unknown 
autoantibodies today.  
4) The difference seems to be more striking in the anti-CCP group between 
positive and negative patients compared to the RF group. This 
observation suggest that anti-CCP might be a stronger predictor of 
response to rituximab treatment compared to RF. The results of the 
multivariate logistic regression analysis supported this finding.  
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The off-label use of rituximab as first biologic DMARD, before a TNFi, appears 
to be highly effective in RA, as it was also shown in RCTs. In this study is was 
shown that the earlier rituximab is introduced the better the results, with the 
mean DAS28 reductions to be significantly greater in patients with 0 or 1 prior 
TNFis compared to those who had already failed to or more TNFis. This was 
independent of other possible confounders, such as anti-CCP and baseline 
disease activity. This observation however is not unique for rituximab. Several 
studies, including the study VII in this thesis, have shown that effectiveness is 
declining parallel with the number of biologic agents used. Risk for selection 
bias is present in this observation, since patients with more difficult to treat 
disease or intolerance are more likely to change more than two biologic agents. 
At the time of initiation of the second or the third biologic most of them will 
have a long disease activity, perhaps with high level of functional disability 
because of chronic damage, which can negatively affect the response to the 
response to the biologic agent. The main conclusion that can be drawn from this 
analysis is that rituximab can be used with good results in biologic naïve 
patients, especially those with contraindications for TNFis. I would also 
personally choose to treat some seropositive patients with rituximab directly 
after the failure of a synthetic DMARDs, an approach closer to the 
‘individualized’ and ‘targeted’ treatment terms. Seropositivity and response to 
rituximab is after all the stronger predictor of good response to treatment with a 
biologic agent today.  
Other studies have found similar results regarding seropositivity and number of 
prior biologic DMARDs used before rituximab
100-102
. Results from RCTs also 
support the higher efficacy of rituximab in the seropositive population. In the 
REFLEX trial protection from joint damage was only evident in the seropositive 
patients
70
. Other predictors of response to rituximab that we did not had the 
possibility to examine in the CERERRA cohort are the degree of B-cell 
depletion
50
, the Fcγ receptor type IIIA polymorphism103, heterozygosis for 
FCGR3A genotype
104
, and several others.  
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Regarding the combination of rituximab with conventional DMARDs, the results 
of the second study suggest that leflunomide is at least as effective as 
methotrexate, if not better. This has important clinical implications, since a 
significant number of patients do not tolerate methotrexate. Leflunomide has a 
different safety profile than methotrexate and can be a very good alternative as 
monotherapy but also as a concomitant DMARD in the treatment with TNFi and 
rituximab. From an immunological aspect, the observation that leflunomide 
would lead to greater improvement in disease activity compared to methotrexate 
raised thoughts about a potential synergistic mechanism between leflunomide 
and rituximab. Indeed, there are studies from the hematology field that have 
shown that leflunomide has an impact on B-cell proliferation and cell cycle 
progression, thus suppressing antibody responses
105,106
. On the contrary, neither 
methotrexate nor TNFis were able to decrease the frequency of autoreactive B-
cell clones. Some other studies have supported our findings
107
. 
Another interesting observation regarding concomitant treatment with 
conventional DMARDs was that no significant difference was observed between 
the RTX+MTX and RTX monotherapy groups. A small study found earlier 
similar results. Almost all RCTs though assessed the efficacy of rituximab in 
combination with methotrexate, except for one study where rituximab 
monotherapy was associated with significant ACR20 and ACR50 responses 
compared to placebo group (methotrexate monotherapy) but not for ACR70
108
. 
These results and our results suggest that when the combination with a 
conventional DMARD is not possible because of contraindications or intolerance 
rituximab can be considered as monotherapy.  
Hitherto there have been no proper dose-response studies for rituximab in RA. 
What is considered the “autoimmune dose and protocol” was developed by Prof 
Jo Edwards based on a small number of patients
109
. Our study provides some 
additional evidence about the lack of any striking difference and perhaps no 
clinically significant difference between two different doses of rituximab used in 
clinical practice. This finding is consistent with those from the DANCER and 
SERENE trials
110,111
. In the MIRROR trial the percentage of EULAR 
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Good/Moderate response was borderline significantly higher in the 1000mg x 2 
(89%) compared to the 500mg x 2 group (73%) (p=0.05)
112
. The overall 
conclusions of the MIRROR trial was that the two rituximab doses could not be 
clearly differentiated, although some clinical outcomes were in favor of the 
higher dose. MTX-naïve patients in the IMAGE trial responded equally well to 
both doses, but only the higher dose of rituximab was proven effective in 
inhibiting progression of joint damage
113
. Despite the fact that the clinical 
significance of this small difference observed can be discussed, it raises an 
important aspect of biologic treatment, and that is the ability to inhibit 
radiographic progression. Unfortunately radiological data have not been 
collected in the CERERRA cohort and thus it was not possible to examine the 
ability of the two different dosing regimens to inhibit joint destruction in clinical 
practice. A recent meta-analysis on four RCTs did not demonstrate a significant 
difference in the clinical responses between the high- and low-dose rituximab 
regimens
114
. 
A study from UK has shown that response to rituximab may be more dependent 
on the level of B-cell depletion, assessed by highly sensitive flow cytometry, 
rather than the dose. In that study complete depletion of B-cells was seen in both 
500mg x 2 and 1000mg x 2 groups and it correlated better with response that the 
dose itself 
115
. This might lead to a more individualized approach, which will 
able to predict which patients could response to a lower dose rituximab.  
Another important clinical aspect of rituximab treatment is the number and time 
of retreatment. This remains unclear today. Our study supports the effectiveness 
of multiple treatment cycles. It is important to know that disease activity can 
further improve with each additional treatment cycle, especially for patients with 
partial response. The ultimate goal of RA treatment today is after all remission, 
so it is important to follow a ‘treat to target’ approach. Several studies hitherto 
support a fixed retreatment strategy, before a patient flares
112,116,117
. The risk with 
a fixed retreatment schedule is the ‘overtreatment’ of a proportion of patients 
that can achieve long-standing response after the first treatment cycle without 
needing retreatment. This subgroup of patients is however quite small, 
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approximately 10% of all rituximab treated patients. It is important to better 
define this subgroup in order to differentiate it from the rest of RA patients who 
will need repeated retreatments with rituximab.  
 
Strengths and limitations 
Significant strengths of these studies were: 
- The large number of patients included. The total number of RTX 
treated patients in the last datacut was over 4000, which makes it the 
largest RTX cohort today. This enables us to perform specific analyses 
on subsets and subgroups that would not be possible with a smaller 
cohort, such as the leflunomide + rituximab, the 500mg x 2 and  the 
multiple retreatment subgroups.  
 
- The real-life character of the cohort. Here I would like to introduce a 
certain terms, the internal validity and external validity. While 
randomized clinical trials are usually characterized by good internal 
validity, meaning the accuracy of  the conclusions about the 
intervention’s effect, the gerenezability of the results to the general 
population can be problematic. Clinical trials have often strict inclusion 
and exclusion criteria, which does not reflect reality. A study showed that 
only a minor proportion of patients in a real-life register would have been 
eligible for the major clinical trials. Comorbidities, intolerance to 
investigational co-medications, previous treatments are some examples 
of exclusion criteria for clinical trials often seen in RA patients in the 
clinic. A major difference between patients included in clinical trials and 
‘real-life’ RA patients is the level of disease activity at the time of 
intitiation of a biologic agent. While most RCTs demand high disease 
activity as inclusion criterion, most RA patients in clinical practice have 
a DAS28 less that 5.1, that means non-high disease activity. As it was 
shown in paper I, 27% of patients did not have high disease activity when 
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they started rituximab. For the above reasons, register-based 
observational studies that examine the effectiveness of treatments have a 
good external validity, and their results are easily generalizable.  
 
- The international character of the CERERRA cohort allowed the 
comparison of different populations, with different treatment protocolls 
and rutines. The off-label treatment of rituximab as first biologic was 
observed in more that one-third of patients. In Russia rituximab was the 
only biologic agent used for many years, and that influenced the results. 
However, around 20-30% of all patients in the other participating 
counties also received rituximab as first biologic agents. The main reason 
for that was comorbidities (tuberculosis, past or current malignancies 
including hematological malignancies).  
Limitations of these studies include: 
- The significant heterogeneity between countries. There were 
differences in laboratory methods for determining RF and anti-CCP 
status. Additionally there were significant differences in baseline 
characteristics, such as disease activity status. Some of  these differences 
of course achieved a statistical lever of significance mainly because of 
the large number of observations, withou t being clinically significant. 
We tried to partially overcome this problem by adljusting for country in 
the regression analysis. In paper IV country was included in the mixed 
model analysis as random variable, in order to take into consideration the 
variability between countries.  
 
- The observational and non-controlled character of the studies 
introduces risk for several biases. In paper II  patients treated with 
leflunomide had most like previously not tolerated methotrexate or had 
contraindications for methotrexate, which can result in confounding by 
indication or selection bias. Confounding by indication would however 
most likely bias the results towards the null, as leflunomide is often 
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prescribed to more difficult patients. Similarly, in paper III we identified 
a  risk for channeling bias, as patients treated with the lower dose were 
older, had higher disease duration, lower disease activity at baseline and 
lower number of prior biologics and were more often treated with 
corticosteroids and less often with concomitant DMARDs. The lower 
dose group may therefore represent a population of patients with more 
comorbidities, for whom the treating rheumatologist chose the lower 
dose of RTX. However, such a population would be more prone to have 
a worse response to therapy, and therefore confounding by indication 
would bias the results against the lower dose RTX. Although several 
analyses were adjusted for differences between groups under 
comparison, the risk for residual confounding or confounding by 
unmeasured factors was present.   
 
-  Some of the improvement in effectiveness can be explained by 
regression to the mean and placebo effect. This however does not 
differ from RCTs.  
 
- Missing data is always a concern in register-based studies and an 
important limitation. For most of the analysis missingness was not 
informative, meaning that the level of missing data was the same for 
subgroups. This is important as one of the reason for missing information 
might be because of discontinuation of treatment. In contrast to other 
biologic agents, the definition of discontinuation for rituximab is more 
complex. Higher rate of missing data in a particular subgoup might 
indicate higher rate of discontinuation and thus worse response to 
treatment or even higher rate of infections.  
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5.2 PAPERS V-VIII 
Interpretation of findings 
To switch or not to switch? True inter-drug differences? 
One of the main findings of the fifth study is that switching to a second TNFi 
may lead to significant clinical improvements. Almost 40% of patients 
achieved low disease activity or remission, regardless of the specific TNFi. So 
switching does make sense, which is very important for both treating 
rheumatologists and patients.  
Some differences were observed between TNFis. Etanercept was associated 
with better results compared to adalimumab. Baseline disease activity was 
significantly higher for those starting etanercept as their second TNFi than 
adalimumab, which (under the assumption that the capacity for DAS28 
reduction is non-linear, or simply through regression to the mean) might 
explain the greater improvement in DAS28 for etanercept as second TNFi 
compared with adalimumab. To exclude effect modification we stratified by 
baseline disease activity and we observed overall greater reductions in DAS28 
among those patients with a disease activity score above 5.1 at the time point 
of the second TNFi start than in the non-high disease activity group, but, as 
expected, a higher percentage of patients achieving low disease 
activity/remission in the latter. Etanercept achieved numerically but not 
significantly better improvements than adalimumab, which might represent a 
true effect but also reflect limited statistical precision. The difference was not 
large enough to assure a true clinical difference. 
Confounding by indication may be responsible for some of the previously 
observed differences in drug survival between ETA and ADA/INF as first 
TNFi. In this study, we could limit some of such confounding by indication by 
assessing drug survival on these drugs when used as the second TNFi (hence, 
when patients starting ETA were recruited from a pool of patients who had 
initially all be channeled to treatment with INF or ADA, and vice versa). We 
found some differences in favor of ETA as second TNFi, similar to what has 
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been shown in previous analyses of first TNFi, suggesting that it is more 
possible that these results represent true difference and are not entirely due to 
confounding by indication related to the choice of the first TNFi. The clinical 
relevance of the observed difference is, however, unclear. Other differences 
between TNFis, such as route of administration, have to be taken into account. 
INF is given intravenously, which might influence negatively its retention rate. 
Such factors limit the possibility of comparing these agents using retention 
rates as surrogates for effectiveness.  
Does effectiveness of switching depend on the type of 1
st
 TNFi and the reason 
for switching? 
Overall better results were achieved with the second TNFi after loss of efficacy 
or intolerance to first TNFi than after lack of efficacy of the first TNFi, 
supporting the results from previous studies. This observation is rational and 
supports the hypothesis that for patients who do not respond to TNFi (primary 
inefficacy), TNF might not play that important role in their disease and a 
second TNFi would yield only modest results. When different switching 
strategies were compared, overall better results were observed for patients who 
switched from INF or ADA (monoclonal antibodies) to ETA than the other 
way round. The production of antidrug antibodies, drug immunogenicity, has 
been proposed as one possible mechanism behind inefficacy
118-121
. Secondary 
inefficacy to a first TNFi might be due to development of antidrug antibodies, 
and non-responders in that case might benefit from a switch to a less 
immunogenic drug, such as ETA. A clinical interpretation of this observation 
might be that after the failure of a monoclonal anti-TNF antibody one could 
consider switching to ETA, but when a patient has failed ETA as first TNFi, 
the choice of a monoclonal antibody as second TNFi might not have the same 
potential to lead to a clinically significant improvement. Indeed, other studies 
have shown that in the latter case it might be more beneficial to change to a 
biologic of a different mechanism of action, as it was shown in study number 
VI. Another mechanism that could explain this finding, could be the following: 
as it is known, ETA competitively inhibits the binding of both TNF and 
lymphotoxin-α to cell surface TNF receptors, rendering TNF biologically 
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inactive
122
, while INF and ADA bind and neutralize both soluble and 
membrane-bound TNF but not lymphotoxin. Lymphotoxin plays a crucial role 
in chronic inflammation
123
. Thus, failing a monoclonal antibody (especially 
because of inefficacy) a patient might respond well to ETA, and the reason 
could be the binding of lymphotoxin
124
. This remains, however, a hypothesis. 
 
Switching from a TNFi to another TNFi versus RTX 
The results of study nr VII support partially the results of the study above. In a 
smaller cohort (which was though part of the larger cohort based on the ARTIS 
register) switching to a TNFi mAb after the failure of a mAb was associated 
with worse results, while switching from a mAb to etanercept can yield equally 
good results as switching to a biologic with a different mechanism of action 
such as RTX. However, when patients fail etanercept switching to a mAb was 
associated with poor results, such as in paper V. For these patients RTX is a 
better alternative. A recent study from Spain concluded similar results
76
.  
Regarding the reason for switching, our results were not in agreement with 
previous study, such as the study from Finckh et al, who found better results 
when switching mechanism of action because of ineffectiveness
74
. In our study 
better results with RTX compared to TNFi were observed when the reason for 
discontinuation of the first TNFi was intolerance or secondary ineffectiveness. 
We would however expect to see a difference when patients switch treatment 
because of primary inefficacy, as for patients who do not respond at all to a 
first TNFi, TNF might not play an important role, and switching biologic class 
is preferable. When interpretating our results, one should take into account two 
important things: first, there was a low power because of the limited number of 
patients, so certain differences could not achieve statistical significance; 
second, this was an observational study, and the choice of biologic in clinical 
practice is never random and there is a significant risk for selection bias. More 
patients switched from TNFi to RTX because of intolerance.  
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Some limitations that we have to address for the two switching studies include 
the observational cohort study design (absence of randomization), which can 
introduce the risk for selection bias, the imbalance between treatment groups 
regarding baseline characteristics, the limited number of patients in some of the 
comparisons (lack of power) and missingness.  
The results could be summarized in the algorithm below.  
 
 
 
 
 
 
 
 
 
 
 
 
Certolizumab pegol: did we need one more TNFi? 
In study nr VII, the effectiveness of the newer TNFi certolizumab pegol was 
clearly demonstrated. As shown in study nr V, cycling between TNFis can lead 
to significant clinical outcomes, which is now well established
69,125,126
. In this 
study, patients who were naïve to TNF inhibition achieved significantly greater 
DAS28 reduction at 3 and 6 months from initiation of certolizumab pegol 
ETA mAb 
ETA mAb mAb RTX RTX = > < 
Figure 18. Algorithm about switching to TNFi or RTX after the failure of a 1st 
TNFi.  
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compared to those having failed one and those having failed two or more prior 
TNFis. The proportion of patients in remission and who achieved EULAR good 
response was significantly greater for TNF naïve patients compared to both other 
groups. This finding was expected and is in agreement with previous findings 
from observational studies showing inferior response rates when switching to a 
second or third TNFi
69,126
.  
However, even after the failure of 2 or more TNFis 55% of patients can achieve 
EULAR good or moderate response and around 20% can achieve remission. 
These results are partially in agreement with the results from the REALISTIC 
study, where the efficacy of certolizumab pegol was demonstrated even for 
patients with previous TNFi use, regardless of the number or type of previous 
TNFi used
127
.  
In this study more than half of patients had low or moderate disease activity 
based on DAS28 at the time of certolizumab pegol initiation, reflecting the real-
life character of the cohort. Clinically and statistically significant responses were 
observed regardless of whether the initial disease activity state was high or not. 
Patients with non-high disease activity initially were more likely to achieve 
remission and to continue with the treatment compared to those with high 
activity. These results are in agreement with the CERTAIN trial, where low-
disease activity or remission was reached by the majority of patients who 
received certolizumab pegol and who had predominantly moderate disease 
activity at baseline
128
.  Finally, the use of concomitant DMARDs was associated 
with longer survival-on-drug in the Cox regression analysis. Previous studies 
have shown that concomitant DMARD treatment is associated with better 
response to treatment with TNFis
129
.   
The end: discontinuation of biologic treatment after remission is achieved, 
possible or not? 
The main result of the last study suggested that patients with established RA who 
are in stable remission on adalimumab and methotrexate can rarely maintain 
remission after discontinuation of the TNFi. Discontinuation of adalimumab 
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might be feasible only for a small, but still considerable, fraction of patients, 
around 20%. Reinstitution of the biological agent was not associated with poorer 
results as before discontinuation or with unexpected safety signals. 
The next step is trying to identify these patients. In this relatively small study 
there was a clear trend regarding achievement of ‘biologic-free remission’ and 
early initiation of the TNFi. So the earlier the biologic treatment is introduced 
from the time of RA diagnosis the higher the chance to discontinue the biologic 
agent and remain in remission. Several studies have suggested this association.  
Thus a more aggressive treatment approach in RA might not only lead to better 
clinical, functional and radiographic outcomes, but it could increase the 
possibility to discontinue treatment without deteriorating. The latter would have 
vast implications both for long-term safety but also for health-economics, taking 
into consideration the high cost of the biologic treatment.  
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6 CONCLUSIONS 
 
i. Rituximab is effective in RA in a real-life setting. The effectiveness is 
higher in seropositive patients and in those who have previously failed at 
most one TNFi. Seronegative patients can also respond but perhaps not 
as quick as seropositive patients.  
ii. Leflunomide is an effective and safe alternative to methotrexate as 
concomitant treatment with rituximab. It can yield even better results 
than methotrexate, suggesting a possible synergistic mechanism. 
Monotherapy can also lead to significant clinical results.  
iii. While the approved dose of rituximab in RA is 1000mg x 2 with two 
weeks interval, the lower dose of 500mg x 2 seems to be equally 
effective in reducing disease activity.  
iv. Repeated rituximab cycles can lead to further DAS28 improvement. A 
fixed retreatement strategy yields better results than retreatment ‘on-
flare’.  
v. After the failure of the first TNFi, up to 40% of patients switching to a 
second TNFi may achieve low disease activity or remission. After the 
failure of a monoclonal antibody as first TNFi because of inefficacy, 
switching to etanercept yielded good clinical results, but not the other 
way round. Etanercept was associated with longer drug survival 
compared with infliximab as second TNFi.  
vi. After failure of etanercept as 1st TNFi, swithing to rituximab yields better 
results compared to switching to a monoclonal antibody TNFi.  
vii. The newer TNFi certolizumab pegol is highly effective in real-life RA 
patients, especially for TNFi-naïve patients but even for patients who 
have previously failed TNF inhibition. Co-treatment with synthetic 
DMARDs is assossiated with longer survival-on-drug..  
viii. Discontinuation of TNFi may be feasible in only a minority of patients 
with established RA in stable clinical remission. Earlier initiation of anti-
TNF treatment might increase the chance to biologic-free remission.  
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7 FUTURE PLANS 
Many interesting questions have been raised and are going to be investigated 
further: 
i. Identification and characterisation of a subset of RA patients who 
achieve long-term response after one treatment cycle of rituximab, 
without need for retreatment. 
ii. What is the optimal dose of rituximab at retreatment? 
iii. Does the level of RF and anti-CCP at the time of rituximab start 
influence the response to treatment? 
Several of the findings of the above studies could be tested further in a 
laboratory setting, from ‘bedside to bench’: 
i. Are there specific immunological characteristics of seronegative patients 
who respond well to rituximab?  Are other autoantibodies present?   
ii. Does the combination of rituximab and leflunomide lead to higher degree 
of B-cell depletion?  
iii. Is the degree of B-cell depletion both in the periphery and in synovium 
similar for the two different doses of RTX?  
Other findings could be examined for confirmation in a different setting, for 
example in a pragmatic clinical trial 
i. Assessment of the efficacy and safety of the higher and lower dose RTX, 
and its effect on radiographic progression, both at the first treatment cycle and 
on retreatment. 
ii. Assessment of different switching strategies (randomization important to 
exclude risk for confounding by indication). Does the presence of neutralizing 
anti-drug antibodies influence the result of switching? 
iii. Is the earlier introduction of a TNFi associated with greater chance to 
achieve biologic-free remission? Is there any difference between TNFis? 
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 ABSTRACT  
 Objective  To assess the 6-month effectiveness of the 
fi rst rituximab (RTX) course in rheumatoid arthritis (RA) 
and to identify possible predictors of response. 
 Method  10 European registries submitted anonymised 
datasets (baseline, 3- and 6-month follow-up) from 
patients with RA who had started RTX, and datasets 
were pooled and analysed. Heterogeneity between 
countries was analysed by analysis of variance. Predictors 
of response were identifi ed by logistic regression. 
 Results  2019 patients were included (mean age/disease 
duration 53.8/12.1 years, 80.3% female, 85.6% rheumatoid 
factor (RF) positive and 76.8% (456/594 patients) anti-
cyclic citrullinated peptide antibodies (anti-CCP) positive). 
For these patients an average of 2.7 disease-modifying 
antirheumatic drugs (DMARDs) (range 0–10) had failed, 
and RTX was given as the fi rst biological agent in 36.6% 
of patients. There was signifi cant heterogeneity between 
countries for several baseline characteristics, including 
the number of previous biological agents. Disease Activity 
Score based on 28 joint counts (DAS28) decreased from 
5.8±1.4 at baseline to 4.2±1.4 at 6 months (p<0.0001) 
and 22.2%/42.5% achieved European League Against 
Rheumatism (EULAR) good/moderate response. Larger 
6-month improvement in DAS28 was observed in 
RF-positive and anti-CCP-positive versus seronegative 
patients. The following predictors of EULAR good response 
at 6 months were identifi ed in a multivariate analysis: anti-
CCP positivity (OR=2.86, p=0.003), number of previous 
DMARDs (OR=0.84, p=0.06), ≤1 previous biological 
agents (OR=1.89, p=0.04), baseline DAS28 level 
(OR=0.74, p=0.003). 
 Conclusion  In this large observational cohort of patients 
with RA treated with RTX, seropositive patients achieved 
signifi cantly greater reductions in DAS28 at 6 months 
than seronegative patients. Effectiveness was best when 
RTX was used as the fi rst biological agent or after failure 
of no more than one anti-tumour necrosis factor agent. 
 INTRODUCTION 
 Rituximab (RTX) (Mabthera, Rituxan), a mono-
clonal antibody which selectively targets CD20-
positive B cells, has been approved for the treatment 
of rheumatoid arthritis (RA) in many countries. 
With the standard approved dosage, a single course 
of two 1000 mg infusions given 2 weeks apart, a 
majority of patients in clinical trials exhibited an 
ACR20 (American College of Rheumatology 20% 
improvement) response and a similar proportion 
a European League Against Rheumatism (EULAR) 
moderate response. 1 This beneﬁ cial effect has been 
demonstrated in patients naive to anti-tumour 
necrosis factor (anti-TNF) treatment as well as in 
patients for whom previous anti-TNF treatment 
has failed. 1  2 Re-treatment after variable intervals 
of 6–12 months has been shown to be effective 
when a relapse occurred. 3  4 Thus, when treatment 
with an anti-TNF agent has failed, RTX is now an 
approved and logical treatment option. Given the 
rapid evolution in the ﬁ eld of biological disease-
modifying antirheumatic drugs (DMARDs), there 
are several treatment alternatives for patients for 
whom one TNF inhibitor has failed—for exam-
ple, alternative TNF inhibitors, interleukin 1 and 
interleukin 6 inhibitors and a modulator of T cell 
costimulation. 5 – 10 For this reason, a major challenge 
is to identify predictors of response, based on clini-
cal, demographic, immunological or genetic data, 
for a more personalised treatment approach. 11 
 Controlled clinical trials are the major source 
of information on efﬁ cacy and safety of drugs 
under experimental conditions. However, patients 
included in these studies do not always represent 
patients in clinical practice owing to strict inclu-
sion and exclusion criteria. Furthermore, the more 
complex questions that govern clinical decision-
making can rarely be considered adequately using 
randomised trials. In such instances longitudinal 
observational studies may provide useful informa-
tion and more reliable answers to speciﬁ c ques-
tions about the use of DMARDs in clinical practice. 
Real-life effectiveness data on RTX in RA may be 
particularly relevant, taking into account questions 
that have been raised about optimal dosing, co-
medication and efﬁ cacy in seropositive versus sero-
negative patients. 
 During the past year we have initiated a European 
collaboration between registries from 10 different 
European countries, the European Collaborative 
Registries for the Evaluation of Rituximab in rheu-
matoid arthritis (CERERRA) initiative. The aim of 
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this study is to present baseline characteristics of patients with 
RA treated with RTX, analyse 6-month effectiveness and iden-
tify possible predictors of response. 
 PATIENTS AND METHODS 
 The CERERRA is an investigator-led, industry-supported initia-
tive aiming to evaluate clinical aspects of RTX use in patients 
with RA. This manuscript was prepared from the authors 
without any inﬂ uence by the supporting medical industry. All 
10 participating European registries (from the Czech Republic, 
Denmark, Finland, The Netherlands, Norway, Russia, Slovenia, 
Spain, Sweden and Switzerland) submitted fully anonymised 
datasets with baseline characteristics, including age, gender, 
disease duration, number of previous synthetic and biologi-
cal DMARDs, rheumatoid factor (RF) and anti-cyclic citrulli-
nated peptide antibodies (anti-CCP) status of all patients with 
an established diagnosis of RA who had been treated with 
RTX. 12 – 20 Levels of RF and anti-CCP were determined by local 
laboratories and local cut-off values for positivity were applied. 
Disease activity markers at baseline and after 3 and 6 months 
were also provided (number of swollen and tender joints, Visual 
Analogue Scales for pain, patient’s and physician’s global assess-
ment, Disease Activity Score based on 28 joint counts (DAS28), 
Health Assessment Questionnaire) as well as information about 
concomitant drugs (DMARDs and glucocorticoids). 
 Statistical analysis 
 Appropriate parametric statistical tests were used for the 
analysis of data. All continuous data were examined for nor-
mal distribution by Kolmogorov–Smirnov test. Heterogeneity 
for baseline characteristics between countries was analysed 
by analysis of variance followed by post hoc test (Bonferroni/
Dunn). Clinical response according to reductions in DAS28 and 
achievement of EULAR response criteria was analysed at 3 and 
6 months. A second analysis was performed according to the 
number of previously used biological agents. Patients re-treated 
with RTX before 6 months were classiﬁ ed in the analyses as 
‘non-responders’, regardless of their response according to the 
EULAR criteria. 
 Predictors of EULAR good response were identiﬁ ed by 
logistic regression analyses. We performed univariate logis-
tic regression analyses adjusted for age and sex with EULAR 
good response at 6 months as the dependent variables and 
several demographic and disease variables considered to be 
clinically important as independent variables. The results from 
these analyses (p<0.25 as the criterion) and correlation analy-
ses (Pearson and Spearman correlations) guided the selection 
of variables for the multivariate logistic regression analyses 
with dichotomised responses as the dependent variables. Age 
and sex were also included in the multivariate analyses. The 
non-signiﬁ cant variables were removed by stepwise back-
ward selection. We then added back into the models, one at 
a time, any variable not originally selected from the univariate 
analyses. The variables were kept in the models if signiﬁ cant. 
Appropriate tests for linearity, interactions and goodness of ﬁ t 
were performed. Statistical analyses were done with StatView 
5.0.1 for PC (SAS Institute, Cary, North Carolina, USA) and 
SPSS 15.0 for Windows. 
 RESULTS 
 Baseline characteristics 
 The baseline characteristics for all patients are summarised in 
 table 1 and shown according to country in online supplementary 
table S1. A total of 2019 patients were included with a mean 
(SD) age/disease duration of 53.8 (13.3)/12.1 (8.9) years. There 
was signiﬁ cant heterogeneity between the countries for age and 
disease duration. Patients in the Russian registry had the lowest 
mean age and shortest disease duration. 
 RF positivity was reported in 85.6% of the patients ( table 1 ). Of 
the 594 patients with available data on anti-CCP status, 76.8% 
 Table 1  Baseline characteristics for all patients from the 10 European registries (Russia (Ru), Sweden (Swe), Norway (Nor), Finland (Fin), Denmark 
(Den), Slovenia (Slo), Spain (Sp), The Netherlands (Nth), the Czech Republic (Cz), Switzerland (Switz)) 
 Baseline characteristics of all 
patients (N=2019) 
 Number of patients with 
available information  Mean (SD) or % 
 Test for heterogeneity 
between countries  Signifi cant difference between 
countries (post hoc analyses)  p Value (ANOVA/χ  2  )
Age (years) 1989 53.8 (13.3) <0.0001 Swe higher vs all other countries. 
Ru lower vs all other countries
Gender (% female) 1993 80.3 <0.0001 Ru higher vs Den, NL.
NL higher vs Cz
Disease duration (years) 1888 12.1 (8.9) <0.0001 Ru shorter vs Nor, Swe, Switz, Fin. 
Fin longer vs all countries.
Swe longer vs Den
N previous DMARDs 1525 2.7 (1.6) <0.0001 Switz and Ru lower vs Slo, Nor, NL, 
Den, Cz
N previous biological agents 1844 1.1 (1.1) <0.0001 Ru lower vs all countries.
Cz lower vs Den, Fin, NL, Nor
RF (% positive) 1724 85.6 <0.0001 Cz lower vs all countries.
Switz higher vs Cz, Den, Nor, Ru and NL
Anti-CCP (% positive) 594 76.8 0.01 Fin highest percentage, Den lowest
DAS28 1730 5.8 (1.4) <0.0001 Between almost all countries. Nor highest, 
Fin lowest.
HAQ 843 1.5 (0.7) 0.002 Cz higher vs Fin, Switz
Concomitant corticosteroids (%) 1824 60.9 <0.0001 Cz and Den lower vs Fin, NL, Nor, Ru, Slo, 
Sp, Swe, Switz.
Ru higher vs Slo, Sp, Swe, Switz
Concomitant DMARDs (%) 1920 76.7 <0.0001 NL lower vs all countries.
Switz higher than Swe, Ru, Den
 ANOVA, analysis of variance; anti-CCP, anti-cyclic citrullinated peptide antibodies; DAS28, 28-joint count Disease Activity Score; DMARDs, disease-modifying antirheumatic drugs; 
HAQ, Health Assessment Questionnaire; RF, rheumatoid factor. 
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were positive. The numbers of conﬁ rmed double seropositive 
and double seronegative patients were 372 and 59, respectively. 
RF-positive patients were signiﬁ cantly older than RF-negative 
patients (mean (SD) age 54.9 (13.0) vs 50.3 (14.5), p<0.0001). No 
difference was found between the RF-positive and RF-negative 
subgroups for the number of previous DMARDs and biologi-
cal agents, baseline DAS28, disease duration or concomitant 
DMARDs. Anti-CCP-positive patients had a signiﬁ cantly smaller 
number of previous biological DMARDs than anti-CCP-negative 
patients, but other differences in baseline characteristics were 
not observed between anti-CCP-positive and anti-CCP-negative 
patients. 
 The mean (SD) numbers of previous synthetic and biological 
DMARDs were 2.7 (1.6) and 1.1 (1.1), respectively. Patients in 
the Russian registry had used a signiﬁ cantly smaller number of 
previous biological DMARDs than patients from the other reg-
istries (online supplementary table S1). 
 Information about previous use of biological DMARDs was 
available in 1844 patients. For these patients two or more biolog-
ical agents had previously failed in 596 (32.3%), one agent had 
failed in 574 (31.1%), and 674 (36.6%) patients received RTX 
as their ﬁ rst biological agent. The baseline characteristics strati-
ﬁ ed by number of previous biological agents are summarised in 
online supplementary table S2. 
 Concomitant synthetic DMARDs were used by 76.7% of 
the patients. The majority were co-treated with methotrexate 
(MTX) (64.8%), a small number received combination treat-
ment with MTX and another synthetic DMARD, while a sig-
niﬁ cant number of patients were treated with other DMARDs, 
such as sulfasalazine, azathioprine, ciclosporin, leﬂ unomide, 
 antimalarial agents and also gold salts in a few patients. 
 Treatment responses 
 The mean (SD) DAS28 at baseline was 5.8 (1.4) and decreased 
to 4.3 (1.3) and 4.2 (1.4) at 3- and 6-month assessments, respec-
tively. The majority of patients (73.0%) had high baseline dis-
ease activity (DAS28>5.1) and 21.8% had moderate disease 
activity (DAS28 between 3.2 and 5.1). At 3 months the percent-
age of patients with high disease activity was markedly reduced 
and remained stable at the 6-month assessment ( ﬁ gure 1 ). A cor-
responding increase in the proportions of patients with low dis-
ease activity or in remission was seen ( ﬁ gure 1 ). EULAR good/
moderate responses at 3 months were achieved by 195/483 
out of 1087 patients (17.9%/44.4%) and by 210/402 out of 945 
patients (22.2%/42.5%) after 6 months. DAS28 improvement of 
>1.2 was observed in 62.5% of patients with available ΔDAS28 
at the 6-month follow-up (616/986 patients). 
The subset of RF-positive patients achieved signiﬁ cantly larger 
reductions in DAS28 than the patients who were RF negative 
(95% CI of the difference at 3 months −0.64 to −0.18, at 6 months 
−0.64 to −0.09) ( table 2 and  ﬁ gure 2 ). Similar results were seen 
when anti-CCP positive and anti-CCP negative, as well as when 
double-positive versus double-negative patients were compared 
( table 2 and  ﬁ gure 2 ). The proportions of patients with EULAR 
good/moderate response are also depicted in  table 2 . 
The majority of patients received a concomitant DMARD. At 
3 months, responses were similar in patients with and without 
synthetic DMARD co-treatment, but after 6 months the mean 
improvement of DAS28 was signiﬁ cantly larger for patients 
receiving concomitant DMARDs (ΔDAS28 1.9 (1.5) vs 1.6 (1.5), 
p=0.04, 95% CI for the difference −0.47 to −0.03). 
 The mean (SD) improvement in DAS28 at 6 months for 
patients with no or one previous biological treatment was 2.2 
(1.4) and 2.0 (1.4), respectively, while for patients for whom 
two or more biological agents had failed, the improvement was 
1.3 (1.6) ( ﬁ gure 3 ). The difference between the ﬁ rst two groups 
and the third group was statistically signiﬁ cant (p<0.0001 at 3 
and 6 months). At 6 months, the percentage of patients who 
achieved EULAR good/moderate response was 23.1%/50.6%, 
20.5%/46.6% and 20.2%/29.8% for patients with no, one or 
more than one previous biological agents, respectively. 
 Predictors of response 
 Possible predictors of EULAR good response at 6 months were 
identiﬁ ed by univariate logistic regression analysis adjusted for 
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 Figure 1 Levels of DAS28 at baseline, after 3 and 6 months.
 Table 2  Reductions in DAS28 at 3 and 6 months (mean (SD)) and achievement of EULAR good/moderate 
response (%) by RF and anti-CCP status 
 
 Positive  Negative  p Value  Positive  Negative  p Value 
 DAS28 improvement at 3 months (N=1073)  DAS28 improvement at 6 months (N=930) 
RF 1.8 (1.3) 1.4 (1.3) 0.0005 1.9 (1.5) 1.6 (1.5) 0.009
Anti-CCP 1.9 (1.4) 1.1 (1.3) <0.0001 2.0 (1.5) 1.4 (1.6) 0.002
Double 1.9 (1.4) 0.9 (1.1) <0.0001 2.1 (1.5) 1.1 (1.6) 0.001
  EULAR good/moderate response at 
3 months (N=1087) 
 EULAR good/moderate response at 
6 months (N=945) 
RF 17.7/45.9% 15.0/39.2% 0.10 23.3/42.9% 20/37.9% 0.17
Anti-CCP 20.2/47.9% 6.4/39.4% <0.0001 25.7/42.5% 14.5/39.1% 0.05
Double 20.4/47.8% 4.4/37.8% 0.001 25.5/43.6% 15.2/36.4% 0.13
 N = total number of patients for whom data on DAS28 improvement/EULAR response at 3 and 6 months were available. 
 anti-CCP, anti-cyclic citrullinated peptide antibodies; DAS28, 28-joint count Disease Activity Score; EULAR, European League Against 
Rheumatism; RF, rheumatoid factor. 
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age and sex ( table 3 ). In the subsequent multivariate analysis 
previous use of ≤1 versus >1 biological DMARDs, lower baseline 
DAS28 level and anti-CCP positivity were signiﬁ cant predictors 
of EULAR good response, while a smaller number of previous 
synthetic DMARDs was borderline signiﬁ cant ( table 3 ). Since 
only a fraction of patients had available anti-CCP status, we 
performed a second multivariate analysis without anti-CCP and 
obtained the same results, but with somewhat stronger levels of 
signiﬁ cance (data not shown). 
 DISCUSSION 
 In this large observational cohort study, the majority of patients 
treated with RTX had longstanding RA and several previous 
synthetic DMARDs and/or at least one anti-TNF had failed as 
in several randomised clinical trials with RTX. 1  2 In addition, 
there was a signiﬁ cant off-label usage of RTX in anti-TNF naive 
patients. 21  22 The heterogeneous population with data from 
10 countries allowed us to evaluate the real-life effectiveness of 
RTX and stratiﬁ cation according to number of previous biologi-
cal agents and seropositivity led to relevant conclusions. 
 Clinical effectiveness of RTX during the ﬁ rst 6 months after 
a treatment course was conﬁ rmed in this observational study. 
Previous studies have indicated that RF seropositivity is a predic-
tor of response to treatment, which is expected since patients 
with RA most likely to respond to treatment with RTX are those 
in whom B cells play a more important role in the pathogenesis 
of their disease. Such patients could potentially be identiﬁ ed 
by analyses of serum autoantibodies, including RF and anti-
CCP. 1   23 24 The study conﬁ rms this observation, as signiﬁ cantly 
better results were seen after 6 months for RF-positive patients 
than for RF-negative patients, but also for anti-CCP-positive ver-
sus negative individuals and double-positive versus double-neg-
ative subjects. However, seronegative patients also responded 
well to RTX. The difference between seropositive and serone-
gative patients at 6 months was not as strong as at 3 months. 
Moreover, DAS28 reduction from 3 to 6 months did not differ 
between the two groups. One possible explanation is that sero-
negative patients respond more slowly than patients who are 
seropositive. While initial reports suggested a lack of effective-
ness of RTX in seronegative patients, 4  25 more recent studies have 
suggested that RTX can be effective for such patients as well. 1  2 
These results could be explained by the observation that B cells 
play an important role in the pathogenesis of RA as autoantibody 
producers and also as antigen-presenting cells and proinﬂ am-
matory cytokine-releasing cells. It is also theoretically possible 
that seronegative responders produce autoantibodies not as yet 
known. There is, however, a risk of underlying bias: only sero-
negative patients with a satisfactory response continue to receive 
RTX for 6 months, and therefore the patients for whom we have 
6 months’ data could be selected from the initial population. To 
recommend use of RTX in seronegative patients further support 
from large observational or clinical studies is needed. 
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 Figure 2 Mean ∆DAS28 (bars: SEM) during the fi rst 6 months for seropositive and seronegative patients. At 3 and 6 months RF positive patients 
(A) as well as anti-CCP positive (B) and double positive patients (C) achieved signifi cantly larger reductions of DAS28 compared to RF negative, 
anti-CCP negative and double negative patients, respectively.
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 Anti-CCP was found in the univariate and multivariate 
analysis to be a signiﬁ cant independent prognostic marker of 
EULAR good response after 6 months, with an OR of 2.86 
(95% CI 1.43 to 5.71). RF positivity was shown to be a sig-
niﬁ cant predictor of EULAR good response in the univariate 
analyses, but did not remain signiﬁ cant in the multivariate 
model, even though the patients numbers with information 
about RF was much higher than the number with information 
about anti-CCP. These observations may indicate that anti-
CCP positivity is a stronger predictor of response to RTX than 
RF seropositivity. Longer follow-up, larger patient numbers 
and prospective data collection will allow us to reach more 
robust conclusions about seropositivity and response to RTX 
in the future. 
 In this study a large proportion of patients (36.6%) received 
RTX before having received an anti-TNF. RTX has more 
recently been tested in randomised controlled clinical trials of 
 inadequate responders to synthetic DMARDs. 21  22 Future exam-
ination of the speciﬁ c reasons for use of RTX as ﬁ rst biological 
agent might be of value. Patients naïve to anti-TNF agents and 
other biological agents, as well as patients for whom only one 
previous biological agent has failed seemed to respond signiﬁ -
cantly better to treatment than patients for whom two or more 
biological agents had failed. This observation suggests that ear-
lier initiation of RTX might lead to better results. Alternatively, 
lack of response to two or more anti-TNF agents might suggest 
resistance to treatment. The latter suggestion was supported by 
the lack of association between delay to RTX treatment (base-
line disease duration) and response. 
 Observational studies have indicated that RTX might be a 
better alternative than switching between TNF antagonists after 
a failure of anti-TNF treatment. 26  27 We had no data available to 
examine this question in this analysis, but this research question 
may be addressed later in the CERRERA database. 
 Another interesting result was a slight decrease in effective-
ness of treatment between 3 and 6 months for patients not being 
co-treated with DMARDs. Thus, concomitant DMARDs seem 
to maintain the therapeutic effect of RTX. In future analyses the 
effect of different DMARDs in combination with RTX will be 
examined. 
 This study started with 2019 patients. However, the number 
of patients analysed at 3 and 6 months was lower ( ﬁ gure 1 ). 
To exclude an important bias, we compared the characteristics 
of patients missing at these time points with those used for 
the analysis, which was particularly relevant for evaluation 
of the responses of seronegative patients with RA. As shown 
in  ﬁ gure 2B , n o difference in the number of anti-CCP-positive 
and anti-CCP-negative patients with available data at 3 and 
6 months could be detected (61.6% vs 68.1% and 46.7% vs 
48.6%, respectively). Contrarily, signiﬁ cantly more RF-negative 
patients than RF-positive patients had available DAS28 at 3 
(61.3% vs 52.3%) and 6 months (56.5% vs 44.6%) ( ﬁ gure 2A ). 
The last observation could support our ﬁ nding that seronega-
tive patients can also respond well to RTX but more slowly 
than those who are seropositive. On the other hand, one could 
suggest that the missing data of a large amount of seroposi-
tive patients, especially at 6 months, might be related to a very 
good response to treatment, thus introducing a selection bias. 
The absence of difference in the anti-CCP subgroup allowed us 
to reach more robust conclusions on anti-CCP positivity as a 
predictor of response to RTX. 
 This study has some limitations, such as the signiﬁ cant 
hetero geneity between countries for baseline characteristics, 
differences in laboratory methods for determining RF and anti-
CCP antibodies and the difﬁ culty of splitting the countries into 
groups in order to include them as a covariate in the multivari-
ate analysis. Another weakness is that the study was observa-
tional and uncontrolled. Perhaps some of the improvements can 
be explained by regression to the mean or the placebo effect. 
Also, we are using observed data and we cannot report whether 
patients who dropped out before follow-up visits or had missing 
data also had worse results. The quite high number of missing 
data is of concern, but it is something we expected, as it is a 
large observational cohort. On the other hand, the large number 
of patients, the fact that there are 10 participating countries with 
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 Figure 3 Mean DAS28 improvement (bars: SEM) for patients 
who failed none, one or more than one biologic DMARD. The mean 
reductions in DAS28 during the fi rst 3 and 6 months were signifi cantly 
greater for patients having failed at most one biologic compared to those 
who had two or more prior biologics (p<0.0001).
 Table 3  EULAR good response: univariate and multivariate logistic 
regression analyses 
 Variable  Coeffi cient  OR (95% CI)  p Value 
Univariate adjusted analyses * 
  Previous synthetic 
DMARDs
−0.17 0.84 (0.75 to 0.94) 0.002
  Previous biological 
DMARDs 0–1 (vs ≥2)
0.55 1.73 (1.25 to 2.38) 0.001
 HAQ at baseline 0.18 1.20 (0.80 to 1.70) 0.30
 Disease duration −0.01 0.99 (0.98 to 1.01) 0.48
  Rheumatoid factor 
positive (vs negative)
0.44 1.50 (1.01 to 2.36) 0.04
 DAS28 at baseline −0.08 0.90 (0.87 to 1.02) 0.11
  Concomitant synthetic 
DMARD yes (vs no)
−0.05 0.95 (0.67 to 1.33) 0.75
  Concomitant 
glucocorticoids yes (vs no)
0.26 0.77 (0.57 to 1.04) 0.09
  Anti-CCP positive 
(vs negative)
1.09 3.00 (1.56 to 5.77) 0.001
Multivariate adjusted analysis * 
  Anti-CCP positive 
(vs negative)
1.05 2.86 (1.43 to 5.71) 0.003
  Previous biological 
DMARDS 0–1 (vs ≥2)
0.64 1.89 (1.02 to 3.51) 0.04
 DAS28 at baseline −0.29 0.74 (0.61 to 0.91) 0.003
  Previous synthetic 
DMARDs
−0.18 0.84 (0.7 to 1.01) 0.06
 * Adjusted for age and sex. 
 anti-CCP, anti-cyclic citrullinated peptide antibodies; DAS28, 28-joint count Disease 
Activity Score; DMARDs, disease-modifying antirheumatic drugs; EULAR, European 
League Against Rheumatism; HAQ, Health Assessment Questionnaire. 
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different treatment protocols, the ‘off-label’ treatment of anti-
TNF naïve patients with RTX, the possibility of examining the 
combination of RTX with other DMARDs apart from MTX, and 
the fact that all data came from ‘real-life’ patients are signiﬁ cant 
strengths of this study. 
 In conclusion in this large observational cohort, RF-positive 
and anti-CCP-positive patients achieved signiﬁ cantly greater 
reductions in DAS28 at 6 months than seronegative patients. 
Anti-CCP positivity was an independent predictor of EULAR 
good response. Effectiveness results were best when RTX was 
used as the ﬁ rst biological agent or in patients for whom at most 
one anti-TNF had failed. Concomitant DMARDs may prolong 
the initial effectiveness, leading to longer relapse-free disease. 
 Ethics approval  This study was conducted with the approval of the registry of 
each country. 
 Provenance and peer review  Not commissioned; externally peer reviewed. 
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 ABSTRACT  
 Objectives  To compare the effectiveness and safety 
of rituximab alone or in combination with either 
methotrexate or lefl unomide. 
 Methods  10 European registries submitted anonymised 
datasets with baseline, 3, 6, 9 and 12-month clinical data 
from patients who started rituximab. 
 Results  1195 patients were treated with rituximab plus 
methotrexate, 177 with rituximab plus lefl unomide and 505 
with rituximab alone. Signifi cantly more patients achieved 
a European League Against Rheumatism good response 
at 6 months when treated with rituximab plus lefl unomide 
(29.1%) compared with rituximab plus methotrexate 
(21.1%) and rituximab alone (19.3%; p=0.02 and p=0.01, 
respectively). Similar results were observed at 12 months. 
Adverse events occurred in 10.2%, 13.2% and 13.9% 
of patients on rituximab plus lefl unomide, rituximab plus 
methotrexate and rituximab alone, respectively. 
 Conclusions  Lefl unomide is an effective and safe 
alternative to methotrexate as concomitant treatment 
with rituximab. Slightly better results were obtained 
by the combination of rituximab and lefl unomide than 
rituximab and methotrexate, raising the possibility of a 
synergistic effect of lefl unomide and rituximab. 
 Rituximab (Mabthera, Rituxan) has been approved 
for the treatment of rheumatoid arthritis (RA). 
Randomised controlled clinical trials with rituximab 
have shown signiﬁ cant clinical improvements for 
patients who failed tumour necrosis factor (TNF) 
inhibition and biological agent naive patients. 1 – 3 In 
all trials rituximab was administered in combina-
tion with methotrexate. 
 Methotrexate and leﬂ unomide are synthetic 
disease-modifying antirheumatic drugs (DMARD) 
that inhibit purine and pyrimidine synthesis, 
respectively. Both drugs have been proved effec-
tive for the treatment of RA, 4 – 7 but the exact phar-
macological mechanisms of action are still unclear. 
Leﬂ unomide is often used in clinical practice as an 
alternative DMARD, either alone or in combina-
tion with biological agents for patients intolerant to 
methotrexate, but limited data on the efﬁ cacy and 
safety of combination treatment with leﬂ unomide 
and anti-TNF or other biological agents from clini-
cal or epidemiological studies are available. 8 
 Controlled clinical trials are the major source of 
information on the efﬁ cacy and safety of medica-
tions. However, since the inclusion of patients in 
these studies is governed by strict inclusion and 
exclusion criteria, the study populations can dif-
fer from real-life patients in several respects. We 
know from experience that a signiﬁ cant number of 
patients do not tolerate methotrexate, but the vast 
majority of clinical trials conducted to assess the 
efﬁ cacy of rituximab used methotrexate as anchor 
therapy. Furthermore, rituximab is sometimes used 
alone in the case of patients intolerant to several 
synthetic DMARD. There is therefore a need for 
evidence of the effectiveness and safety of ritux-
imab either alone or in combination with synthetic 
DMARD other than methotrexate. 
 PATIENTS AND METHODS 
 The European Collaborative Registries for 
the Evaluation of Rituximab in Rheumatoid 
Arthritis (CERERRA) is an investigator-led, industry-
supported initiative with the aim of evaluating the 
clinical aspects of rituximab use in patients with RA 
(K Chatzidionysiou, E Lie, E Nasonov,  et al , unpub-
lished observation). All 10 participating European 
registries submitted fully anonymised datasets with 
baseline characteristics of all RA patients who had 
been treated with rituximab. Levels of rheumatoid 
factor and anti-cyclic citrullinated peptide (CCP) 
were determined by local laboratories and local 
cut-off values for positivity were applied. Disease 
activity markers and disability score at baseline 
and after 3, 6, 9 and 12 months were also provided 
(see supplementary data, available online only). 
 Patients were separated into three groups: ritux-
imab plus methotrexate, rituximab plus leﬂ uno-
mide and rituximab alone. A small number of 
patients was excluded (see supplementary data, 
available online only). 
▶ Additional supplementary 
data are published online only. 
To view these fi les please visit 
the journal online (http://ard.
bmj.com/content/71/3.toc)
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 Statistical analysis 
 Overall differences between the groups for baseline values were 
tested with analysis of variance (ANOVA). For those variables 
that ANOVA showed to have signiﬁ cant heterogeneity pairwise 
comparison was performed with the two-tailed Student’s t test 
(for normally distributed continuous data) and the χ 2 test (for 
categorical variables). The univariate and multivariate logistic 
regression analyses are described elsewhere (see supplementary 
data, available online only). 
 RESULTS 
 Among the 2265 RA patients who started treatment with ritux-
imab, 1195 were treated with rituximab plus methotrexate, 177 
with rituximab plus leﬂ unomide and 505 with rituximab alone. 
The baseline characteristics of the patients in the three treat-
ment groups are shown in  table 1 . The majority of patients were 
treated with 2×1000 mg rituximab according to recommenda-
tions: 91.5% of patients in the rituximab plus methotrexate, 
91.4% in the rituximab plus leﬂ unomide and 86.4% in the ritux-
imab monotherapy group (the difference being signiﬁ cant only 
between rituximab plus methotrexate and rituximab monother-
apy, p=0.003). The rest of the patients received 2×500 mg ritux-
imab. The mean dose (±SD) of methotrexate was 14.4±5.4 mg 
a week. The majority of patients on rituximab plus leﬂ unomide 
(95.1%) were treated with 20 mg leﬂ unomide a day (mean±SD 
daily dosage 17.6±3.6 mg). 
 Patients on rituximab plus leﬂ unomide achieved a greater 
reduction in disease activity score in 28 joints (DAS28) values 
from baseline to the 6 and 12-month assessments compared 
with rituximab plus methotrexate and rituximab alone ( ﬁ g-
ure 1A ). At 6 months the mean±SD ΔDAS28 from baseline in 
the rituximab plus leﬂ unomide, rituximab plus methotrexate 
and rituximab-alone groups were 2.1±1.3, 1.9±1.5 and 1.7±1.5, 
respectively (p=0.02 for rituximab plus leﬂ unomide vs rituximab 
alone). At 12 months ΔDAS28 from baseline in the rituximab 
plus leﬂ unomide, rituximab plus methotrexate and rituximab-
alone groups were 2.2±1.6, 1.8±1.5 and 1.7±1.3, respectively 
(p=0.06 for rituximab plus leﬂ unomide vs rituximab plus metho-
trexate and p=0.05 for rituximab plus leﬂ unomide vs rituximab 
alone). The mean±SD health assessment questionnaire (ΔHAQ) 
from baseline in the rituximab plus leﬂ unomide, rituximab plus 
methotrexate and rituximab-alone groups were 0.5±0.7, 0.5±0.6 
and 0.4±0.6, respectively, at 6 months, and 0.5±0.6, 0.4±0.6 
and 0.3±0.6 at 12 months, respectively. No signiﬁ cant differ-
ences were observed in the HAQ reductions at 6 and 12 months 
between the treatment groups. 
 Signiﬁ cantly more patients achieved a European League 
Against Rheumatism (EULAR) good response at 6 months 
when treated with rituximab plus leﬂ unomide (29.1%) com-
pared with rituximab plus methotrexate (21.1%) and rituximab 
alone (19.3%), p=0.02 and p=0.01, respectively ( ﬁ gure 1B ). At 
12 months an even higher percentage of good responders was 
observed in the rituximab plus leﬂ unomide group (42.6%), 
while the percentage of good responders remained stable in 
the rituximab plus methotrexate and rituximab-alone groups 
(p=0.001 and p=0.08 respectively;  ﬁ gure 1B ). The number of 
good responders was signiﬁ cantly higher in patients treated 
with rituximab alone than in the rituximab plus methotrexate 
group (p=0.04). 
 The combination rituximab plus leﬂ unomide was signiﬁ -
cantly associated with a good EULAR response compared with 
rituximab plus methotrexate and rituximab monotherapy in a 
 Table 1 Baseline characteristics of rituximab-treated patients who received concomitant treatment with methotrexate, lefl unomide or no DMARD 
(rituximab monotherapy) 
 Baseline characteristics of patients 
 Rituximab plus 
methotrexate 
(N=1195) 
 Rituximab plus 
lefl unomide 
(N=177) 
 Rituximab 
monotherapy 
(N=505) 
 ANOVA 
(overall 
differences)  Pairwise comparisons (t test/χ  2  )
Age, years (mean±SD) 51.9±13.1 52.3±12.1 55.2±12.9 p<0.0001 Methotrexate plus rituximab vs rituximab p<0.0001, 
Lefl unomide plus rituximab vs rituximab p=0.001N 1188 177 500
Gender (% female) 81.3 83.1 81.1 NS NS
N 1194 177 503
Disease duration, years (mean±SD) 11.7±8.8 11.4±7.9 13.2±10.1 p=0.007 Methotrexate plus rituximab vs rituximab p=0.003, 
Lefl unomide plus rituximab vs rituximab p=0.04N 1161 169 465
No of previous DMARD (mean±SD) 2.6±1.5 2.5±1.4 2.8±1.8 p=0.008 Methotrexate plus rituximab vs rituximab p=0.003, 
Lefl unomide plus rituximab vs rituximab p=0.05N 1019 162 400
No of previous biological agents (mean±SD) 0.9±0.8 0.6±0.8 1.0±0.8 p<0.0001 Methotrexate plus rituximab vs rituximab p=0.01, 
Lefl unomide plus rituximab vs rituximab p<0.0001, 
Methotrexate plus rituximab vs Lefl unomide plus 
rituximab p=0.001
N 1136 170 464
RF (% positive) 74.5 77.6 78.8 NS NS
N 1044 147 415
Anti-CCP (% positive) 73.6 76.1 76.9 NS NS
N 444 71 143
DAS28 (mean±SD) 5.9±1.3 5.9±1.2 5.7±1.3 p=0.029 Methotrexate plus rituximab vs rituximab p=0.02
N 1108 155 433
HAQ (mean±SD) 1.6±0.7 1.6±0.7 1.7±0.7 NS NS
N 850 137 323
Use of glucocorticoids (%) 59.9 53.2 56.6 NS NS
N 1175 171 442
Glucocorticoids dose (mg) 8.9±7.9 7.1±5.0 9.9±10.4 p=0.008 Methotrexate plus rituximab vs Lefl unomide plus 
rituximab p=0.02, Lefl unomide plus rituximab vs 
rituximab p=0.01N 696 99 251
 N=number of patients in each group with available data. 
 ANOVA, analysis of variance; CCP, cyclic citrullinated peptide; DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug; HAQ, health 
assessment questionnaire; RF, rheumatoid factor. 
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univariate regression analysis at 6 and 12 months adjusted for 
age and sex. In the multivariate analysis model adjusted for age, 
sex and country, a lower number of previous biological agents 
and concomitant leﬂ unomide remained predictive at 6 months 
( table 2 ). At 12 months concomitant leﬂ unomide and positive 
anti-CCP were signiﬁ cant predictors of EULAR good response 
to rituximab treatment ( table 2 ). 
 Fewer patients with rituximab plus leﬂ unomide required 
retreatment during the ﬁ rst 12 months (21.5%) compared with 
rituximab plus methotrexate (31.9%) or rituximab monotherapy 
(27.9%), but these differences were not statistically signiﬁ cant. 
 Adverse events occurred in 10.2%, 13.2% and 13.9% of 
patients in rituximab plus leﬂ unomide, rituximab plus metho-
trexate and rituximab monotherapy, respectively. No difference 
Figure 1 (A) Effi cacy of different concomitant treatments with rituximab at 6 and 12 months after fi rst treatment according to the disease 
activity score in 28 joints (DAS28) reductions from baseline to 12 months. Patients treated with rituximab plus lefl unomide achieved 
numerically greater DAS28 reductions at 6 and 12 months compared with rituximab plus methotrexate and rituximab-alone-treated patients, 
with the differences being statistically signifi cant between rituximab plus lefl unomide and rituximab alone at 6 (p=0.02) and 12 months 
(p=0.05), and borderline signifi cant between rituximab plus lefl unomide and rituximab plus methotrexate at 12 months (p=0.06). The 
numbers of patients in each treatment group with available ΔDAS28 at each time point are shown. †p=0.02 rituximab plus lefl unomide 
versus rituximab alone. ††p=0.06 rituximab plus lefl unomide versus rituximab plus methotrexate and p=0.05 rituximab plus lefl unomide 
versus rituximab alone. (B) Effect of different concomitant treatments with rituximab at 6 and 12 months after fi rst treatment according 
to the European League Against Rheumatism (EULAR) response (good, moderate or none). Signifi cantly more patients achieved a EULAR 
good response at 6 months when treated with rituximab plus lefl unomide (29.1%) compared with rituximab plus methotrexate (21.1%) and 
rituximab alone (19.3%), p=0.02 and p=0.01, respectively. At 12 months an even higher percentage of good responders was observed in the 
rituximab plus lefl unomide group (42.6%), while the percentage of good responders remained stable in the rituximab plus methotrexate (17.1) 
and rituximab-alone groups (24%) (p=0.001 and p=0.08, respectively). LEF, lefl unomide; MTX, methotrexate; RTX, rituximab.
 Table 2 Results of the separate univariate analyses for each variable, adjusted for age and sex, at 6 and 12 months 
  Variables 
 6 Months  12 Months 
 OR (95% CI)  p Value  OR (95% CI)  p Value 
Univariate analysis* Disease duration 1.0 (0.9 to 1.0) 0.28 1.0 (0.7 to 1.5) 0.82
RF (positive vs negative) 1.4 (0.9 to 2.0) 0.1 1.5 (1.1 to 2.2) 0.02
Anti-CCP (positive vs negative) 2.5 (1.4 to 4.5) 0.002 2.5 (1.4 to 4.4) 0.001
Previous DMARD (n) 0.8 (0.7 to 0.9) 0.001 1.0 (0.9 to 1.1) 0.36
Previous biological agents (n) (0–1 vs >1) 1.8 (1.3 to 2.5) <0.0001 1.6 (1.2 to 2.2) 0.004
Baseline DAS28 0.8 (0.5 to 1.1) 0.17 1.0 (0.9 to 1.1) 0.96
Baseline HAQ 0.9 (0.8 to 1.2) 0.7 0.9 (0.6 to 1.0) 0.15
Lefl unomide plus rituximab vs methotrexate plus rituximab 2.1 (1.2 to 3.5) 0.009 2.0 (1.2 to 3.3) 0.005
Lefl unomide plus rituximab vs rituximab 2.3 (1.2 to 4.1) 0.008 2.0 (1.2 to 3.5) 0.01
Methotrexate plus rituximab vs rituximab 1.1 (0.8 to 1.6) 0.6 1.0 (0.7 to 1.5) 0.93
Use of glucocorticoids 1.3 (1.0 to 1.8) 0.06 1.3 (1.0 to 1.8) 0.04
Glucocorticoids dose 0.9 (0.9 to 1.0) 0.45 0.9 (0.9 to 1.0) 0.02
Country †  0.001  0.002
Multivariate analysis ‡ Previous biological agents (n) (0–1 vs >1) 1.5 (0.9 to 2.3) 0.05 NS NS
Lefl unomide plus rituximab 2.0 (1.1 to 3.7) 0.03 2.8 (1.0 to 7.9) 0.04
Anti-CCP (positive vs negative) NS NS 2.2 (1.1 to 4.2) 0.02
 * The dependent variable was EULAR good response at 6 and 12 months, respectively. The combination of lefl unomide with rituximab was signifi cantly associated with a good 
EULAR response compared with the combination of rituximab and methotrexate and rituximab monotherapy. Methotrexate was not associated with good response to therapy 
compared with rituximab monotherapy. 
 † ’Country’ was a signifi cant independent variable (but no country on its own was signifi cantly associated with good response to therapy). 
 ‡ Multivariate analysis was adjusted for age, sex and country. Concomitant treatment with lefl unomide remained signifi cant at both 6 and 12 months. 
 CCP, cyclic citrullinated peptide; DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism; 
HAQ, health assessment questionnaire; RF, rheumatoid factor. 
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in the infection rate was observed (6.2% for rituximab plus 
leﬂ unomide, 6.6% for rituximab plus methotrexate and 7.9% 
for rituximab alone). One death was reported due to aspira-
tion pneumonia in the rituximab plus methotrexate group. 
In the same group, one patient was diagnosed with prostate 
cancer 3 months after the initiation of rituximab and one patient 
had an acute myocardial infarction after 6 months. In the ritux-
imab-alone group, one acute myocardial infarction and one hae-
morrhagic stroke were reported. A stroke was also reported in 
the rituximab plus leﬂ unomide group, 6 months after the start 
of rituximab treatment. 
 DISCUSSION 
 The results of this large observational cohort of RA patients 
support the ﬁ ndings of previous smaller studies reporting good 
results with the combination of rituximab and leﬂ unomide. 9  10 
At both 6 and 12 months a signiﬁ cantly greater number of 
patients treated with rituximab plus leﬂ unomide achieved a 
EULAR good response than patients treated with rituximab plus 
methotrexate and rituximab alone, and fewer patients in the 
rituximab plus leﬂ unomide group required retreatment during 
the ﬁ rst year. The latter observation may suggest a longer dura-
tion of response to therapy, but this difference was not statisti-
cally signiﬁ cant and the criteria for retreatment were not deﬁ ned 
according to any speciﬁ c protocol. However, a consensus had 
been published guiding physicians about how rituximab could 
be used according to available evidence and expert opinion. 11 
Co-medication with leﬂ unomide did not lead to more adverse 
events. These ﬁ ndings thus indicate that leﬂ unomide is a good 
alternative to methotrexate when used in combination with 
rituximab in RA. 
 Studies have shown that leﬂ unomide has an impact on B-cell 
proliferation and cell cycle progression, thus suppressing B-cell 
antibody responses. 12  13 These ﬁ ndings may provide a rationale 
regarding the mechanism of action of leﬂ unomide in RA with 
a possible synergistic effect when used in combination with 
rituximab. Of note, methotrexate and/or TNF antagonists were 
not able to decrease the frequency of autoreactive B-cell clones, 
indicating that these anti-inﬂ ammatory therapies are not able to 
correct the presence of defective B-cell tolerance. 14 
 We did not observe any difference in efﬁ cacy between patients 
treated with rituximab plus methotrexate or rituximab alone. 
Owczarczyk  et al 15 came to a similar conclusion in a small study 
with 40 patients. 
 The strengths of our study are the inclusion of a large num-
ber of patients from 10 participating countries and the ‘real-life’ 
character of the study, which provided the possibility to examine 
the combination of rituximab with other DMARD apart from 
methotrexate. This analysis has potential limitations inherent 
to the analysis of observational data. Almost all of the patients 
treated with leﬂ unomide had either potential contraindications 
to methotrexate treatment or had previously not tolerated meth-
otrexate, which could result in selection bias or confounding by 
indication. However, confounding by indication would most 
likely bias the results towards the null, as leﬂ unomide is usually 
prescribed to more difﬁ cult patients with either problems of tol-
erance or inadequate response to methotrexate. While we could 
adjust our analysis for many important disease characteristics, 
we cannot exclude the possibility of residual confounding or 
confounding by unmeasured factors. Missing data are another 
concern with observational studies. Nevertheless, the propor-
tion of patients at these time points with available effectiveness 
data was similar for the rituximab plus methotrexate group 
(57.5% and 31.9%) and the rituximab plus leﬂ unomide group 
(51% and 29.7%) at 6 and 12 months, respectively. The absence 
of radiological data was also a limitation of this study. The mean 
dose of methotrexate in the rituximab plus methotrexate group 
was relatively low (14.4 mg/week). Higher doses could lead to 
better results, but they are not always well tolerated. 
 Concomitant treatment with leﬂ unomide remained signiﬁ -
cant in the multivariate analysis, which was adjusted for coun-
try, as well as for age, sex and the number of previous biological 
agents, thus allowing us to draw more robust conclusions. The 
weaknesses of observational studies have to be put in the per-
spective that no optimal randomised controlled trial has been 
performed to address the effectiveness and safety of co-therapy 
with synthetic DMARD apart from methotrexate in rituximab-
treated patients. In addition, this study provides important 
information on patients intolerant to various DMARD who can 
be treated with rituximab monotherapy. 
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ABSTRACT 
Background: The approved dose of rituximab (RTX) in rheumatoid arthritis is 1000 
mg x 2, but some data have suggested similar clinical efficacy with 500 mg x 2. The 
purpose of this study was to compare the effectiveness of the regular and low doses 
given as first treatment course.  
Methods: Twelve European registries participating in the CERERRA collaboration 
submitted anonymized datasets with demographic, efficacy and treatment data for 
patients who had started RTX. Treatment effectiveness was assessed by DAS28 
reductions and EULAR responses after 6 months.  
Results: Data on RTX dose were available for 2,873 patients, of whom 2,625 (91.4%) 
and 248 (8.6%) received 1000 mg x 2 and 500 mg x 2, respectively. Patients treated 
with 500 mg x 2 were significantly older, had longer disease duration, higher number 
of prior DMARDs, but lower number of prior biologics and lower baseline DAS28 
than those treated with 1000 mg x 2. Fewer patients in the low-dose group received 
concomitant DMARDs but more frequently received concomitant corticosteroids.  
Both doses led to significant clinical improvements at 6 months. DAS28 reductions at 
6 months were comparable in the 2 dose regimens [mean DeltaDAS28±SD -2.0±1.3 
(high dose) vs. -1.7±1.4 (low dose), p=0.23 adjusted for baseline differences]. Similar 
percentages of patients achieved EULAR good response in the two dose groups, 
18.4% vs. 17.3%, respectively (p=0.36).  
Conclusions: In this large observational cohort initial treatment with RTX at 500 mg 
x 2 and 1000 mg x 2 led to comparable clinical outcomes at 6 months.  
 
 
Keywords: rituximab, rheumatoid arthritis, dose 
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INTRODUCTION 
Rituximab (MabThera, Rituxan) is a chimeric, monoclonal anti-CD20 antibody 
approved for the treatment of rheumatoid arthritis (RA) in combination with 
methotrexate in patients with active RA who have failed at least one tumor necrosis 
factor (TNF) inhibitor. The efficacy and acceptable safety profile of rituximab (RTX) 
have been demonstrated in randomized controlled trials
1, 2
 and in large observational 
cohorts
3, 4
. The approved dose is 1000 mg twice (with a 2-week interval) per treatment 
course.  
There is however evidence suggesting that a lower dose of RTX, 500 mg twice, is 
also effective, although not approved. In the SERENE trial both 500 mg x 2 and 1000 
mg x 2 RTX significantly improved clinical outcomes (ACR responses, EULAR 
responses, DAS28 and HAQ improvement) compared to placebo in a biologic naïve 
RA population
5
. The MIRROR, DANCER and IMAGE trials yielded similar results
6-
8
. In all the above trials no significant difference could be detected between the 
different doses regarding almost all clinical outcomes
5-8
. 
The purpose of this study was to assess and compare the effectiveness at 6 months 
between the higher (1000 mg x 2) and lower (500 mg x 2) dose of RTX given as first 
treatment course in a merged dataset from observational cohorts.  
METHODS 
The CERERRA (The European Collaborative Registries for the Evaluation of 
Rituximab in Rheumatoid Arthritis) is an investigator-led initiative aiming to evaluate 
clinical aspects of RTX use in patients with RA
3, 9
. Twelve participating European 
registries (from the Czech Republic, Denmark, Finland, The Netherlands, Norway, 
Portugal, Romania, Russia, Slovenia, Spain, Sweden and Switzerland) submitted fully 
anonymized datasets with baseline demographic and disease characteristics, including 
age, gender, disease duration, number of previous synthetic and biological DMARDs, 
rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP) 
status of all patients with an established diagnosis of RA who started treatment with 
RTX. Disease activity markers at baseline and after 3 and 6 months were also 
provided (number of swollen and tender joints, Visual Analogue Scales (VAS) for 
pain, patient’s and physician’s global assessment, Disease Activity Score based on 28 
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joint counts and erythrocyte sedimentation rate (ESR), (DAS28-ESR), Health 
Assessment Questionnaire (HAQ)). Information about RA treatment, such as doses of 
rituximab and use of concomitant DMARDs and glucocorticoids was also included in 
the dataset. Effectiveness of rituximab in the higher (1000mg x 2) and the lower dose 
(500mg x 2) was assessed by DAS28 and HAQ status at 3 and 6 months, by the 
improvement of DAS28 and HAQ at 3 and 6 months, by disease activity at 3 and 6 
months based on DAS28 status and by EULAR responses at 6 months. 
 
A small number of patients were treated with other than the above doses (e.g. 750 mg) 
or did not provide information on the RTX dose and were therefore not included in 
the analysis.  
 
Statistical analysis 
Baseline characteristics of the two groups were analysed by means of descriptive 
statistics. For normally distributed variables mean ± standard deviation (SD) and 
independent samples t-test was used, while median (interquartile range (IQR)) and 
Mann-Whitney U-test were used for the non-normally distributed variables. Chi-
square test was used for comparison of categorical data. 
Changes in DAS28 and HAQ were first compared in unadjusted analyses by 
independent samples t-test. Comparative adjusted analyses with correction for 
baseline group differences were subsequently performed by analyses of covariance 
(ANCOVA). In the ANCOVA analysis we adjusted for baseline variables found to 
differ significantly between the two groups (age, disease duration, number of prior 
biologics, baseline DAS28, concomitant DMARD) and for those thought to be 
clinically significant (concomitant corticosteroids). The number of prior DMARDs 
although significantly different between groups was not included in the ANCOVA 
because of the small number of patients with available information in the 500mg 
group and because of the high correlation with the number of prior biologics.  
Multivariate logistic regression analysis with EULAR response as dependent variable 
(a first analysis with EULAR good vs. moderate/no and a second one with EULAR 
good/moderate vs. no) and RTX dose (500 vs. 1000 mg) as well as several baseline 
variables as explanatory variables was performed [age, gender, RA disease duration, 
previous biologics, baseline DAS28, anti-CCP status, concomitant DMARDs and 
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corticosteroids]. Country was included in the model in an additional analysis. All 
statistical tests were evaluated at the 0.05 significance level. P-values and 95% 
confidence intervals are presented. The statistical analysis was performed with IBM 
SPSS Statistics version 20.  
RESULTS 
The total number of patients included in the cohort was 3,266, and 2,873 patients 
(88%) were eligible for the analyses. The large majority of patients [n=2,625, 91.4%] 
received 1000 mg x 2 (higher dose), and 248 patients (8.6%) received 500 mg x 2 
(lower dose). The demographics and baseline disease characteristics for the two 
treatment groups are shown in Table 1. Patients who were treated with the lower RTX 
dose were older, had longer disease duration, fewer prior biologic agents but more 
prior DMARDs and lower baseline DAS28 than those treated with the higher dose. 
Additionally, fewer patients in the low-dose group received concomitant DMARDs 
but more frequently received concomitant corticosteroids. Baseline characteristics for 
those patients with available DAS28-ESR at 6 months are also shown in table 1. No 
significant differences between the two populations (all patients at baseline and 
patients with available response data at 6 months) were observed, so the missingness 
was not informative.  
In the unadjusted analysis, the mean DAS28 improvement was greater for patients 
treated with the higher dose than for those treated with the lower dose at 3 months 
[1.9±1.4 (N=991) vs. 1.3±1.3 (N=125), p<0.0001) and it remained significant in the 
ANCOVA analysis (p=0.004) (table 2). The difference in mean DAS28 improvement 
was significant also at 6 months (2.0±1.3 (N=1344) vs. 1.7±1.4 (N=100), p=0.02) in 
the unadjusted analysis. However, difference disappeared after adjustment (p=0.23). 
Inclusion of country as a random variable in the ANCOVA analysis did not change 
the results. Improvements in function as assessed by HAQ were also similar between 
the groups both at 3 and 6 months (table 2). The proportion of patients with high, 
moderate and low disease activity and remission based on DAS28 was similar in the 
two groups at baseline, 3 and 6 months (Figure 1a), and so was the proportion of 
EULAR good, moderate and non-responders at 6 months (Figure 1b).  
Multivariate logistic regression analysis was performed in order to examine the 
possible association of RTX dose with EULAR good (vs. moderate/no) and EULAR 
6 
 
good/moderate (vs. no) response, with adjustment for possible confounders, such as 
age, gender, RA disease duration, previous biologics, baseline DAS28, anti-CCP 
status, concomitant DMARDs and corticosteroids. RTX dose (lower dose vs. higher 
dose) was not a statistically significant predictor of achieving EULAR good response 
(OR: 1.08, 95% CI: 0.40-2.94, p=0.88) or EULAR good/moderate response (OR: 
1.22, 95% CI: 0.37-4.09, p=0.74). When country was introduced in the model similar 
results were observed.  
 
DISCUSSION 
In this study based on data from the CERERRA collaboration RTX provided 
significant clinical improvement at 3 and 6 months in patients with active RA. The 
comparison between the higher (1000 mg x 2) and lower dose (500 mg x 2) of RTX 
showed significant difference for DAS28 improvement at 3 months but no significant 
difference on clinical effectiveness, as assessed by change in DAS28 and HAQ score 
at 6 months, after adjusting for baseline characteristics.  EULAR response rates and 
remission rates were also similar between groups. The results of our study are thus 
consistent with those from the SERENE, IMAGE and MIRROR trials
5,6, 8
In the 
MIRROR trial the percentage of EULAR Good/Moderate response was borderline 
significantly higher in the 1000mg x 2 (89%) compared to the 500mg x 2 group 
(73%) (p=0.05). The overall conclusions of the MIRROR trial was that the two 
rituximab doses could not be clearly differentiated, although some clinical outcomes 
were in favor of the higher dose
6
.  
Hitherto there have been no proper dose-response studies for rituximab in RA. What 
is considered the “autoimmune dose and protocol” was developed by Prof Jo Edwards 
based on a small number of patients
10
. Our study provides some additional evidence 
about the lack of any striking difference and perhaps no clinically significant 
difference between two different doses of rituximab used in clinical practice. Recently 
interesting data from the UK Leeds group showed that response to rituximab may be 
more dependent on the B-cells depletion rather than the dose. Although, in the small 
number of patients studied “incomplete” peripheral blood depletion was more often 
seen in the patients treated with the lower dose, “complete” depletion was seen in 
both groups and correlated better with response than dose itself
11
. 
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There are several limitations that should be addressed: the observational character of 
the study, the different size of the two treatment groups under comparison (only 248 
patients treated with the lower dose), and the fact that the two groups compared were 
not balanced for all baseline characteristics. Hence, there is a risk for channeling bias, 
as patients treated with the lower dose were older, had higher disease duration, lower 
disease activity at baseline and lower number of prior biologics and were more often 
treated with corticosteroids and less often with concomitant DMARDs. The lower 
dose group may represent a population of patients with more comorbidities, for whom 
the treating rheumatologist chose the lower dose of RTX. However, such a population 
would be more prone to have a worse response to therapy, and therefore confounding 
by indication would bias the results against the lower dose RTX.   
The lack of radiological data is an additional limitation of the study. The ‘golden 
triad’ of current treatment guidelines in RA is remission (or low disease activity when 
remission is not possible), preservation of functional ability, and prevention of 
structural damage. Tak et al. showed in the IMAGE study that the 1000 mg x 2 RTX, 
but not the 500 mg x 2 dose, significantly inhibited progression of joint damage 
during the first 6 months, but inhibition of structural progression was similar from 6 
months onwards
8, 12
. However, the IMAGE trial included MTX-naïve patients of 
whom the majority had early RA, and its population was thus different from the 
population of our study. It would be interesting to further evaluate the ability of the 
lower RTX dose to prevent radiological progression in an established RA population 
that is more consistent with the routine use of RTX.  
The length of response was not examined in the present study. The risk that the lower 
dose might be associated with shorter response cannot be ruled out and should be 
assessed in future studies. 
The large number of patients included in the cohort, which made the comparison of 
the different doses of RTX possible, and the real-life character of the study are 
important strengths of the study.  
CONCLUSIONS 
In this large observational cohort initial treatment with RTX at 500 mg x 2 and 1000 
mg x 2 led to comparable clinical outcomes after 6 months. This result may have 
some important cost implications in the treatment of patients with RA. 
8 
 
REFERENCES 
 
1. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted 
therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 
2004;350:2572–81. 
 
2. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid 
arthritis refractory to anti-tumor necrosis factor therapy: results of a 
multicenter, randomized, double-blind, placebo-controlled, phase III trial 
evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 
2006;54:2793–806. 
 
3. Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectiveness of 
rituximab in autoantibody-positive patients with rheumatoid arthritis and in 
those for whom no more than one previous TNF antagonist has failed: pooled 
data from 10 European registries. Ann Rheum Dis. 2011;70:1575-80. Epub 
2011 May 12 
 
4. Vander Cruyssen B, Durez P, Westhovens R, et al. The Belgian MIRA 
(MabThera In Rheumatoid Arthritis) registry: clues for the optimization of 
rituximab treatment strategies. Arthritis Res Ther. 2010;12:R169. Epub 2010 
Sep 10. 
 
5. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses 
and retreatment of rituximab: a randomised, placebo-controlled trial in patients 
who are biological naive with active rheumatoid arthritis and an inadequate 
response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX 
iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;691629-35. Epub 
2010 May 20. Erratum in: Ann Rheum Dis. 2011;70:1519.  
 
6. Rubbert-Roth A, Tak PP, Zerbini C, et al; MIRROR Trial Investigators. 
Efficacy and safety of various repeat treatment dosing regimens of rituximab 
in patients with active rheumatoid arthritis: results of a Phase III randomized 
study (MIRROR). Rheumatology (Oxford). 2010;49:1683-93. Epub 2010 May 
12. 
 
7. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al; DANCER Study 
Group. The efficacy and safety of rituximab in patients with active rheumatoid 
9 
 
arthritis despite methotrexate treatment: results of a phase IIB randomized, 
double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 
2006.;54:1390-400. 
 
8. Tak PP, Rigby WF, Rubbert-Roth A, et al; IMAGE Investigators. Inhibition 
of joint damage and improved clinical outcomes with rituximab plus 
methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum 
Dis. 2011;70:39-46. Epub 2010 Oct 11. 
 
9. Chatzidionysiou K, Lie E, Nasonov E, et al; Effectiveness of disease-
modifying antirheumatic drug co-therapy with methotrexate and leflunomide 
in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up 
study from the CERERRA collaboration. Ann Rheum Dis. 2012;71:374-7. 
Epub 2011 Oct 4. 
 
 
10. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with 
rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 
2002 Oct;61(10):883-8. 
 
11.  Vital EM, Rawstron AC, Dass S, Henshaw K, Madden J, Emery 
P, McGonagle D. Reduced-dose rituximab in rheumatoid arthritis: efficacy 
depends on degree of B cell depletion. Arthritis Rheum. 2011 Mar;63(3):603-
8. doi: 10.1002/art.30152. 
 
 
12.    Tak PP, Rigby W, Rubbert-Roth A, et al; Sustained inhibition of 
progressive joint damage with rituximab plus methotrexate in early active 
rheumatoid arthritis: 2-year results from the randomised controlled trial 
IMAGE. Ann Rheum Dis. 2012;71:351-7. Epub 2011 Oct 19. 
 
 
 
 
 
 
10 
 
 
 All patients 
Patients with available response data 
at 6 months* 
 
RTX  
500mg x 2 
 N=248 
RTX 
1000mg x 2 
N=2625 
p-value  
(t-test, 
chi-
square 
test) 
RTX 
500mg x 2 
N=109 
RTX 
1000mg x 2 
N=1385 
p-value  
(t-test, 
chi-square 
test) 
Sex,% female 
83.9% 
[248] 
80.3% 
[2625] 
0.17 
88.1% 
[109] 
81.2% 
[1125] 
0.08 
Age, years 
55.2±15.8 
[247] 
52.6±12.6 
[2615] 
0.002 
55.5±15.1 
[109] 
51.1±11.8 
[1380] 
<0.0001 
Disease 
duration,  years 
10.5 (5-18) 
[240] 
8.1 (5-14) 
[2360] 
0.02 
10 (5-16.8) 
[108] 
7.5 (5.1-12) 
[1329] 
0.02 
RF, % positive 
81.7% 
[241] 
81.2% 
[2031] 
0.84 
83% 
[106] 
81.5%  
[876] 
0.7 
Anti-CCP, % 
positive 
71.3% 
[101] 
73.4%  
[806] 
0.64 
68%  
[50] 
74.9%  
[363] 
0.29 
Number of prior 
biologics 
0 (0-1)  
[207] 
1 (0-2) 
[2560] 
<0.0001 
0 (0-1) 
[102] 
1 (0-1) 
[1371] 
0.003 
Anti-TNF-naive 
(%) 
58%    
[207] 
37.5% 
[2560] 
<0.0001 
58.8% 
[102] 
37.1% 
[1371] 
 
<0.0001 
Number of prior 
DMARDs 
2.6±1.3 
[126] 
2.4±1.4 
[2248] 
0.04 
2.7±1.3 
[55] 
2.3±1.1 
[1256] 
0.02 
Baseline DAS28-
ESR 
5.7±1.3  
[215] 
6.1±1.3 
[2069] 
<0.0001 
5.9±1.3 
[100] 
6.3±1.2 
[1344] 
0.002 
Baseline HAQ 
score 
1.6±0.7 
[212] 
1.7±0.7 
[1584] 
0.48 
1.6±0.7 
[100] 
1.8±0.7 
[695] 
0.001 
Concomitant 
medication: 
 
– Any DMARD 
72.6%  
[248] 
83.1% 
[2625] 
<0.0001 
75.2% 
[109] 
87.5% 
[1385] 
<0.0001 
MTX 
46.4%  
[248] 
63.4% 
[2625] 
<0.0001 
50.5% 
[109] 
75.1% 
[1385] 
<0.0001 
Glucocorticoids 
65.7% 
[248] 
59.3% 
[2221] 
0.06 
71.6% 
[109] 
64.7%  
[983] 
0.15 
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Table 1. Baseline demographics, disease and treatment characteristics of patients treated 
with rituximab 500 mg x 2 or 1000 mg x 2 for all patients in the cohort at baseline and 
for those with available response data (DAS28-ESR) at 6 months.  
 [RF=rheumatoid factor, anti-CCP= anti-cyclic citrullinated peptide antibodies, 
DMARDs=disease modifying antirheumatic drugs, DAS28-ESR=disease activity score 
based on 28 joints and ESR, HAQ=health assessment questionnaire, 
MTX=methotrexate]. The number of patients with available information for each 
variable is included in brackets. 
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 RTX 500 
mg x 2 
RTX 1000 
mg x 2 
Unadjusted 
p-values 
(ANOVA) 
Adjusted p-
values** 
DAS28 
baseline 
5.7±1.3 
[215] 
6.1±1.3 
[2069] 
<0.0001  
DAS28 3m 4.4±1.2 
[138] 
4.2±1.3 
[1046] 
0.15  
DAS28 6m 4.3±1.3 
[109] 
4.3±1.2 
[1385] 
0.99  
DeltaDAS28 
3m 
-1.3±1.3 
[125] 
-1.9±1.4 
[991] 
<0.0001 0.004 
DeltaDAS28 
6m 
-1.7±1.4 
[100] 
-2.0±1.3 
[1344] 
0.02 0.23 
     
HAQ baseline 1.6±0.7 
[212] 
1.6±0.7 
[1584] 
0.48  
HAQ 3m 1.3±0.7 
[127] 
1.3±0.7 
[957] 
0.83  
HAQ 6m 1.2±0.7 
[109] 
1.3±0.7 
[912] 
0.21  
DeltaHAQ 3m -0.3±0.5 
[115] 
-0.5±0.6 
[859] 
0.02 0.10 
DeltaHAQ 6m -0.4±0.6 
[103] 
-0.5±0.7 
[826] 
0.13 0.27 
Table 2. Effectiveness of treatment across the two treatment groups as assessed by DAS28 
and HAQ status and reductions at 3 and 6 months. Crude and adjusted p-valued are 
presented.  
** Analysis of covariance (ANCOVA) adjusted for age, sex, disease duration, number of 
prior biologics, baseline DAS28, concomitant DMARDs and glucocorticoids.  
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Figure 1A. Disease activity based on DAS28-ESR at baseline, 3 and 6 months in the two treatment groups 
(RTX 500mg x 2 and RTX 1000mg x 2). No significant differences were observed.  
(Remission: DAS28<2.6, Low disease activity: 2.6≤DAS28≤3.2, Moderate disease activity: 3.2<DAS28≤5.1, 
High disease activity: DAS28>5.1).  
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Figure 1B. EULAR Good, Moderate and No response at 6 months for the two 
treatment groups (RTX 500mg x 2 and RTX 1000mg x 2). No significant differences 
were observed.  
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Abstract 
 
Background: Retreatment with rituximab (RTX) is common clinical practice, although 
several aspects regarding retreatment need to be further elucidated. The aim of this study was 
to describe the effectiveness of repeated courses of RTX and to compare two retreatment 
strategies, fixed retreatment and on-flare, in a large observational cohort of real-life RA 
patients. 
 
Methods: Pooled data from the Collaborating European Registries for Rituximab in RA 
(CERERRA) cohort were used. In a first analysis, patients with RA who received at least 4 
cycles with RTX were identified and included in the analysis. In a second analysis, patients 
who received at least 2 RTX retreatments and for whom information about the strategy for 
retreatment was available (according to the physician’s opinion) were identified. The two 
retreatment strategies were compared by fitting an adjusted mixed effects model analysis to 
the longitudinal DAS28. 
 
Results: 777 patients met the eligibility criteria for the first analysis. Significant improvement 
in DAS28 (p<0.001) was observed for each course of RTX. Comparison between curves 
revealed significant difference between all treatment cycles. 
A total of 800 patients were retreated at least 2 times: 616 retreated because of a flare and 184 
at a fixed interval. Patients receiving fixed retreatment had a significantly higher (in absolute 
number) DeltaDAS28 (p<0.0001) at the start of each cycle, compared to those retreated on-
flare. In the adjusted mixed model analysis, we compared the two retreatment groups for the 
1
st
 and the 2
nd
 retreatment separately using estimated marginal means. For the 1
st
 retreatment a 
fixed retreatment yielded significantly better results than the “on-flare’’: mean DeltaDAS28=-
2.4 (95% CI: -3.0; -1.7) vs. -1.8 (95% CI: -3.6; -0.03), p<0.0001. Similar results were found 
for the 2
nd
 retreatment: mean DeltaDAS28=-2.6 (95% CI: -3.1; -2.2) vs. -1.6 (95% CI: -1.8; -
1.4), p<0.0001.  
 
Conclusion: To conclude, repeated retreatment with RTX can lead to further clinical 
improvement after the first course of RTX. A fixed retreatment strategy with RTX in RA 
seems to be more effective than the retreat ‘on-flare’ strategy.  
 
 
 
 
 
 
 
 
 
 
 
Rituximab (RTX) is an anti-CD20 chimeric monoclonal antibody approved for the treatment 
of active Rheumatoid Arthritis (RA). Its efficacy and acceptable safety profile has been 
shown in large randomized controlled trials
1-4
. A course of rituximab consists of two infusions 
of 1000mg each with two weeks interval. It is common clinical practice to retreat patients 
who respond to the first cycle of rituximab, but there is still no clear consensus about how 
often should one retreat and when. 
 
Initially it was shown that clinical response did not correlate with B-cell depletion, as B cells 
were depleted in all patients after rituximab treatment, but only a proportion of patients 
responded to therapy
5
. This would suggest that patients who did not respond to therapy with 
rituximab might have a B-cell independent disease. More recent studies however have shown 
a correlation between depth of B-cell depletion both in the circulation and in the synovium 
and clinical response
6,7
. Persistence of B-cells is associated with poorer prognosis
8
. This 
would suggest that retreatment with rituximab even in those patients who do not exhibit a 
response after the first cycle could yield good results. Indeed, while a study by Thurlings et 
al
6
 showed that for patients who did not exhibit clinical improvement after the first course of 
rituximab retreatment with rituximab was not effective, later studies showed enhanced clinical 
response after retreatment even in non-responders
9
.  
Regarding time to retreatment, there are two main strategies: to retreat on flare or to retreat on 
a fixed interval, before the patient flares. Some data have suggested that the later strategy 
would be of preference, but that needs to be further elucidated
10
.  
 
The aims of this study were: 1) to evaluate and compare the effectiveness of repeated 
treatment cycles with rituximab and 2) to compare retreatment ‘on-flare’ and fixed 
retreatment rituximab in a large real-life cohort of RA patients.  
 
 
Methods 
 
Patients’ selection 
 
The European Collaborative Registries for the Evaluation of Rituximab in Rheumatoid 
Arthritis (CERERRA) is an investigator-led, industry-supported initiative with the aim of 
evaluating the clinical aspects of rituximab use in patients with RA
11
. All 12 participating 
European registries (Czech Republic, Denmark, Finland, the Netherlands, Norway, Portugal, 
Romania, Russia, Slovenia, Spain, Sweden and Switzerland) submitted fully anonymized 
datasets with baseline characteristics of all patients with a diagnosis of RA who had started 
treatment with rituximab. It is a retrospective observational cohort, but the data are collected 
prospectively. Data were pooled and analyzed.  
The following information was collected: demographic data (age, sex); RA disease duration 
(from the time of diagnosis); rheumatoid factor (RF); anti-cyclic citrullinated peptide 
antibodies (anti-CCP); number of prior synthetic disease modifying anti-rheumatic drugs 
(DMARDs) and number of prior biologic DMARDs;  disease activity score based on 28-joint 
status (DAS28) and its components (swollen joint count, tender joint count, visual analogue 
scale general health and erythrocyte sedimentation rate (ESR)); functional ability based on 
health assessment questionnaire (HAQ); concomitant glucocorticoid and synthetic DMARD 
use. Information about the retreatment was also collected, such as the number of retreatment, 
date and reason for retreatment. The reason for retreatment was based on the rheumatologist's 
opinion and was either flare (deterioration of the disease) or fixed retreatment. The latter is a 
common clinical practice in some countries.  
 
From the whole cohort of patients we excluded those who had no follow-up visit. These were 
patients who were mainly lost to follow up or patients who started treatment with RTX close 
to the time of the data collection and therefore had not enough time to contribute with a 
follow up visit.  For the first analysis we identified and selected patients who received at least 
4 cycles with RTX. The purpose of this was to reduce the risk for selection bias, as it is 
expected that mainly responders will continue with retreatment. By selecting only patients 
who receive at least 3 retreatments we can examine the real effectiveness of retreatment and 
examine the feasibility of further improvement in disease activity. Five subgroups were 
formed, 1
st
, 2
nd
, 3
rd
, 4
th
 treatment and a fifth group (called 5
th
 treatment) where all treatments 
after the 5
th
 were pooled together.  
In the second analysis, patients who received at least 1 retreatment (2 courses) with RTX and 
for whom information about the strategy for retreatment was available (according to the 
physician’s opinion) were identified. The two retreatment strategies were compared by 
applying an adjusted mixed model analysis with DAS28 improvement as the dependent 
variable. 
 
Statistical analysis 
 
The different subgroups of patients were characterized by means of descriptive statistics. The 
normality of variables was tested by skewness. Normally distributed continuous variables 
were presented as mean ± standard deviation (SD). Student’s t-test was used to compare 
continuous variables while χ2 test was used for nominal variables. The level of statistical 
significance was set to 5%. 
 
Effectiveness of treatment was assessed by disease activity score (DAS28) and health 
assessment questionnaire (HAQ) reduction during the first 12 months from the start of each 
treatment. Disease activity state (based on DAS28) and EULAR response at the start 
(baseline) of each treatment cycle were also used to assess the feasibility of further 
improvement with each cycle.  
The number of measurements (follow-up visits) were not the same for all patients and were 
not done at fixed times, as it was expected in a real-life setting. Some follow-up visits were 
even missing for some patients. For these reasons mixed models analysis was used, as it can 
naturally handle uneven spacing of repeated measurements and even missing data (as long as 
missingness is at random). A linear mixed-effects models with ΔDAS28 as dependent 
variable and treatment cycle as fixed effect was initially performed to assess the effectiveness 
of each treatment cycle. Time was also fitted in the model. Country and individual patient 
were included in the model as random variables. Different association models for the 
covariance structure between the repeated measures of the primary outcomes were performed 
and compared using the Akaike information criterion. In a second analysis, the two 
retreatment strategies were compared by fitting an adjusted mixed effects model analysis to 
the longitudinal DAS28 for patients with complete covariate information, including country, 
sex, age, anti-CCP status, number of prior biologics and concomitant DMARD treatment. 
Time was fitted in the model.  
 
Results 
 
A total of 4353 RA patients started treatment with rituximab in the cohort. Of these 3718 
patients had at least 1 follow-up visit and were included in the analysis. The number of 
patients who received at least 4 cycles of rituximab (retreated at least 3 times during the 
observational period) was 777. Of those 81.6% were female, 83.8% were RF positive and 
78.1% were anti-CCP positive. The mean ± SD age was 55.7 ± 12.1 years and median disease 
duration 11 years (IQR=6-18). Patients had failed a mean of 3.0 (SD=1.6) prior synthetic 
DMARDs and 1.3 (SD=1.1) prior biological DMARDs. Mean baseline (=time of 1
st
 rituximab 
cycle) DAS28-ESR and HAQ was 5.7 (SD=1.4) and 1.6 (SD=0.7), respectively. The majority 
(80.3%) of all patients received concomitant synthetic DMARD treatment, while 66% 
received concomitant glucocorticoids.  
 
Effectiveness of repeated retreatments   
 
The total number of observations during the first 12 months from the beginning of each cycle 
(1
st
, 2
nd
, 3
rd
, 4
th
 and 5
th
 or more) was 2029, 2025, 1892, 1743 and 2317, respectively. The 
mean ± SD DAS28-ESR improved significantly through treatment cycles: 5.0 ± 1.5 at 1
st
 
cycle; 4.3 ± 1.3 at 2
nd
 cycle; 4.0 ± 1.4 at 3
rd
 cycle; 3.9 ± 1.3 at 4
th
 cycle; and 3.7 ±1.3 at 5
th
 or 
more cycle. The mean ± SD HAQ on the contrary reduced significantly from 1
st
 to 2
nd
 cycle 
but remained stable after the second treatment cycle (mean ± SD = 1.4 ± 0.7, 1.3 ± 0.7, 1.2 
±0.7, 1.2 ± 0.7 and 1.3 ± 0.7 from the 1
st
 to the 5
th
 cycle, respectively). In the mixed model 
analysis with DeltaDAS28 as the dependent variable, time and treatment cycle as fixed factors 
and country and individual patient as random factors, each treatment course was associated 
with significant changes in DeltaDAS28 (p<0.0001). Comparison between curves revealed 
significant difference between all cycles. In figure 1 fixed predicted DeltaDAS28 during the 
first 12 months from the beginning of each treatment cycle (1
st
, 2
nd
, 3
rd
, 4
th
 and 5
th
 or more 
RTX cycle) is shown. In figure 2A and 2B the percentage of patients in different disease 
activity state and EULAR responses, respectively, at baseline (start) of each treatment cycle 
are shown.  
 
 
‘On-flare’ versus ‘fixed’ retreatment 
 
A total of 800 patients were retreated at least 2 times and the reason for retreatment was 
stated: for 616 of them the reason was flare (442 at 1
st
 and 174 at 2
nd
 retreatment) and for 184 
of them it was a fixed retreatment (128 at 1
st
 and 56 at 2
nd
 retreatment). In table 1A and 1B 
baseline characteristics of patients in the two retreatment groups at 1
st
 and 2
nd
 retreatment, 
respectively, are summarized and compared.  
Patients receiving fixed retreatment had a significantly higher (in absolute number) 
DeltaDAS28 (p<0.0001) at the start of each cycle, compared to those retreated on-flare. In the 
adjusted mixed model analysis, we compared the two retreatment groups for the 1
st
 and the 
2
nd
 retreatment separately using estimated marginal means. For the 1
st
 retreatment a fixed 
retreatment yielded significantly better results than the “on-flare’’: mean DeltaDAS28=-2.4 
(95% CI: -3.0; -1.7) vs. -1.8 (95% CI: -3.6; -0.03), p<0.0001. Similar results were found for 
the 2
nd
 retreatment: mean DeltaDAS28=-2.6 (95% CI: -3.1; -2.2) vs. -1.6 (95% CI: -1.8; -1.4), 
p<0.0001. The evolution of the predicted DeltaDAS28 – ESR according to retreatment 
strategy which resulted from the adjusted mixed model analyses for the 1
st
 and 2
nd
 retreatment 
is shown in figure 3A and 3B, respectively. The retreatment strategy had a significant effect 
on the model. 
 
Discussion 
  
The results of this large, observational, international, cohort study supports the findings from 
earlier studies about the effectiveness of repeat treatment cycles with rituximab in RA. 
Patients who continue with rituximab are likely to improve further in their disease activity 
with repeated rituximab treatment cycles. This is a clinically relevant and important 
observation. Previous clinical trials and observational studies concluded similar findings
10,12
. 
In our study the possibility of further improvement was demonstrated both by DAS28 
reduction (figure 1) and proportion of patients in low disease activity/remission and EULAR 
good responders (figure 2A and 2B). By selecting only patients with at least 4 treatment 
cycles we minimized the risk for selection bias.  
The optimal retreatment strategy remains until today unclear. As it was observed in this 
cohort the majority of patients were retreated on flare but there was a respectable number of 
patients who were retreated at a fixed interval. The results of the mixed model regression 
analysis suggested that a fixed retreatment approach, before a flare occurs, might lead to more 
favorable results. This finding is in agreement with previous findings from the MIRA registry, 
where patients who were retreated before they flared achieved significantly greater reduction 
in their disease activity compared to those retreated after they flared
10
. In a retrospective 
analysis of RA patients receiving multiple courses of rituximab a retreatment regimen based 
on 24-week evaluations and a treat-to-target approach was associated with better efficacy and 
tighter control of disease activity compared with treatment as-needed
13
.  
This study has certain limitations. It is a retrospective observational cohort, although the data 
were collected prospectively. Patients were not randomized to the two retreatment strategy 
groups, and therefore the two groups were not completely balanced with regard to baseline 
characteristics. We tried to partially overcome this problem by adjusting for baseline 
differences. Significant heterogeneity between countries was observed, and country was 
therefore included as a random variable in the mixed model analysis.  
Since patients who are retreated on fixed interval are expected to receive more treatment 
cycles, it would be interesting and important to know if these patients are in a higher risk for 
adverse events, such as infections. The systematic collection of safety data in this study was 
not feasible, and therefore data on adverse events were not available. Data from other sources 
however have not shown any significant impact of repeated treatment cycles on safety
13,14
.  
Significant strengths on the other hand include the large number of patients, the possibility to 
examine different treatment strategies in different countries, the possibility of examine 
multiple courses of rituximab in a real-life cohort and the long follow up.  
 
To conclude, repeated retreatment with RTX can lead to further clinical improvement after 
the first course of RTX. A fixed retreatment strategy with RTX in RA seems to be more 
effective than the retreat ‘on-flare’ strategy. 
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Tables and figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  1
st
 Retreatment  
 On-flare 
N=442 
Fixed 
N=128 
Difference 
Months from BL 10.0±5.7 [442] 8.5±7.1 [128] 0.02 
Age (years) 49.5±11.8 [439] 51.1±12.6 [125] 0.2 
Sex (% female) 88% [442] 85% [128] 0.5 
Disease Duration (years) 11.0±7.9 [439] 11.0±8.0 [125] 0.9 
RF (% positive) 79% [382] 79% [104] 1.0 
Anti-CCP (% positive) 78% [138] 66% [58] 0.07 
N. Previous DMARDs 2.4±1.2 [430] 2.5±1.5 [119] 0.4 
N. Previous biologics 0.5±0.7 [432] 0.6±0.7 [118] 0.2 
Baseline DAS28 5.1±1.3 [424] 4.1±1.4 [120] <0.0001 
DAS28 at RTX start 6.3±1.0 [414] 6.1±1.2 [122] 0.03 
Baseline HAQ 1.5±0.7 [355] 1.3±0.8 [90] 0.001 
Concomitant DMARDs 82% [442] 92% [128] 0.02 
Concomitant 
corticosteroids 
58% [442] 46% [128] 0.004 
                                      2nd Retreatment 
 On-flare 
N=174 
Fixed 
N=56 
Difference 
Months from BL 19.9±7.0 [174] 14.4±6.6 [56] <0.0001 
Age (years) 50.3±12.3 [174] 51.3±10.8 [56] 0.6 
Sex (% female) 86% [174] 91% [56] 0.5 
Disease Duration (years) 11.7±8.6 [173] 11.2±8.6 [55] 0.7 
RF (% positive) 82% [147] 88% [50] 0.5 
Anti-CCP (% positive) 82% [56] 63% [30] 0.07 
N. Previous DMARDs 2.4±1.3 [169] 2.8±1.5 [55] 0.07 
N. Previous biologics 0.7±0.7 [167] 0.7±0.9 [55] 0.7 
Baseline DAS28 5.2±1.3 [168] 4.0±1.3 [53] <0.0001 
DeltaDAS28 from 
baseline 
-0.7±2.0 [163] -2.1±1.4 [53] <0.0001 
DAS28 at RTX start 6.2±1.1 [163] 6.3±1.1 [53] 0.7 
Baseline HAQ 1.6±0.7 [141] 1.4±0.7 [26] 0.1 
Concomitant DMARDs 54% [174] 54% [54] 0.9 
Concomitant 
corticosteroids 
81% [174] 86% [56] 0.4 
Table 1A. Baseline (=start of 2
nd
 RTX cycle) characteristics of patients who were 
retreated on flare or at fixed intervals. Number of patients with available 
information is shown in square brackets.  
 
Table 1B. Baseline (=start of 3
rd
 RTX cycle) characteristics of patients who 
were retreated on flare or at fixed intervals. Number of patients with available 
information is shown in square brackets.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Reduction of DAS28-ESR (DeltaDAS28) during the first 12 months after 
start of 1
st
, 2
nd
, 3
rd
, 4
th
 and 5
th
 or more treatment cycle for patients who received at least 
4 RTX treatment cycles (5
th
 treatment = all treatments after the 4
th
 pooled together). 
Significant DeltaDAS28 was observed for all treatment cycles and the difference 
between curves was significant in all comparisons (p<0.0001).  
  
 
 
 
 
 
 
 
Figure 2A. Disease activity state based on DAS28 at baseline (visit 1) of each 
treatment cycle for patients who received at least 4 RTX treatment cycles. A significant 
reduction of the proportion of patients in high disease activity is observed parallel to an 
increase of the proportion of patients in low disease activity and remission.  
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Figure 2B. EULAR response rates at baseline (visit 1) of each treatment cycle for 
patients who received at least 4 RTX treatment cycles. A significant reduction of the 
proportion of non-responders was observed parallel to an increase of the proportion of 
EULAR good and moderate responders.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3A and 3B. Predicted DeltaDAS28 – ESR according to retreatment strategy resulted 
from the adjusted mixed model analyses for the 1
st
 (figure 3A) and 2
nd
 (figure 3B) 
retreatment. The models were adjusted for age, sex and baseline characteristics that differed 
significantly between groups. The retreatment strategy had a significant effect on the model.  
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ABSTRACT
Background Switching to a second tumour necrosis
factor inhibitor (TNFi) after discontinuation of a ﬁrst in
rheumatoid arthritis (RA) is a common strategy. The
reason for the switch from the ﬁrst TNFi could
potentially inﬂuence the response to therapy. Data on
direct comparisons between TNFi after switching are
limited.
Methods The national Swedish register was used. RA
patients who switched to a second TNFi (inﬂiximab,
etanercept or adalimumab) after failure of a TNFi as
ﬁrst-ever biologic were identiﬁed. Effectiveness of
treatment was compared across the three drugs
according to the ﬁrst TNFi used, the reason for
discontinuing and the drug survival. Drug survival across
TNFi used as second biologic was compared.
Results Half of all patients starting inﬂiximab,
adalimumab or etanercept during the period 2005–2012
discontinued treatment for various reasons. Of these
patients, a third switched within 2 months to a second
TNFi (inﬂiximab, etanercept or adalimumab). Around
35% of all patients achieved low disease activity or
remission at 6 months. Regarding the switching strategy,
best results were observed among patients who switched
from inﬂiximab to etanercept because of (secondary)
inefﬁcacy. Etanercept as second TNFi was associated
with longer drug survival compared with inﬂiximab.
Conclusions Switching to a second TNFi after the
failure of the ﬁrst may lead to good clinical results. The
inter-drug differences in drug survival on the second
TNFi mirror those reported previously for the ﬁrst TNFi,
suggesting that these differences are not solely due to
channelling bias.
INTRODUCTION
The ﬁrst biologic agents to be approved for the
treatment of active rheumatoid arthritis (RA),
refractory to conventional antirheumatic therapy,
were the tumour necrosis factor inhibitors (TNFis)
etanercept (ETA), inﬂiximab (INF) and adalimumab
(ADA).1–3 ETA is a soluble TNF receptor, INF a
chimeric anti-TNF monoclonal antibody and ADA
a fully human anti-TNF monoclonal antibody. In
the last 3 years, two new anti-TNF monoclonal
antibodies have become available, namely, certoli-
zumab pegol and golimumab.4–6
The signiﬁcant efﬁcacy and acceptable safety proﬁle
of these drugs have been demonstrated in large rando-
mised controlled clinical trials.1–11 However, it has
also been shown that a signiﬁcant number of patients
discontinue treatment for various reasons, mainly due
to inefﬁcacy or intolerance. Indeed, a number of
studies from clinical practice indicate that as many as
50% of all patients discontinue their TNFi treatment
during the ﬁrst 3 years.12–14
In clinical practice, switching to a second TNFi is
common, the rationale being that the different TNFis
differ in their molecular structure, immunological
action, immunogenicity and pharmacokinetics. Both
clinical trials and epidemiological studies have
demonstrated the efﬁcacy of TNF inhibition after
TNF failure.15–20 To optimise switching between
TNFis in clinical practice, more information is
needed on whether factors such as reason for switch-
ing (inefﬁcacy or intolerance of the ﬁrst TNFi) or
type of the ﬁrst TNFi inﬂuence the response to the
second TNFi. Previous studies have examined the
effectiveness of switching from the ﬁrst
TNFi.13 14 20 21 However, no study to our knowl-
edge has hitherto compared speciﬁc switching strat-
egies (switching between individual TNFis).
In many observational studies, slightly better
retention rates and effectiveness have been reported
for ETA than for ADA and INF, but there is some
uncertainty whether this superiority reﬂects chan-
nelling bias or a true difference.14 22 One way to
‘disconnect’ such channelling from drug-related
effects is to make inter-drug comparisons of drug
survival and effectiveness of individual TNFis used
as second TNFi (ie, when the initial channelling
was to another TNFi).
The aims of this study were therefore to (1)
assess switching from ﬁrst to second TNFi under
different circumstances (according to the reason for
discontinuation and the type of the ﬁrst TNFi)
trying to identify an optimal switching strategy and
(2) examine drug survival of ADA, ETA and INF
when used as second TNFi after switching from a
ﬁrst TNFi in patients with RA identiﬁed in clinical
practice.
METHODS
Study population
Data from the nationwide Swedish Biologics
Register (Anti-Rheumatic Therapy in Sweden
(ARTIS)) were used. To this register, data on adult
patients prescribed biologic agents for the treatment
of rheumatic diseases in Sweden have been collected
since 1999. The coverage of the ARTIS database has
been estimated to be nearly 90% of all eligible
patients with RA.23 24 Most RA patients in Sweden
start an anti-TNF after failure of at least one syn-
thetic disease modifying antirheumatic drug.
Patients included in this observational cohort
study had a diagnosis of RA and had started
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treatment with a ‘ﬁrst-ever’ used TNFi (INF, ETA or ADA)
during the period 01 January 2005–01 September 2012. We
chose to include patients who started TNFi treatment after
2005 since all three TNFis were available and switching from
one TNFi to another was common in clinical practice. Among
these, we further identiﬁed those patients who switched to INF,
ETA or ADA as second TNFi. Patients switching to another bio-
logic (rituximab, tocilizumab or abatacept), to one of the newest
TNFis (golimumab, certolizumab pegol), or those who stopped
and restarted the same TNFi were excluded from the analysis.
Although many patients who discontinue a ﬁrst biologic may
eventually start a second, for the purpose of this study, we
deﬁned ‘switching’ as starting a second and different TNFi
within 2 months from the date of discontinuation of the ﬁrst
TNFi. By setting this time frame, we eliminated the risk that a
patient would start another non-biologic disease modifying anti-
rheumatic drug before switching to a second TNFi, as the
assessment of treatment efﬁcacy takes place after 3 months.
Patients who did not have enough follow-up time (started the
second TNFi within 8 months from the last observation date
(01 September 2012)) were also excluded from this analysis.
Four different reasons for discontinuation of the ﬁrst TNFi were
considered: primary inefﬁcacy (lack of efﬁcacy, including partial
efﬁcacy), secondary inefﬁcacy (loss of efﬁcacy), intolerance and
other (pregnancy, patient’s or physician’s decision, inactive
disease, death, unknown).
The following information was collected: demographic data
(age, sex); RA disease duration (from the time of diagnosis);
rheumatoid factor; type of ﬁrst TNFi, date and reason for dis-
continuation of the ﬁrst TNFi; date of initiating therapy with
the second TNFi and, if discontinued, date and reason; disease
activity score based on 28-joint status (DAS28) and its compo-
nents (swollen joint count, tender joint count, visual analogue
scale general health and erythrocyte sedimentation rate); and
functional ability based on health assessment questionnaire. The
reason for discontinuation was based on the rheumatologist’s
opinion and was recorded according to a predeﬁned list of dif-
ferent options.
Effectiveness of treatment was assessed by DAS28 change
(ΔDAS28) between baseline and 6 months (150–240 days from
baseline), the percentage of patients achieving low disease activ-
ity or remission (according to DAS28 status: low disease
activity=DAS28≤3.2, remission=DAS28≤2.6) as well as the
percentage of patients achieving DAS28 improvement ≥1.2 at
6 months. Baseline was deﬁned as start of second TNFi. Drug
survival of the three TNFis as second biologic was also assessed.
Statistical analysis
Three exposure categories of interest were deﬁned: patients
who switched to INF, ETA or ADA after the failure of either of
these drugs used as the ﬁrst-ever TNFi. Baseline characteristics
across the three groups were summarised and compared. The
normality of all continuous variables was tested by skewness.
Variables which were similar to normal distribution were pre-
sented as mean±SD, while non-normally distributed variables
were presented as median with IQR. One-way analysis of vari-
ance was used to compare continuous variables (with a distribu-
tion similar to normal) followed by Bonferroni test for post hoc
comparisons between the groups, while χ2 test was used for
nominal variables. Kruskal–Wallis test was used to compare non-
normally distributed variables. The level of statistical signiﬁ-
cance was set to 5%.
We used two time frames for follow-up, 3 and 6 months. To
comply with clinical practice, the time window was 30–150 days
from baseline for the 3-month visit and 150–240 days from
baseline for the 6-month visit. The median time to ﬁrst visit in
ARTIS is 4.5 months after the start date. We prioritised
6 months data over 3 months data, when available, but when no
such data were available, we used data from the 3-month visit.
Non-responder imputation (deﬁned as high or moderate disease
activity at 6 months) was used for patients switching to another
biologic during the follow-up period and for patients who did
not have a follow-up visit but for whom the stated reason for
stopping treatment was primary or secondary inefﬁcacy. Three
main analyses were performed. (1) The effectiveness of INF,
ETA and ADA as second TNFi was directly compared in a ﬁrst
analysis. Stratiﬁcation for baseline DAS28 (high baseline disease
activity deﬁned as DAS28≥5.1 vs non-high with DAS28<5.1)
was performed to investigate effect modiﬁcation by disease
activity, that is, any inter-drug difference would differ for differ-
ent levels of baseline disease activity. (2) The effectiveness of the
three TNFis was assessed as a function of the ﬁrst TNFi. In
total, six different switching strategies were thus compared (ﬁrst
ADA then ETA, ﬁrst ADA then INF, ﬁrst ETA then ADA, etc).
(3) Effectiveness of the second TNFi was assessed as a function
of the reason for discontinuation of the ﬁrst TNFi. Four differ-
ent reasons for discontinuation of the ﬁrst TNFi were consid-
ered: intolerance, primary inefﬁcacy (lack of efﬁcacy, including
partial efﬁcacy), secondary inefﬁcacy (loss of efﬁcacy) and other
(pregnancy, patient’s or physician’s decision, inactive disease,
death, unknown).
Kaplan–Meyer curves were plotted to determine continuation
rates for the second TNFi during the ﬁrst 2 years following
switch. Curves were compared with the Log-Rank test.
Discontinuation of treatment (for the reasons described above)
was considered an event. Continuation of treatment at the time
of data collection was treated as censored observations during
the analysis.
RESULTS
We identiﬁed 7052 patients with a diagnosis of RA who started
treatment with a ﬁrst-ever TNFi (INF, ETA or ADA) during the
period 01 January 2005–01 September 2012: 2174 with INF,
3076 with ETA and 1802 with ADA. During the same time-
period, 50% of these patients discontinued their TNFi treat-
ment. Of these, 2649 (38%) patients started a second biologic,
1457 to a second TNFi. In the ﬁnal study population, 952
patients who switched (according to our deﬁnition) to a second
TNFi and had long enough follow-up time were included (74
switched to INF, 448 to ETA and 430 to ADA within 2 months
after discontinuing the ﬁrst TNFi). In ﬁgure 1, the ﬂow chart of
patients is shown.
Baseline for our analyses was deﬁned as the time of start of
the second TNFi. Patients in the three groups were quite well
balanced regarding baseline characteristics, except for baseline
DAS28 which was signiﬁcantly lower in the ADA group com-
pared with the other two groups (table 1). Regarding baseline
DAS28 status, the completeness of available data was 80% for
INF, 83% for ETA and 78% for ADA. Regarding available
DAS28 status/ΔDAS28 at 6 months, completeness of available
data was 81/64% for INF, 86/74% for ETA and 86/73% for
ADA. The percentage of missing data at 3 and 6 months was
similar across the three TNFi groups.
Effectiveness of second TNFi, per drug
At 6 months patients in all three groups achieved signiﬁcant
reductions in DAS28: ΔDAS28 0–6 months=−1.1±1.5 [n=38]
for INF, −1.4±1.6 [n=275] for ETA and −0.8±1.5 [n=244]
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for ADA. The inter-drug difference was statistically signiﬁcant
between ETA and ADA (p<0.0001). After adjustment for base-
line DAS28, this difference remained signiﬁcant (p=0.04). The
percentage of patients who achieved ΔDAS28≥1.2 was 47%
(18/38) for INF, 55% (151/275) for ETA and 36% (87/244) for
ADA (p<0.0001 ETA vs ADA). The percentage of patients with
low disease activity or remission at 6 months, however, was
similar for all groups: 37% (18/49) for INF, 34% (113/332) for
ETA and 35% (103/294) for ADA. When stratiﬁed by baseline
DAS28, the ETA group achieved numerically higher but statistic-
ally not signiﬁcantly different DAS28 reductions than ADA
(table 2).
Effectiveness of second TNFi as a function
of the type of ﬁrst TNFi
In the second analysis, we examined the effectiveness of the
second TNFi taking into consideration the TNFi switched from.
The six possible switching groups were distributed as follows:
from ADA to ETA (N=206), from ADA to INF (N=16), from
ETA to ADA (N=329), from ETA to INF (N=58), from INF to
ADA (N=101) and from INF to ETA (N=242). The effective-
ness observed for each switching strategy is shown in table 3.
For the two largest groups, statistically greater ΔDAS28 was
observed in the group switching from INF to ETA than for the
group switching from ETA to ADA (p<0.0001, after adjustment
for baseline DAS28, p=0.004). Overall better results were
observed for the INF→ETA and the ADA→ETA groups
compared with ETA→ADA (the two reciprocal groups,
ETA→INF and ADA→INF, were too small to allow any
comparisons).
Effectiveness of second TNFi by reason for discontinuation
of ﬁrst TNFi
In the third analysis, we examined the effectiveness of the
second TNFi according to the reason for switch from the ﬁrst
TNFi. The majority of patients switched to the second TNFi
after lack or loss of efﬁcacy of the ﬁrst TNFi (66%), while
17.4% of patients switched due to intolerance. The number of
patients as well as effectiveness data according to the reason for
switch is shown in table 4. Overall numerically higher ΔDAS28
at 6 months was observed after loss of efﬁcacy (mean ΔDAS28
at 6 months=−1.4±1.6) than after lack of efﬁcacy (mean
ΔDAS28=-1.2±1.6) or intolerance (mean ΔDAS28=−1.1±1.5)
to the ﬁrst TNFi. Signiﬁcantly higher rates of low disease activ-
ity/remission at 6 months were achieved when the reason for
switch was secondary inefﬁcacy (40%) or intolerance (39%)
than primary inefﬁcacy (26%) (p<0.0001). The best responses
were observed when switching to ETA after losing efﬁcacy of
ADA or INF as the ﬁrst TNFi.
Drug survival on the second TNFi, per drug
During the ﬁrst 24 months after switching to the second TNFi,
567 patients (60%) discontinued their second TNFi: 46 out of 74
in the INF group (62%), 257 out of 448 (57%) in the ETA group
Figure 1 Flow chart of patients (selection as described in the methods). 7052 Swedish RA patients started treatment with inﬂiximab (INF),
etanercept (ETA) or adalimumab (ADA) as 1st TNFi during 2005-2012. Around 50% discontinued treatment during the observational period (number
and percentage of patients discontinued indicated in the boxes). 1457 patients continued with a 2nd TNFi, of which 1068 ‘switched’ to INF, ETA or
ADA within 2 months after discontinuing the 1st TNFi. (Grey boxes: patients excluded).
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and 264 out of 430 (61%) in the ADA group (ﬁgure 2).
The median (95% CI) survival time for INF, ETA and ADAwas 14
(7–21), 24 (16–32) and 16 (9–23) months, respectively. Since the
survival curves crossed at approximately 8 months (ﬁgure 2), two
separate analyses were performed; up to 8 months following
switch, no signiﬁcant differences in drug survival among ADA,
ETA and INF were observed, but for the second time-period sig-
niﬁcant differences were observed (ﬁgure 2).
Table 2 Effectiveness of second TNF inhibitor (INF, ETA and ADA) based on ΔDAS28, % of patients with low disease activity or remission at
6 months and % of patients achieving ΔDAS28 of at least 1.2 at 6 months, stratified by disease activity at baseline (high vs no high)
No high disease activity at baseline
INF
N=31
ETA
N=184
ADA
N=199
Difference between
groups (p value)
Post hoc comparisons
between groups
DAS28 baseline 4.0±0.8
(31)
4.0±0.9
(184)
3.8±1.0
(199)
0.12
DAS28 6 months 3.4±1.6
(22)
3.3±1.3
(125)
3.4±1.2
(145)
0.81
ΔDAS28 6 months −0.6±1.4
(22)
−0.8±1.3
(125)
−0.4±1.3
(145)
0.09 0.09 ETA vs ADA
% Low disease activity or remission 6 m 52.2%
(23)
44.3%
(131)
46.6%
(146)
0.77
% ΔDAS28≥1.2 31.8%
(22)
37.6% (125) 26.9%
(145)
0.17
High disease activity at baseline
INF
N=28
ETA
N=188
ADA
N=136
Difference between
groups (p value)
Post hoc comparisons
between groups
DAS28 baseline 6.1±0.6
(28)
6.2±0.8
(188)
6.0±0.7
(136)
0.13
DAS28 6 months 4.3±1.1
(16)
4.2±1.5
(150)
4.6±1.5
(99)
0.19
ΔDAS28 6 months −1.8±1.3
(16)
−1.9±1.5
(150)
−1.4±1.6
(99)
0.05 0.05 ETA vs ADA
% Low disease activity or remission 6 m 18.8%
(16)
24.8%
(153)
19.8%
(101)
0.60
% ΔDAS28≥1.2 68.8%
(16)
69.3%
(150)
48.5%
(99)
0.003 0.003 ETA vs ADA
ADA, adalimumab; DAS28, disease activity score based on 28-joint status; ΔDAS28, DAS28 change; ETA, etanercept; INF, infliximab; TNF, tumour necrosis factor.
Bold typeface indicates statistical significance.
Table 1 Characteristics for Swedish patients with RA starting a second TNFi (INF, ETA or ADA) during 2006–2012 at the time-point of their
second TNFi start
INF
N=74
ETA
N=448
ADA
N=430
Difference among
groups (p value)
Post hoc comparisons
between groups
Age in years (mean±SD) 52.7±15.0
(74)
53.8±13.0
(448)
54.4±13.4
(430)
0.56
Sex (% female) 77.0%
(74)
77.0% [448) 77.2%
(430)
0.99
Disease duration (median, IQR) 9.9 (3.2–15.1)
(67)
8.4 (3.7–15.9)
(408)
8.6 (4.3–16.8)
(381)
0.66
RF (% positive) 85.9%
(71)
81.1%
(429)
74.6%
(410)
0.02 INF vs ADA
ETA vs ADA
Baseline DAS28 (mean±SD) 5.0±1.3
(59)
5.1±1.4
(372)
4.7±1.4
(335)
0.001 ETA vs ADA
Baseline HAQ (mean±SD) 1.2±0.7
(63)
1.2±0.6
(385)
1.1±0.6
(363)
0.38
Concomitant DMARDs (% yes) 86.5%
(74)
76.8%
(448)
69.5%
(430)
0.002 INF vs ADA
ETA vs ADA
Concomitant MTX (%) 82.4% 65.0% 59.5% 0.001 INF vs ETA
INF vs ADA
ETA vs ADA
Concomitant Glucocorticoids (% yes) 41.9%
(74)
52.9%
(448)
50.5%
(430)
0.21
Number in brackets indicates the number of patients with available information for each variable. One-way analysis of variance was used to compare continuous variables followed by
Bonferroni test for post hoc comparisons between the groups, while χ² test was used for nominal variables. Kruskal–Wallis test was used to compare non-normally distributed continues
variables across groups.
ADA, adalimumab; DAS28, disease activity score based on 28-joint status; DMARD, disease modifying antirheumatic drug; ETA, etanercept; HAQ, health assessment questionnaire; INF,
infliximab; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; TNFi, tumour necrosis factor inhibitor.
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DISCUSSION
The results of our study support the ﬁndings from previous
studies that switching to a second TNFi may lead to signiﬁcant
clinical improvements, with almost 40% of patients achieving
low disease activity or remission, regardless of the speciﬁc TNFi.
Because of the real-world setting, our ﬁndings must be inter-
preted in light of a number of potential or real differences
among the three groups of switchers. As shown in table 1, most
baseline demographic and disease variables were quite similar
across groups. However, baseline disease activity was signiﬁ-
cantly higher for those starting ETA as their second TNFi than
ADA, which (under the assumption that the capacity for DAS28
reduction is non-linear, or simply through regression to the
mean) might explain the greater improvement in DAS28 for
ETA as second TNFi compared with ADA. Indeed, when strati-
ﬁed by baseline disease activity, we observed overall greater
reductions in DAS28 among those patients with a disease activ-
ity score above 5.1 at the time point of the second TNFi start
than in the non-high disease activity group, but, as expected, a
higher percentage of patients achieving low disease activity/
remission in the latter. ETA achieved numerically but not signiﬁ-
cantly better improvements than ADA, which might represent a
true effect but also reﬂect limited statistical precision. The dif-
ference was not large enough to assure a true clinical difference.
Overall better results were achieved with the second TNFi
after loss of efﬁcacy or intolerance to ﬁrst TNFi than after lack of
efﬁcacy of the ﬁrst TNFi, supporting the results from previous
studies.18 20 This observation is rational and supports the hypoth-
esis that for patients who do not respond to TNFi (primary inef-
ﬁcacy), TNF might not play that important role in their disease
and a second TNFi would yield only modest results. Best
responses were observed when switching to ETA after losing efﬁ-
cacy of ADA or INF as the ﬁrst TNFi. The production of antidrug
antibodies, drug immunogenicity, has been proposed as one pos-
sible mechanism behind inefﬁcacy.25–28 Secondary inefﬁcacy to a
ﬁrst TNFi might be due to development of antidrug antibodies,
Table 3 Effectiveness of six different switching strategies (first TNFi→second TNFi) based on ΔDAS28 after 6 months, % of patients with low
disease activity or remission at 6 months and % of patients achieving ΔDAS28 of at least 1.2 at 6 months
First TNFi→second TNFi
INF→ETA
N=242
INF→ADA
N=101
ETA→INF
N=58
ETA→ADA
N=329
ADA→INF
N=16
ADA→ETA
N=206
DAS28 baseline* 5.3±1.4
(197)
4.7±1.4
(78)
5.1±1.3
(45)
4.7±1.4
(257)
4.8±1.5
(14)
4.9±1.3
(175)
DAS28 6 months** 3.8±1.5
(180)
3.3±1.5
(64)
3.7±1.5
(38)
4.0±1.5
(225)
3.6±1.5
(10)
3.9±1.5
(141)
ΔDAS28 6 months*** −1.6±1.5
(150)
−1.2±1.6
(48)
−1.2±1.6
(30)
−0.7±1.5
(196)
−0.6±0.9
(8)
−1.2±1.6
(125)
% Low disease activity or remission at 6 months 38.0%
(184)
47.0%
(66)
31.6%
(38)
31.6% [228) 54.5%
(11)
29.1% [148)
% With DAS28 improvement ≥1.2 at 6 months 58.7%
(150)
45.8%
(48)
56.7%
(30)
33.2%
(196)
12.5%
(8)
50.4%
(125)
*p<0.0001 INF→ETA vs ETA→ADA, p=0.04 INF→ETA vs INF→ADA.
**p=0.01 INF→ADA vs ETA→ADA.
***p<0.0001 INF→ETA vs ETA→ADA (remained significant after correction for baseline DAS28, p=0.004).
ADA, adalimumab; DAS28, disease activity score based on 28-joint status; ΔDAS28, DAS28 change; ETA, etanercept; INF, infliximab; TNFi, tumour necrosis factor inhibitor.
Figure 2 Drug survival during the
ﬁrst 2 years of treatment for INF, ETA
and ADA as 2nd TNFi. Signiﬁcant
difference was observed between INF
and ETA as well as INF and ADA
during the period 8–24 months
(p=0.02 ETA vs. INF, p=0.05 ADA vs.
INF by Log–rank test).
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and non-responders in that case might beneﬁt from a switch to a
less immunogenic drug, such as ETA.
When different switching strategies were compared, overall
better results were observed for patients who switched from INF
or ADA (monoclonal antibodies) to ETA than the other way
round. We acknowledge, however, that some of the switching
strategies included a too limited number of patients to allow for
meaningful interpretation. The observed difference was present
mainly when the reason for switching was inefﬁcacy rather
than intolerance (see online supplementary ﬁle). A clinical
interpretation of this observation might be that after the failure
of a monoclonal anti-TNF antibody one could consider switch-
ing to ETA, but when a patient has failed ETA as ﬁrst TNFi, the
choice of a monoclonal antibody as second TNFi might not
have the same potential to lead to a clinically signiﬁcant
improvement. Indeed, other studies have shown that in the
latter case it might be more beneﬁcial to change to a biologic
of a different mechanism of action.29 30 This might imply an
underlying mechanism that could explain this ﬁnding: as it is
known, ETA competitively inhibits the binding of both TNF
and lymphotoxin-α to cell surface TNF receptors, rendering
TNF biologically inactive,31 while INF and ADA bind and neu-
tralise both soluble and membrane-bound TNF but not lym-
photoxin. Lymphotoxin plays a crucial role in chronic
inﬂammation.32 Thus, failing a monoclonal antibody (espe-
cially because of inefﬁcacy) a patient might respond well to
ETA, and the reason could be the binding of lymphotoxin.33
This remains, however, a hypothesis.
A limitation of this study was the observational cohort study
design, as patients were not randomly placed in the treatment
groups. The risk of selection bias is therefore present. The treat-
ment groups under comparison were not entirely balanced for
baseline characteristics and some signiﬁcant differences were
observed, which might introduce the risk for confounding.
Other and unknown baseline factors may also differ between
the drugs. Indeed and as mentioned in the Introduction section,
confounding by indication may be responsible for some of the
previously observed differences in drug survival between ETA
and ADA/INF as ﬁrst TNFi. In this study, we could limit some
of such confounding by indication by assessing drug survival on
these drugs when used as the second TNFi (hence, when
patients starting ETA were recruited from a pool of patients
who had initially all be channelled to treatment with INF or
ADA, and vice versa). We found some differences in favour of
ETA as second TNFi, similar to what has been shown in previ-
ous analyses of ﬁrst TNFi, suggesting that it is more possible
that these results represent true difference and are not entirely
due to confounding by indication related to the choice of the
ﬁrst TNFi. The clinical relevance of the observed difference is,
however, unclear. Other differences between TNFis, such as
route of administration, have to be taken into account. INF is
given intravenously, which might inﬂuence negatively its reten-
tion rate. Such factors limit the possibility of comparing these
agents using retention rates as surrogates for effectiveness. We
tried to partially overcome the problem with selection bias by
ﬁrst adjusting for baseline DAS28 and then by stratifying accord-
ing to disease activity (high vs low).
The limited number of patients in some of the comparisons
was a challenge. Some numerical differences did not reach statis-
tical signiﬁcance, and this might be due to lack of power.
Missingness is a common problem in register-based observa-
tional studies. In our study, missingness did not differ between
drugs. Due to the limitations described above, however, the
results of this study have to be interpreted with caution.
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In summary, after the failure of the ﬁrst TNFi, up to 40% of
patients switching to a second TNFi may achieve low disease
activity or remission. After the failure of a monoclonal antibody
as ﬁrst TNFi because of inefﬁcacy, switching to ETA yielded
good clinical results, but not the other way round. ETA was
associated with longer drug survival compared with INF as
second TNFi. The inter-drug differences in drug survival on the
second TNFi mirror those reported previously for the ﬁrst
TNFi, suggesting that these differences are not solely due to
channelling bias.
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Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor
in an observational cohort
K Chatzidionysiou, RF van Vollenhoven
Unit for Clinical Research Therapy, Inflammatory Diseases (ClinTRID), Karolinska Institute, Stockholm, Sweden
Objective: The purpose of this study was to characterize and compare responses in patients who had failed one tumour
necrosis factor (TNF) inhibitor when switching to another TNF inhibitor or rituximab (RTX).
Methods: The Stockholm TNF follow-up registry (STURE) was used. Treatment results at 6 months were analysed by
(i) the biologic used, (ii) the type of anti-TNF switch, and (iii) the reason for discontinuation (inefficacy or intolerance).
Results:A total of 328 patients who failed an anti-TNF switched to an alternative biologic, 69 to RTX, 161 to an anti-TNF
monoclonal antibody (mAb), and 98 to etanercept (ETA). Significant reductions in the 28-joint Disease Activity Score
(DAS28) at 6 months were observed for all groups. The mean SD reduction in DAS28 was 1.70 1.18 for RTX, 1.40
1.51 for ETA, and 0.67 1.36 for mAb, the difference being statistically significant between RTX and mAb (p< 0.0001).
For patients who had failed ETA, RTX led to significantly greater DAS28 reductions than mAb (p ¼ 0.01). When the
reason for discontinuation of the previous anti-TNF was intolerance or secondary inefficacy, RTX led to significantly
greater DAS28 reduction compared to mAb and ETA (p ¼ 0.01 and p ¼ 0.03, respectively).
Conclusions: In this observational cohort, patients who failed one anti-TNF had better overall results when treated with
RTX than with a subsequent anti-TNF mAb. Having failed ETA, RTX yielded greater DAS28 reductions and European
League Against Rheumatism (EULAR) responses than mAb. The advantage of RTX was most clearly seen in patients
who had failed anti-TNF because of intolerance or secondary inefficacy.
An increasing number of biological therapeutic agents for
rheumatoid arthritis (RA) are now available. Besides the
tumour necrosis factor (TNF) blocking agents [inflixi-
mab, etanercept (ETA), adalimumab, and the newest
golimumab and certolizumab pegol], the efficacy of
other biological therapies has also been established,
including the B-cell depleting agent rituximab (RTX),
the interleukin-6 inhibitor tocilizumab, and the inhibitor
of T-cell co-stimulation abatacept (1–10). Not every
patient will benefit from all of these therapies (11), and
the question that has been raised during the past few years
is which subgroup of RA patients would be the ‘target
group’ for each biological agent.
Various research articles have shown that, after the
failure of one TNF antagonist, switching to an alternative
anti-TNF can provide clinical benefit for some patients
(12–20). However, switching to an agent with a different
mechanism of action after the failure of a TNF antagonist
might seem more logical. Finckh et al examined the
efficacy of RTX in comparison to that of an alternative
anti-TNF agent in patients with inadequate response to
one or more anti-TNFs, and reached the conclusion that
the former biological agent led to better results (21).
The aim of this observational study was to determine
whether patients who failed one TNF inhibitor achieved
better results when switching to a second TNF inhibitor,
a monoclonal antibody (mAb), the soluble receptor ETA,
or RTX. The potential influence of the type of anti-TNF
switch and the relationship between the reason for dis-
continuation of the previous agent and the efficacy of the
next treatment were also examined.
Methods
The Stockholm TNF follow-up registry (STURE) data-
base collects efficacy data for all patients starting bio-
logical treatments at the major hospitals in Stockholm,
as part of the nationwide registry of AntiRheumatic
Therapies in Sweden (ARTIS). The design of the study
was approved by local ethical committees. The assess-
ments are performed at baseline, 3, 6, and 12 months,
and annually thereafter, and include the American
College of Rheumatology (ACR) core outcomes [the
28 swollen (SJC) and tender joint count (TJC), visual
analogue scales (VAS) for global health and for pain, the
Health Assessment Questionnaire (HAQ) disability
index, erythrocyte sedimentation rate (ESR), C-reactive
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protein (CRP)], the DAS28 score, and record of concur-
rent medications.
Patients with a diagnosis of RA who started treatment
with a TNF inhibitor between 1 January 2005 and 31
December 2010 were included in the cohort. Patients
who failed one TNF inhibitor (infliximab, adalimumab,
ETA) for various reasons and switched to an anti-TNF
monoclonal antibody (mAb: infliximab or adalimumab),
the soluble receptor ETA, or RTX were identified and
included in the analysis. Of duplicate segments with the
same anti-TNF, only the first one was used. The efficacy of
each treatment was assessed by DAS28 improvement and
European League Against Rheumatism (EULAR)
response (Good, Moderate, None) at 6 ( 1) months after
treatment start. For those patients with no available DAS28
value at 6 months, the 3-month DAS28 was used [as last
observation carried forward (LOCF)], if they were still on
treatment. Treatment results at 6 months were analysed by
(i) the biologic used; (ii) the type of anti-TNF switch, and
(iii) the reason for discontinuation of the previous biologic
(primary inefficacy, including complete and partial lack of
efficacy (21), secondary loss of efficacy, intolerance, or
other reasons). The reason of discontinuation was based on
the opinion of the treating physician. Three treatment
groups were formed according to the second biologic:
RTX, anti-TNF mAb, and ETA. A sensitivity analysis
gave similar results for the two biologics infliximab and
adalimumab, and therefore these were merged together
into one group (mAb).
The baseline characteristics of the three main groups
were analysed by means of descriptive statistics. For
normally distributed variables (given as mean  SD), an
independent Student’s t-test was used, while for the non-
normally distributed variables [given as median (IQR)],
the Mann–Whitney U-test was used. Fisher’s exact test
was used for comparison of categorical data. Difference
between the groups regarding DAS28 improvements was
investigated by an analysis of variance (ANOVA). An
analysis of covariance (ANCOVA) was performed for
correction of baseline differences between groups. All
statistical tests were evaluated at a 0.05 significance
level. P-values and 95% confidence intervals (CIs) are
presented. The statistical analysis was performed with
SPSS version 20.
Results
A total of 328 patients who previously failed one TNF
inhibitor were identified. Of these, 259 switched to
another TNF inhibitor (161 received an anti-TNF mAb
as a second biologic and 98 received treatment with ETA)
and 69 switched to RTX.
Baseline characteristics
The baseline characteristics for patients in the three
groups are summarized in Table 1. Significant differences
were found between the groups regarding age, rheuma-
toid factor (RF) positivity, baseline HAQ score, number
of SJC, and CRP. Patients who switched to RTX had
higher disease activity (as assessed with DAS28, HAQ,
SJC, and CRP) at baseline, mainly compared to mAb.
Effectiveness of treatment
The course of treatment was followed during the first
6 months. There was a significant improvement in
DAS28 for both RTX and anti-TNF groups from baseline
to 6 months (paired t-test, p < 0.0001 for all groups)
(Table 2). The mean ( SD) improvement in DAS28 was
significantly lower for mAb vs. RTX and ETA, and the
difference remained statistically significant after correction
for baseline differences (age, RF, baseline DAS28, and
HAQ) (Table 2). In Table 2 changes at 6 months in
DAS28 components as well as CRP and HAQ are also
included. At the end of 6months the proportions of patients
who achieved a EULAR Good/Moderate/No response
were: 22.9/54.2/22.9% for RTX (total number of patients
with available information n ¼ 35), 33.3/33.3/33.4% for
ETA (n ¼ 48), and 13.8/29.9/56.3% for mAb-treated
Table 1. Baseline demographics, disease and treatment characteristics of patients who switched to rituximab (RTX), a monoclonal
antibody (mAb), or etanercept (ETA) after the failure of one TNF inhibitor.
anti-TNF mAb [161] ETA [98] RTX [69] p-value
Age (years), mean  SD 55.8  13.8 [161] 52.7  14.4 [98] 60.3  14.0 [69] 0.02 (mAb vs. RTX)
0.001 (ETA vs. RTX)
Sex (% female) 78.9 [161] 87.8 [98] 84.1 [69] NS
Disease duration (years), median (IQR) 6 (3–15) [160] 7 (2–15) [98] 9 (3–16) [69] NS
RF (% positive) 78.9 [161] 77.6 [98] 91.3 [69] 0.05 mAb and ETA vs. RTX
Pain VAS, mean  SD 52.5  24.8 [133] 51.4  25.3 [79] 58.4  20.6 [51] NS
DMARDs (%) 68.9 [161] 71.4 [98] 59.4 [69] NS
MTX (%) 64.0 [161] 61.2 [98] 42.0 [69] NS
Corticosteroids (%) 45.3 [161] 54.1 [98] 58.0 [69] NS
RF, Rheumatoid factor; VAS, visual analogue scale; DMARD, disease-modifying anti-rheumatic drug; MTX, methotrexate.
The numbers of patients under study are given in square brackets.
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patients (n ¼ 87). The difference in Good vs. No respon-
ders was statistically significant between ETA and mAb
(p ¼ 0.003) and between RTX and mAb (p ¼ 0.02).
Effectiveness of switching according to the type of TNF
switch
Weanalysed the effectiveness of RTX and anti-TNF accord-
ing to the type of TNF switch. Table 3 shows the number of
patients who switched frommAb andETA tomAb, ETA, or
RTX.Having failed ETA, RTXwas significantly better than
mAb [improvement in DAS28 0–6 months ¼ 1.96  0.90
(n¼ 18) vs. 0.69 1.34 (n¼ 68), p¼ 0.01, 95% CI 0.10–
0.75, p corrected for age, RF, baseline DAS28, and HAQ].
For patients who had failed mAb, RTX and ETA led to
similar improvements in DAS28 [improvement in DAS28
0–6 months ¼ 1.42  1.40 (n ¼ 16) and 1.40  1.51 (n ¼
47), respectively]. These improvements were numerically
higher than for TNF mAb [improvement in DAS28 0–6
months ¼ 0.55  1.53 (n ¼ 15)].
Similar results were observed when we examined the
effectiveness based on the percentages of EULAR Good/
Moderate/No responders (Figure 1).
Reasons for discontinuation of previous treatment
In general, when the reason for discontinuation of the first
TNF inhibitor was inefficacy, more patients switched to a
second TNF inhibitor (either mAb or ETA) than RTX
(57.9% and 31.9%, respectively, p < 0.0001) (Table 4).
The opposite was seen for the group of patients who
experienced an adverse event during the first anti-TNF
therapy. A greater percentage of patients switched then to
RTX (43.5%) than a second anti-TNF (19.7%) (Table 4).
The reason for discontinuation of the previous treat-
ment appeared to be related to the efficacy of the next
treatment. When the cause for switching was intolerance,
RTX achieved significantly greater improvement in
DAS28 (p ¼ 0.02, 95% CI 0.08–0.89) and significantly
greater EULARGood/Moderate response rates (p¼ 0.04)
compared to anti-TNF mAb (Table 4). RTX-treated
patients achieved numerically greater DAS28
Table 3. Number of patients who failed one TNF inhibitor (mAb
or ETA) and switched to an alternative TNF inhibitor (mAb or
ETA) or RTX, according to the type of TNF switch.
First TNF inhibitor
Second biologic mAb ETA Total
mAb 24 137 161
ETA 98 NA 98
RTX 35 34 69
Total 157 171 328
p = 
0001
40%
20%
0%
ETA to
RTX
ETA to
mAb
mAb to
RTX
mAb to
mAb
mAb to
ETA
60%
80%
100% 10.5%
52.6%
36.9%
33.3%
55.6%
11.1% 6.3%
56.2%
37.5%
60%
13.3%
26.7% 33.4%
33.3%
33.3%
No Moderate Good
Figure 1. EULAR Good, Moderate, and No response for patients treated
with RTX, mAb, or ETA according to the type of switch (whether they
switched from mAb or ETA). After the failure of ETA, a significantly
greater EULAR Good response rate was observed for RTX (36.9%)
compared to mAb (11.1%); p ¼ 0.001. After the failure of mAb, RTX
and ETA yielded similar EULAR Good/Moderate response rates (no
statistical difference was observed) that were numerically higher than mAb.
Table 4. Number and effectiveness of the second biologic (RTX, anti-TNF mAb, and ETA) after failure of one TNF inhibitor according to
the reason for discontinuation of the first biologic (inefficacy, primary or secondary, intolerance, or other reasons, including pregnancy,
patient’s decision, unknown reasons).
Reason for discontinuation of the first TNF inhibitor RTX [n ¼ 69] anti-TNF mAb [n ¼ 161] ETA [n ¼ 98]
Inefficacy, n (%) 22 (31.9) 97 (60.3) 53 (54.1)
Improvement in DAS28 0–6 months, mean  SD 1.22  1.52 [10] 0.70  1.41 [45] 1.54  1.43 [30]
EULAR Good/Moderate/No responders (n) 1/5/4 (10) 6/13/28 (47) 9/12/9 (30)
Primary inefficacy, n (%) 9 (13.0) 47 (29.2) 33 (33.7)
Improvement in DAS28 0–6 months, mean  SD 0.18  0.83 [4] 0.64  1.51 [22] 1.76  1.20 [19]
EULAR Good/Moderate/No responders (n) 0/0/4 (4) 2/6/16 (24) 5/10/4 (19)
Secondary inefficacy, n (%) 13 (18.9) 50 (31.1) 20 (20.4)
Improvement in DAS28 0–6 months, mean  SD 2.16  1.05 [6] 0.75  1.34 [23] 1.18  1.76 [11]
EULAR Good/Moderate/No responders (n) 1/5/0 (6) 4/7/12 (23) 4/2/5 (11)
Intolerance, n (%) 30 (43.5) 26 (16.1) 25 (25.5)
Improvement in DAS28 0–6 months, mean  SD 2.09  0.87 [16] 0.63  1.44 [11] 0.91  1.62 [10]
EULAR Good/Moderate/No responders (n) 5/9/3 (17) 2/4/7 (13) 4/1/5 (10)
Other, n (%) 17 (24.6) 38 (23.6) 20 (20.4)
Improvement in DAS28 0–6 months, mean  SD 1.55  1.12 [8] 0.63  1.30 [27] 1.44  1.75 [7]
EULAR Good/Moderate/No responders (n) 2/5/1 (8) 4/7/14 (25) 3/3/1 (7)
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improvements (p ¼ 0.3, 95% CI 0.52–1.60) and EULAR
Good/Moderate responses (p ¼ 0.09) compared to ETA.
When the cause for switching was ineffectiveness, the
improvement in DAS28 was similar for RTX, ETA, and
mAb. The EULARGood/Moderate responders were 60, 70,
and 40.4% for RTX, ETA, and mAb, respectively (p¼ 0.05
between RTX and mAb, p¼ 0.02 between mAb and ETA).
However, after a closer examination of the type of ineffec-
tiveness of the prior TNF inhibitor, we observed that, after
loss of efficacy (secondary inefficacy) to a TNF inhibitor,
RTX achieved significantly greater DAS28 improvements
than mAb (p ¼ 0.03, 95% CI 0.26–2.55) as well as better
EULAR response rates (p ¼ 0.03). Numerically but not
significantly greater results were observed for RTX vs.
ETA. No significant difference in DAS improvement or
EULAR response between the groups was observed after
primary inefficacy of the first TNF inhibitor, and the number
of patients was fairly small. The p-values shown were
corrected for age, RF, baseline DAS28, and HAQ.
Discussion
The results of this observational cohort suggest that, after
the failure of one TNF inhibitor, a treatment approach
with the B-cell depleting agent RTX leads to better over-
all results, based on DAS28 improvement and EULAR
Good/Moderate response, than a second TNF inhibitor.
However, a significant difference was observed only
between RTX and anti-TNF mAb and not between RTX
and ETA. The absence of a significant difference might be
due to a true difference (if we also consider the molecular
differences in etanercept and monoclonal antibodies), but
it could also be due to insufficient power. In all three
groups (mAb, ETA, and RTX), significant DAS28
improvements were observed, suggesting that switching
from one anti-TNF to another is also effective.
Whenwe compared the efficacy of RTX to the efficacy of
anti-TNF by the type of anti-TNF switch, we observed the
smallest improvements in DAS28 for the subgroup of
patients who switched from one anti-TNF mAb to an alter-
native mAb. By contrast, after the failure of a first mAb,
ETA yields as good results as RTX (Figure 1). Although
statistical significance was not achieved, this finding might
suggest that, after a failure of one TNF mAb, ETA or RTX
could be a better choice as the next treatment than an
alternative mAb. Previous studies have also shown greater
benefits when switching between ETA and mAb (22). The
greatest reduction in DAS28 was observed in patients trea-
ted with RTX after having failed ETA, which was signifi-
cantly greater than the observed DAS28 reduction for
patients who switched to mAb. Significantly better
EULAR responses were also observed (Figure 1).
Regarding the reason for discontinuation of a prior
TNF inhibitor, our results do not agree with those of a
large observational study from Switzerland (23), in which
Finckh et al showed that patients who stopped a previous
TNF inhibition treatment due to ineffectiveness had better
results when they switched to RTX rather than an
alternative TNF inhibitor. By contrast, we unexpectedly
observed better results of treatment with RTX when the
reason for discontinuation of a previous anti-TNF agent
was intolerance and secondary inefficacy. In Stockholm,
most patients fail at least two TNF antagonists before
switching to a different biological agent. Ineffectiveness
of a previous treatment could more frequently be the
motive to switch from a TNF mAb to ETA, rather than
to switch to another category of biologics, as shown in
Table 4. We should take into consideration the fact that
the choice of the biologic agent is not random, as it is the
individual rheumatologist who decides based on the
patient’s clinical assessment and according to the hospi-
tal’s protocols, and these factors of course vary between
countries and even within a particular country. The risk
for selection bias is therefore present. In addition, the
reason for discontinuation of a prior biologic given by a
significant number of patients was neither lack of efficacy
nor intolerance, but ‘other’. This could be the patient’s
own decision, pregnancy, or an unknown reason.
Importantly, one such reason could also be ‘failure by
partial efficacy’, which can in fact represent a substantial
percentage of patients who have neither an outstanding
response nor a completely lack of response to therapy
(21). This will be examined further in future analyses.
One weakness of this observational study was the fact
that the three main treatment groups were not balanced for
baseline characteristics, and differences in several baseline
characteristics were observed. Patients who switched to
RTX had higher disease activity at baseline (based on
HAQ, DAS28, SJC, and CRP), and therefore a greater
improvement in disease activity markers could be
explained, at least in part, by regression to the mean.
Nevertheless, the majority of RTX-treated patients were
patients with high inflammatory activity and long-
standing, difficult to control RA, who had failed to respond
to previous therapies, and might be considered to have
more refractory, ‘hard-to-treat’ disease. To partially over-
come this problem we adjusted for baseline differences
when comparing treatment effect between the groups and
subgroups. The number of missing data was another con-
cern, but it is a common problem in observational cohorts.
We used LOCF for DAS28 at 6 months to increase the
number of patients with available information, but the
number of patients in some comparisons was still fairly
small (especially in the subanalysis of ‘reason of disconti-
nuation), so we have to interpret some results with caution.
Among the strengths of this study is the fact that we
investigated real-life patients with demographic, serologi-
cal, and disease-related characteristics consistent with
populations seen in clinical praxis. The number of patients
is reasonably large, and they represent a relatively homo-
geneous population. We chose to examine the efficacy of
only the first switch, and not merge switches together to
avoid the bias of ‘common patients’ history’ in the cohort.
In conclusion, for patients who failed one TNF inhibi-
tor, RTX leads to better clinical results than a subsequent
anti-TNF mAb. Having failed ETA, RTX is better than
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mAb, but having failed mAb, RTX and ETA yield similar
improvements in disease activity. In this cohort, patients
who previously did not tolerate or who lost efficacy of the
first TNF inhibitor achieved better results with RTX.
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Abstract 
Objectives: Evidence regarding the efficacy and effectiveness of certolizumab pegol in RA 
patients who have already failed a TNF inhibitor is limited. The aim of this study was to 
describe the effectiveness and survival-on-drug of certolizumab pegol in a real-life setting, 
both in TNF-inhibitor (TNFi)-naïve patients and in patients who had failed previously TNFis, 
and in relation to disease activity at baseline.  
Methods: The national Swedish Rheumatology Quality of Care Register was used to identify 
patients with RA starting treatment with certolizumab pegol 2009 through 2013. Effectiveness 
of treatment was assessed using DAS28, HAQ, measures of remission, EULAR response and 
survival-on drug through 0-8 months from treatment start.  
Results: A total of 945 RA patients started treatment with certolizumab pegol. 540 patients 
(57.1%) received certolizumab as 1
st
 biologic treatment, 215 patients (23%) had failed one 
previous TNFi and 190 (20%) had failed at least two TNFis. Overall 71% achieved at least a 
EULAR Moderate Response and 38% had a EULAR Good Response at 6 months from 
baseline. TNFi-naïve patients achieved significantly better results and had better survival-on-
drug compared to patients who had failed previous TNFis. Around 20% of patients who had 
not responded to two or more prior TNFis achieved EULAR good response to therapy and 
around 20% achieved remission. Patients who had high baseline disease activity had higher 
risk to discontinue treatment compared to those with non-high disease activity.  
Conclusions: In this real-life RA cohort, certolizumab pegol was associated with significant 
clinical improvement. The effectiveness and survival-on-drug varies depending on line of 
treatment. 
/Word count: 255/ 
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Introduction 
Certolizumab pegol is one of five tumor necrosis factor inhibitors (TNFis) approved for the 
treatment of RA. It is a recombinant antigen-binding fragment (Fab´) of a humanized 
antibody against TNF, conjugated to a polyethylene glycol (PEG) moiety [1 2]. Its efficacy 
and acceptable safety profile has been demonstrated in phase III, randomized, controlled 
clinical trials in methotrexate non-responders with RA of high disease activity [3-7].  
So far,only one study has examined the efficacy of certolizumab pegol also in patients with 
moderate disease activity[8]. However, since more than half of patients in contemporary 
clinical practice do not have high disease activity at the time of start or switch of biologic 
therapy, it is important to examine the effectiveness of treatment in patients with moderate or 
even low disease activity at baseline[9].  
Additionally, only one study has examined the efficacy of certolizumab pegol after the failure 
of one or more TNFis[10]. Among patients starting a first TNFi, half will discontinue 
treatment during the first two years of treatment because of inefficacy or intolerance[11 12]. 
Starting a second or more TNFi is common in clinical practice, and it is important to know if 
certolizumab pegol is effective in TNF-non-responders. Its different molecular structure 
makes it theoretically possible that it can be effective even after the failure of previous TNF 
inhibition with other agents. Furthermore, randomized controlled trials often have strict 
inclusion and exclusion criteria that do not reflect clinical practice[13 14]. This is the reason 
why register-based observational studies can provide important additional information about 
the effectiveness of treatment in a real-life RA population of patients.  
The aim of this study was 1) to describe the real-life RA population that receives? treatment 
with certolizumab pegol; 2) to assess the effectiveness of treatment and survival-on-drug in 
TNFi naïve patients as well as in patients who have previously failed one TNFi and two or 
more TNFis; and 3) to examine the effectiveness of treatment and survival-on-drug in patients 
with high versus non-high disease activity at baseline.  
Methods 
Study population 
 
Data from the nationwide Swedish Rheumatology Register were used. RA patients who start 
treatment with biologic agents have been included in this register since 1999. The coverage of 
the SRQ in terms of biologics-treated RA has been estimated to be nearly 90% of all eligible 
patients with RA[15 16]. The majority of RA patients in Sweden start a biologic treatment 
(most often an anti-TNF agent unless contraindicated) after failure of at least one synthetic 
DMARD, like methotrexate.  
For the purpose of this study patients with a diagnosis of RA who started treatment with 
certolizumab pegol during the period 01 October 2009 – 31 June 2013 were identified and 
selected. The last observation date was 01 March 2014, so all patients could contribute with 
follow-up data.  Four different reasons for discontinuation of certolizumab were considered: 
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primary inefficacy (lack of efficacy, including partial efficacy), secondary inefficacy (loss of 
efficacy), intolerance and other (pregnancy, patient's or physician's decision, inactive disease, 
death, unknown). The reason for discontinuation was based on the rheumatologist's opinion 
and was recorded according to a predefined list of different options. 
The following information was collected: demographic data (age, sex); RA disease duration 
(from the time of diagnosis); rheumatoid factor; number and type of prior biologics, date and 
reason for discontinuation of certolizumab pegol; disease activity score based on 28-joint 
status (DAS28) and its components (swollen joint count, tender joint count, visual analogue 
scale general health and erythrocyte sedimentation rate); functional ability based on health 
assessment questionnaire (HAQ); concomitant DMARD and glucocorticoid treatment.  
Effectiveness of treatment was assessed as: 1) DAS28 change (ΔDAS28) and HAQ change 
(ΔHAQ), 2) Proportion of patients in state of DAS28-remission, 3) EULAR response rates 
and 4) Survival-on-drug.  
The endpoints 1-3 were assessed at 3 and 6 months from baseline. Baseline was defined as 
start of certolizumab pegol. The time window was 30-110 days from baseline for the 3-month 
visit and 110-240 days from baseline for the 6-month visit. In case of multiple visits within a 
visit-window we used the first observation chronologically. When no data were available for 
the 6-month visit we used data from the 3-month visit. Patients who discontinued treatment 
during the follow-up period but had no  follow-up visit were considered non-responders. The 
dataset was not complete. Non-completeness is expected in register-based observational 
studies. We explored missingness and the summary is reported in figure 1.  
Statistical analysis  
Initially we characterized the whole cohort by means of descriptive statistics. At a second step 
three subgroups were formed based on the number of prior biologic TNFis: 0 (TNFi-naïve 
patients), 1 (maximum of one prior TNFi) and ≥2 (two or more prior TNFi). An additional 
subanalysis was performed with patients stratified according to baseline DAS28 disease 
activity state: high (defined as DAS28>5.1) versus other (DAS28≤5.1). Baseline 
characteristics across the groups were summarized and compared. The normality of all 
continuous variables was tested by assessing the skewness. Variables which were similar to 
normal distribution were presented as mean±SD, while non-normally distributed variables 
were presented as median with IQR. Analysis of variance (ANOVA) was used to compare 
continuous variables (with a distribution similar to normal) followed by Bonferroni test for 
post hoc comparisons between the groups when the ANOVA showed significant difference 
across the groups, while χ2 test was used for nominal variables. Kruskal–Wallis test was used 
to compare non-normally distributed variables. The level of statistical significance was set to 
5%.  
The mean DAS28, ΔDAS28, HAQ and ΔHAQ at each time-point were compared across the 
groups by ANOVA followed by Bonferroni test for post hoc comparisons between the groups. 
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The rates of EULAR good responders and patients that achieve DAS28 remission were 
compared by χ2 test. All analyses were performed for the whole cohort and stratified by 
number of TNFis previously discontinued for various reasons (ineffectiveness, intolerance, 
other) and by baseline disease activity state.   
A Cox regression analysis was performed to determine the risk for discontinuation of 
certolizumab pegol during the first 30 months according to the number of prior TNFis and 
according to the disease activity state at baseline (two separate analyses). Both analyses were 
adjusted for age, sex, disease duration and concomitant DMARDs. Kaplan-Meier plots were 
designed. Discontinuation of treatment and death were considered events. Continuation of 
treatment during follow-up was treated as censored observations during the analysis. Patients 
who had no follow-up visit were also censored.  
 
Results 
Baseline characteristics  
A total of 945 RA patients started treatment with certolizumab pegol during the study period. 
Baseline characteristics (baseline=start of treatment) are presented in table 1. Patients had 
long disease duration when they started treatment (median duration 9.1 years). The majority 
was RF positive and received concomitant treatment with a synthetic DMARD. Half of 
patients were treated with glucocorticoids.  
Stratification according to the number of prior TNFis and disease activity state at baseline 
540 patients (57.1%) received certolizumab as 1
st
 biologic treatment, 215 patients (23%) had 
tested 1 previous TNFi and 190 (20%) had tested at least 2 TNFis. Baseline characteristics for 
patients according to the number of prior TNFis are shown in table 1. Patients who had failed 
at least 2 prior TNFis had significantly longer disease duration, higher disease activity and 
more functional disability at baseline compared to TNFi-naïve patients. 
Out of 753 patients with available DAS28 information at baseline, 292 (39%) had high 
disease activity (DAS28>5.1) while 461 (61%) had lower disease activity. Patients with high 
disease activity were significantly older compared to those with lower disease activity (mean 
age ± SD in years = 58.6 ± 13.7 vs. 55.3 ± 13.6, respectively), had significantly higher HAQ 
at baseline (mean HAQ ± SD = 1.4 ± 0.6 vs. 0.9 ± 0.6, p<0.0001) and were less likely to be 
treated with concomitant DMARDs (62% vs. 70%, p=0.02). The two groups did not differ 
significantly with regard to disease duration, sex, RF and concomitant corticosteroids.  
Effectiveness of treatment 
In table 2 the mean DAS28, ΔDAS28, HAQ and ΔHAQ at baseline, 3 and 6 months for all 
patients and after stratification according to the prior TNFis group is shown. Significant 
reductions in DAS28 and HAQ were achieved for the whole cohort of patients and for each 
group separately (table 2). DAS28 and HAQ were significantly lower in TNFi-naïve patients 
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compared to patients with 1 and ≥2 prior TNFis at 3- and 6 month-visit. TNFi-naïve patients 
also achieved significantly greater DeltaDAS28 compared to both other two groups (table 2).  
The proportion of patients in remission at 6 months for patients with 0, 1 and ≥2 prior TNFis 
was 42%, 26% and 18%, respectively (the difference being statistically significant between all 
three groups, p<0.0001). Overall 33%/28%/39% achieved EULAR good/moderate/no 
response at 6 months from baseline. The proportion of EULAR good responders was 
significantly greater for patients with 0 prior TNFis compared to those with 1 and ≥2 prior 
TNFis at 3 and 6 months (figure 2).  
At 6 months patients with high disease activity at baseline achieved significantly greater 
DeltaDAS28 compared to those with lower disease activity at baseline (-2.1±1.4 vs. -1.0±1.4, 
respectively, p<0.0001), as expected. Conversely, patients with non-high disease activity 
achieved remission to a significantly greater extent compared to those with high disease 
activity initially (43% vs. 21%, p<0.0001). EULAR Good response rates were similar 
between the two groups (35% and 34%, p=0.6).  
Survival-on-drug 
During the observation period 365 patients (39%) discontinued treatment. The reason for 
discontinuation was primary inefficacy (N=159), secondary inefficacy (N=62), intolerance 
(N=86) and other reasons such as patient’s decision, pregnancy and others (N=58). The 
number of patients discontinuing treatment was positively correlated to the number of prior 
TNFis (30% in TNFi naïve patients, 54% in patients having failed 1 prior TNFi and 46% in 
those having failed 2 or more TNFis).  
The survival-on-drug curve stratified by number of prior TNFis group is shown in figure 3A. 
In the adjusted Cox regression analysis patients with 1 and ≥2 prior TNFis had significantly 
higher risk of discontinuing treatment compared to TNFi naïve patients [HR=1.4 (95% CI: 
1.1-1.9), p=0.004 and HR=1.7 (95% CI: 1.3-2.2), p<0.0001, respectively]. In the regression 
model the use of concomitant DMARDs at start of certolizumab pegol treatment was also 
associated with significantly better survival-on-drug [HR=1.4 (95% CI: 1.1-1.7), p=0.003). In 
figure 3B survival-on-drug by baseline disease activity state (high vs. non-high) is shown. 
Patients with non-high disease activity at the time of certolizumab pegol start had 
significantly lower risk to discontinue treatment compared to those with high disease activity 
[HR=0.7 (95% CI: 0.6-0.9), p=0.02].  
Discussion 
The results of this observational study supports the findings of double-blind, placebo-
controlled trials, that certolizumab pegol is effective for patients with active RA. Significant 
clinical improvements were observed during the first 8 months of treatment as assessed by 
DAS28 reduction, remission rates and EULAR responses. The survival-on-drug was similar 
to other TNFis as demonstrated in other observational studies[17 18].  
This large national cohort included patients with long-standing RA (median disease duration 9 
years). Even patients who were TNFi naïve had a median of disease duration of 6 years (table 
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2). More than half of all patients in the cohort were TNFi naïve. We differentiated previous 
TNFis used from previous biologics used in order to examine the effectiveness of 
certolizumab pegol after the failure of TNF inhibition. Only a small percentage (13 out of 
540) of TNFi-naïve patients had tested another biologic (rituximab, tocilizumab, anakinra or 
abatacept) before certolizumab pegol.  
It has been shown from previous studies that switching to a second or a third TNFi after 
inadequate response to one or two TNFis might still yield clinically significant results[12 19 
20]. This is most likely due to the fact that there are differences in the molecular structure, 
pharmacodynamics and pharmacokinetics that differentiate the TNFis that are available today, 
even though they target the same cytokine. In this study, patients who were naïve to TNF 
inhibition achieved significantly greater DAS28 reduction at 3 and 6 months from baseline 
compared to those having failed one and those having failed two or more prior TNFis (table 
2). We also observed a further increase of the absolute magnitude of the DeltaDAS28 from 3 
to 6 months for the group 0 and 1, while DeltaDAS28 decreased in group ≥2 (table 2). The 
proportion of patients in remission and who achieved EULAR good response was 
significantly greater for TNF naïve patients compared to both other groups (figure 2). This 
finding was expected and is in agreement with previous findings from observational studies 
showing inferior response rates when switching to a second or third TNFi[19 20]. An 
interesting and important observation was that even after having previously received 2 or 
more TNFis 55% of patients can achieve EULAR good or moderate response and around 20% 
can achieve remission.  
These results are partially in agreement with the results from the REALISTIC study, where 
the efficacy (defined as ACR20 response) of certolizumab pegol was demonstrated even for 
patients with previous TNFi use, regardless of the number or type of previous TNFi used[10]. 
In that trial TNF naïve patients achieved higher ACR 50 and 70 responses compared to 
patients with previous TNFi use (29.6% vs. 21.6% and 15.3% vs. 9.1%, respectively). 
However the trial was not designed to detect significant differences between these groups. 
In this study more than half of patients had low or moderate EULAR disease activity based on 
DAS28 at the time of certolizumab pegol initiation, reflecting the real-life character of the 
cohort. Clinically and statistically significant responses were observed regardless of whether 
the initial disease activity state was high or not. Patients with high disease activity initially 
were less likely to achieve remission and to continue with the treatment compared to other 
patients. These results are in agreement with the CERTAIN trial, where low-disease activity 
or remission was reached by the majority of patients who received certolizumab pegol and 
who had predominantly moderate disease activity at baseline[8].   
The use of concomitant DMARDs was associated with longer survival-on-drug in the Cox 
regression analysis. Previous studies have shown that concomitant DMARD treatment is 
associated with better response to treatment with TNFis[21 22].  Since significant difference 
in concomitant DMARD rates was found across the prior TNFis groups (table 1), it was 
important to include concomitant DMARDs in the Cox regression analysis in order to 
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minimize risk for confounding when comparing the risk for discontinuing treatment according 
to the number of prior TNFis.  
The observational character of this study is connected to certain limitations. Baseline 
characteristics between groups under comparison were not completely balanced and 
significant differences were observed which introduce the risk for confounding. We tried to 
partially overcome this problem by adjusting for variables that differed significantly between 
groups in the Cox regression analysis. Missingness is another common problem in register-
based observational studies. In this study 70% of patients who had available DAS28 at 
baseline had available DAS28 information at 6 months. As it is shown in figure 1, however, 
only 52 patients out of 753 patients with baseline DAS28 information (7%) were lost to 
follow up. On the other hand there are significant strengths, such as the large number of 
patients included in the cohort, the opportunity to examine the effectiveness of treatment in a 
TNFi naïve population and in patients who have already failed one or more TNFis, as well as 
in patients with moderate or even low disease activity at baseline. This is the first 
observational study to our knowledge that has examined the effectiveness of certolizumab 
pegol in this context.  
To conclude, certolizumab pegol is effective in a real-life RA population. Response rates are 
highest and survival-on-drug best when given as first-line TNFi, but can lead to significant 
clinical results even after the failure of one or more TNFis. Patients with non-high disease 
activity at baseline were more likely to achieve remission and to continue with the treatment 
compared to those with high activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
 
References 
 
1. Barnes T, Moots R. Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on 
certolizumab pegol. Int J Nanomedicine 2007;2(1):3-7  
2. Deeks ED. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. 
Drugs 2013;73(1):75-97 doi: 10.1007/s40265-013-0009-3[published Online First: Epub 
Date]|. 
3. Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol 
monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-
modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68(6):805-11 
doi: 10.1136/ard.2008.099291[published Online First: Epub Date]|. 
4. Keystone E, Heijde D, Mason D, Jr., et al. Certolizumab pegol plus methotrexate is significantly 
more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a 
fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, 
parallel-group study. Arthritis Rheum 2008;58(11):3319-29 doi: 10.1002/art.23964[published 
Online First: Epub Date]|. 
5. Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate 
in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum 
Dis 2009;68(6):797-804 doi: 10.1136/ard.2008.101659[published Online First: Epub Date]|. 
6. Keystone E, Landewe R, van Vollenhoven R, et al. Long-term safety and efficacy of certolizumab 
pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year 
results from the RAPID 1 trial and open-label extension. Annals of the rheumatic diseases 
2013 doi: 10.1136/annrheumdis-2013-203695[published Online First: Epub Date]|. 
7. Tanaka Y, Yamamoto K, Takeuchi T, et al. Long-term efficacy and safety of certolizumab pegol in 
Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-
week results from an open-label extension of the J-RAPID study. Modern rheumatology / the 
Japan Rheumatism Association 2014 doi: 10.3109/14397595.2014.881709[published Online 
First: Epub Date]|. 
8. Smolen JS, Emery P, Ferraccioli GF, et al. Certolizumab pegol in rheumatoid arthritis patients with 
low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. 
Annals of the rheumatic diseases 2014 doi: 10.1136/annrheumdis-2013-204632[published 
Online First: Epub Date]|. 
9. Chatzidionysiou K, Askling J, Eriksson J, et al. Effectiveness of TNF inhibitor switch in RA: results 
from the national Swedish register. Ann Rheum Dis 2014 doi: 10.1136/annrheumdis-2013-
204714[published Online First: Epub Date]|. 
10. Weinblatt ME, Fleischmann R, Huizinga TW, et al. Efficacy and safety of certolizumab pegol in a 
broad population of patients with active rheumatoid arthritis: results from the REALISTIC 
phase IIIb study. Rheumatology (Oxford) 2012;51(12):2204-14 doi: 
10.1093/rheumatology/kes150[published Online First: Epub Date]|. 
11. Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-tumor necrosis 
factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with 
10 
 
rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 
2007;56(1):13-20 doi: 10.1002/art.22331[published Online First: Epub Date]|. 
12. Chatzidionysiou K, Askling J, Eriksson J, et al. Effectiveness of TNF inhibitor switch in RA: results 
from the national Swedish register. Annals of the rheumatic diseases 2014 doi: 
10.1136/annrheumdis-2013-204714[published Online First: Epub Date]|. 
13. Zink A, Strangfeld A, Schneider M, et al. Effectiveness of tumor necrosis factor inhibitors in 
rheumatoid arthritis in an observational cohort study: comparison of patients according to 
their eligibility for major randomized clinical trials. Arthritis Rheum 2006;54(11):3399-407 
doi: 10.1002/art.22193[published Online First: Epub Date]|. 
14. Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not 
meet inclusion criteria for most recent clinical trials or american college of rheumatology 
criteria for remission. J Rheumatol 2003;30(6):1138-46  
15. Askling J, Fored CM, Geborek P, et al. Swedish registers to examine drug safety and clinical issues 
in RA. Ann Rheum Dis 2006;65(6):707-12 doi: 10.1136/ard.2005.045872[published Online 
First: Epub Date]|. 
16. Neovius M, Simard J, Sundstrom A, et al. Generalisability of clinical registers used for drug safety 
and comparative effectiveness research: coverage of the Swedish Biologics Register. Ann 
Rheum Dis 2011;70(3):516-9 doi: 10.1136/ard.2010.130914[published Online First: Epub 
Date]|. 
17. Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission 
rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, 
etanercept, or infliximab: results from eight years of surveillance of clinical practice in the 
nationwide Danish DANBIO registry. Arthritis and rheumatism 2010;62(1):22-32 doi: 
10.1002/art.27227[published Online First: Epub Date]|. 
18. Neovius M, Arkema EV, Olsson H, et al. Drug survival on TNF inhibitors in patients with 
rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Annals of the 
rheumatic diseases 2013 doi: 10.1136/annrheumdis-2013-204128[published Online First: 
Epub Date]|. 
19. Gomez-Reino JJ, Carmona L, Group B. Switching TNF antagonists in patients with chronic arthritis: 
an observational study of 488 patients over a four-year period. Arthritis research & therapy 
2006;8(1):R29 doi: 10.1186/ar1881[published Online First: Epub Date]|. 
20. Karlsson JA, Kristensen LE, Kapetanovic MC, et al. Treatment response to a second or third TNF-
inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. 
Rheumatology 2008;47(4):507-13 doi: 10.1093/rheumatology/ken034[published Online First: 
Epub Date]|. 
21. Kristensen LE, Kapetanovic MC, Gulfe A, et al. Predictors of response to anti-TNF therapy 
according to ACR and EULAR criteria in patients with established RA: results from the South 
Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008;47(4):495-9 doi: 
10.1093/rheumatology/ken002[published Online First: Epub Date]|. 
22. Kristensen LE, Saxne T, Nilsson JA, et al. Impact of concomitant DMARD therapy on adherence to 
treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year 
11 
 
observational study in southern Sweden. Arthritis research & therapy 2006;8(6):R174 doi: 
10.1186/ar2084[published Online First: Epub Date]|. 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Baseline characteristics for Swedish patients with RA starting treatment with 
certolizumab pegol in the SRQ register stratified by the number of prior TNF inhibitors (0, 1 or 
≥2). Number in brackets indicates the number of patients with available information for each 
variable. One-way analysis of variance was used to compare normally distributed continuous 
variables followed by Bonferroni test for post hoc comparisons between the groups, while 
χ2 test was used for nominal variables. Kruskal-Wallis test was used to compare non-normally 
distributed continuous variables across groups. 
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Table 2. DAS28 and HAQ status at baseline, 3 and 6 months as well as ΔDAS28 and 
ΔHAQ at 3 and 6 months from baseline for the whole cohort and stratified by the 
number of prior TNF inhibitors (0, 1 or ≥2). Number in brackets indicates the number 
of patients with available information at each time-point. One-way analysis of 
variance was used to compare responses across groups followed by Bonferroni test 
for post hoc comparisons between the groups. N.S.=non-significant 
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Figure 1. Type of missingness regarding DAS28. Out of 753 patients who had available 
DAS28 information at baseline 513 had available DAS28 at 6 month-visit (68%).  
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Figure 2. EULAR response at 3 and 6 months from baseline according to the number of prior 
TNFi (0, 1 and ≥2). Patients who were TNFi naïve (group 0) achieved significantly higher 
proportion of EULAR good responders at both time-points compared to those who had two or 
more prior TNFis (p-values shown). No significant differences were observed between groups 1 
and 2. In the lowest line the number of patients with available information at each time point in 
each group is shown.  
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Figure 3A. Survival-on-drug during the first 30 months from baseline for certolizumab pegol 
stratified by the number of prior TNFis (0, 1 or ≥2) and adjusted for age, sex, disease duration and 
concomitant DMARDs in a Cox regression analysis. Patients with 1 and ≥2 prior TNFis had 
significantly higher risk to discontinue treatment compared to TNFi naïve patients [HR=1.4 (95% 
CI: 1.1-1.9), p=0.004 and HR=1.7 (95% CI: 1.3-2.2), p<0.0001, respectively]. At the bottom of the 
plot the number of patients who are on-treatment at each time-point and at each subgroup is shown 
(blue=0, green=1 and brown=≥2 prior TNFis).   
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Figure 3B. Survival-on-drug during the first 30 months from baseline for certolizumab pegol 
stratified by the disease activity state at baseline (high=1 vs. non-high=0) and adjusted for 
age, sex, disease duration and concomitant DMARDs in a Cox regression analysis. Patients 
with non-high disease activity at the time of certolizumab pegol start had significantly lower 
risk to discontinue treatment compared to those with high disease activity [HR=0.7 (95% CI: 
0.6-0.9), p=0.02].  At the bottom of the plot the number of patients who are on-treatment at 
each time-point and at each subgroup is shown (blue=no high disease activity, green= high 
disease activity at baseline).  
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Abstract 
Background: Treatment with tumor necrosis factor (TNF) blockers, once started as therapy 
for rheumatoid arthritis (RA), is usually continued indefinitely.   
Objective: To assess the possibility, in RA patients in stable remission on combination 
therapy with adalimumab (ADA) and methotrexate (MTX), of discontinuing ADA treatment 
while maintaining remission.  
Methods: In a randomized, controlled, open pilot study of RA patients in stable remission 
treated with adalimumab + MTX patients were randomized in a 1:1 ratio to continue with 
adalimumab plus MTX (arm AM) or MTX monotherapy (arm M) for 52 weeks. Flare was 
defined as DAS28≥2.6 or an increase in DAS28 (DAS28) of more than 1.2 from baseline at 
any time. Patients in arm M with a flare restarted ADA.  The primary endpoint was the 
proportion of patients in remission at week 28 in both arms.  
Results: Thirty-three patients were enrolled in the study and were randomized to arm AM (16 
patients) and arm M (15 patients). At 28 weeks, 15/16 patients (94%) and 5/15 patients (33%) 
in arms AM and M, respectively, were in remission (p=0.001). The proportion of patients 
with a flare during the first 28 weeks in the AM and M arms was 50% (8/16) and 80% 
(12/15), respectively (p=0.08). The number of patients in the AM and M arms with at least 
one DAS28>1.2 during first 28 weeks was 1/16 (6%) and 8/15 (53%), respectively 
(p=0.005).  
Conclusions: In this study remission was rarely maintained in patients with long-standing 
disease on remission who discontinued adalimumab. Discontinuation may be feasible in only 
a minority of patients with established RA in stable clinical remission. 
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Introduction 
The field of RA treatment has changed dramatically during the last decade. Better 
understanding of the pathophysiology and the underlying immunological mechanisms of the 
disease has led to tighter disease control, earlier treatment and the emergence of a new class 
of drugs, the biologic disease modifying antirheumatic drugs. TNF inhibitors were the first 
biologics to be approved for the treatment of severe RA. Adalimumab is a recombinant 
human immunoglobulin (IgG1) monoclonal antibody which binds with high affinity and 
specificity to TNF [1]. Its efficacy in RA and acceptable safety profile has been proven in 
large randomized, controlled clinical trials [2, 3].    
The goal of treatment today is remission, clinical, functional and radiological. A further step 
is the sustained remission state without the need of continuous treatment with a biologic 
agent, the achievement of ‘biologic-free’ remission. If remission could be sustained even after 
cessation of anti-TNF therapy, this would have vast clinical (regarding long-term safety) as 
well as economic implications. Treatment with tumor necrosis factor (TNF) blockers, once 
started as therapy for rheumatoid arthritis (RA), is usually continued indefinitely. This is 
mainly due to the fact that information about the feasibility to discontinue anti-TNF therapy in 
RA patients who have obtained remission is limited. In the ATTRACT study, RA patients 
with longstanding disease received treatment with infliximab, and in 17 patients this was 
discontinued after 2 years [4]. All 17 patients experienced a flare. In contrast, in a study of 
patients with early RA, 70% of those initially treated with infliximab could discontinue the 
TNF inhibitor while remaining in remission [5]. In the RRR study by Tanaka et al., of 102 
patients 56 (55%) maintained low disease activity and 44 (43%) fulfilled the criteria for 
clinical  remission 1 year after discontinuation of infliximab [6]. The mean disease duration in 
this study was 6 years, suggesting that discontinuation of the TNF inhibitor might be feasible 
not only in patients with early RA, but also in those with  established, long standing disease.  
Apart from the duration of RA, other factors can influence the chance of biologic-free 
remission, such as the time from diagnosis to anti-TNF introduction. In the BeST study, it was 
shown that significantly more patients who received initial combination therapy with 
infliximab and methotrexate were able to discontinue infliximab, compared to those with 
delayed introduction of the biologic agent (56% vs. 29%, p=0.008)[7]. In the OPTIMA trial 
RA patients with early RA who achieved stable low disease activity on adalimumab plus 
methotrexate who withdrew adalimumab mostly maintained their good responses[8]. Even in 
more established RA, discontinuation of adalimumab can be feasible but mainly for patients 
on deep remission, as shown in the HONOR study[9].  
Taken together, most of the available data on discontinuation of TNF-inhibitors comes from 
non-randomized trials or from early RA patients enrolled in double-blind clinical trials. These 
results may not be applicable to many patients with long standing disease seen in clinical 
practice.  
The aim of this pilot study was to assess the possibility of discontinuing adalimumab 
treatment while maintaining remission in RA patients with established disease in stable 
clinical remission on combination therapy with adalimumab + methotrexate (MTX).  
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Methods 
Study design 
This was a multi-center, randomized, controlled, open-label, pilot study. The main inclusion 
criteria were: age ≥18; diagnosis of RA based on 1987 revised American College of 
Rheumatology (ACR) classification criteria[10], positive rheumatoid factor (RF) or at least 
one erosion on the radiograph of hands or feet; treatment with adalimumab in the approved 
dose of 40mg every other week for at least 6 months; concomitant treatment with 
methotrexate (MTX) in a dose of at least 10mg per week for a minimum of 6 months (stable 
dose for a minimum of 2 months); stable remission according to the Disease activity score 
(DAS) 28[11], based on 28-joint counts, (DAS28<2.6) for at least 3 months based on 
assessments at baseline and on at least one more occasion 3-6 months prior to baseline, 
documented in patient record or registry. Concomitant corticosteroids were allowed if the 
dose was 10mg per day or less (prednisolone or equivalent) and has been stable for at least 3 
months at study entry.  
Patients fulfilling the inclusion criteria were randomized in a 1:1 ratio to arm AM (continue 
with ADA and MTX or to arm M (discontinue ADA and continue with MTX monotherapy) 
for 52 weeks (figure 1). Any patient experiencing a ‘flare’ at any visit should continue in the 
rescue arm, where ADA would be reinstituted. Flare was defined as DAS28≥2.6 or an 
increase in DAS28 (ΔDAS28) >1.2 from baseline at any time. After week 52 an observational 
extension phase ensued where patients were treated at the discretion of the investigator for an 
additional period of 52 to 104 weeks.   
The study was conducted in accordance with the protocol, International Conference on 
Harmonization (ICH) guidelines, applicable regulations and guidelines governing clinical 
study conduct and the ethical principles that have their origin in the Declaration of Helsinki. It 
was registered at Clinical Trials.gov (NCT00808509). 
Endpoints 
The primary endpoint of this trial was the proportion of patients in DAS28 remission at week 
28. Secondary endpoints included incidence of flare and the evolution of physical function 
(assessed using the Health assessment questionnaire (HAQ)[12]). 
Further exploratory analyses were performed and included the following endpoints:  
1) Incidence of flare (DAS28≥2.6 or a ΔDAS28 >1.2 from baseline at any time. 
2) Incidence of at least one DAS28 ≥2.6 from baseline to week 28 
3) Incidence of at least one ΔDAS28 >1.2 from baseline to week 28 
4) Proportion of patients with at least one of the following from BL to week 28:  
a. DAS28 >0.6 
b. DAS28 ≥2.6 AND DAS28 >1.2 
c. DAS28 ≥2.6 AND DAS28 >0.6 
5) Proportion of patients in DAS28 remission at week 52 
6) Flare-free survival during first 28 weeks 
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7) Change in functional status (assessed by HAQ) at week 28  
8) Change in radiological status (analysis of X-ray data at week 52) 
In a secondary analysis we applied the EULAR/ACR Boolean remission criteria to the two 
arms and assessed the frequency of remission. Remission was defined according to these 
criteria as swollen joints count ≤1 and tender joints count ≤1 and patient global assessment ≤1 
(on a 0-10 scale) and ESR (erythrocyte sedimentation rate) ≤ 20 mm/hour[13, 14].  
 
Analysis of radiological data, safety data 
X-rays of hands (PA view) and feet (AP view) were performed at baseline (unless comparable 
radiograph had been obtained within 3 months from baseline), at week 52 and at week 104-
156. The Sharp/van der Heijde (SvH) scoring method was used to assess radiological 
progression[15]. Adverse events were assessed at every visit throughout the study.  
Statistical analysis 
Proportions were compared between the two arms using Fisher’s exact test. Continuous 
variables were presented as median (IQR=interquartile range) and were compared by the non-
parametric Mann-Whitney test. The Wilcoxon Signed Ranks test was used as non-parametric 
paired test. Survival curves representing patients free of flares were compared by Log-Rank 
test. Analyses were performed by intention to treat (ITT) with non-responders imputation for 
patients in both groups who experienced flare.   
 
Results 
Patient population 
Patient disposition is shown in figure 2. From a total of 237 screened patients only 33 patients 
(14%) were enrolled in the study. A significant number of patients (30%) were not willing to 
stop adalimumab; 16% of patients did not fulfill the criteria for stable remission; 12% were on 
adalimumab monotherapy or had a lower dose of methotrexate than 10mg/week; 5% had 
another dose of adalimumab than 40mg every other week. The remaining 40% of patients 
screened could not be enrolled for other reasons. Of the 33 patients enrolled, 17 were 
randomized to arm AM and 16 to arm M. One patient was later excluded from each arm, one 
in the M arm due to a major protocol violation at week 8 and one in the AM arm who did not 
fulfil the inclusion criteria. Patient baseline characteristics from the time of randomization are 
shown in table 1.  
Primary, secondary and exploratory endpoints 
At week 28, 15/16 patients in AM group and 5/15 patients in M group were in remission 
(p=0.001) (figure 3-A). Two patients in the M group who did flare did not want to restart 
ADA. The proportion of patients with at least one flare (defined as at least one DAS28≥2.6 or 
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ΔDAS28 >1.2) during the first 28 weeks was 50% (8/8) in AM group and 80% (12/15) in M 
group (p=0.08) (figure 3-B). Analysis on the subgroups of flare showed significant difference 
in the proportion of patients with at least one ΔDAS28>1.2 (figure 3-D) but no difference in 
the proportion of patients with at least one DAS28≥2.6 (figure 3-C). When different 
definitions of ‘flare’ were tested (exploratory analysis nr. 4 as described in methods), the 
difference between the AM and the M group became clearer (figure 3-E, 3-F, 3-G). Survival 
curves suggested higher flare-free survival over time in those randomized to ADA 
continuation, although the difference did not reach statistical significance (p=0.07, figure 4).  
Around half of the patients in the two arms fulfilled the EULAR/ACR remission criteria at 
baseline (7/16 in arm AM and 9/15 in arm M). By the end of 28 weeks, 2/16 patients in arm 
AM and 1/15 patients in arm M fulfilled these criteria (no statistically significant difference).  
Patients who flared had longer disease duration and started treatment with ADA later than 
those who did not flare in both M and AM groups during the study period (table 2). There was 
also a tendency for lower baseline DAS28 in the non-flared patients.  
At week 52 81% of patients in arm AM (13/16) and 13% in arm M (2/15) were on remission 
while the rest of each arm were non responders after imputation. At the observatory visit 
(week 104-152) 3 of the patients originally randomized to the M arm had not restarted ADA, 
and only 2 of these were in remission. 
 
Functional and radiological status 
In group AM the median (IQR) HAQ was 0.13 (0-0.7) at baseline and 0.32 (0-0.7) at week 28 
(Wilcoxon Signed Ranks test: p=0.8). In group M the mean (SD) HAQ was 0.38 (0.1-0.6) at 
baseline and 0.5 (0.1-0.8) at week 28 (p=0.4). Median HAQ from baseline to week 28 was 0 
(0-0) in arm AM and 0 (-0.12-0.13) at arm M (p=0.6). The percentage of patients with at least 
one clinically significant HAQ increase (0.22) during the first 28 weeks was 5/16 in AM arm 
and 7/15 in M arm (p=0.4).  
The median (IQR) total Sharp score at baseline was 22.5 (11.3-52.5) for AM and 42.5 (22-
95.3) for M arm. One year after randomization, the total score was 25 (13.8-51.8) and 35.5 
(18.3-70.8) for arms AM and M, respectively (three patients in arm M had no radiological 
data at year 1). No statistically significant difference was observed from baseline to year 1 for 
the two arms.  
A total of 9 patients entered the rescue arm during the first 28 weeks. Remission was restored 
in 8 of them within 12 weeks (the remaining one patient achieved remission at  the final 
observational follow-up visit (DAS28=2.5)).  
Safety data 
The incidence of adverse events was similar in both treatment groups with 88.2% of the 
patients in the adalimumab + MTX arm and 100.0% of the patients in the MTX arm reporting 
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at least one adverse event. No adverse events were reported to cause discontinuation of study 
treatment or death. One serious adverse event (femur fracture) was reported by a patient in the 
adalimumab + MTX arm and three (malignant melanoma, chest pain and pleuritis) in the 
MTX arm.  
Discussion 
In this randomized, open-label, pilot study, RA patients with established disease who were in 
stable remission under treatment with adalimumab and methotrexate rarely maintained 
remission after discontinuation of the biologic agent. This result is in agreement with previous 
discontinuation trials, such as the ATTRACT trial [6].  
Several important points need to be considered when interpreting these results. First, patients 
enrolled in this study had long-standing disease (median 8 years). The results should therefore 
be applicable to RA patients with more established disease. In early disease the possibility of 
discontinuing the biologic agent while maintaining remission seems to be greater, as shown in 
other trials[7][8]. 
A second important point is the definition of flare. It is obvious from figures 2A, 2B and 2C 
that the way to define flare greatly influences the results. When a strict definition of flare was 
used (a single DAS28≥2.6), then the difference between the AM and M group was no longer 
significant, since as many as half of patients continuing with ADA flared. This was not 
unexpected, as DAS28 can vary normally and can be slightly increased even in the absence of 
a true clinical flare. When different definitions of disease deterioration were used, for example 
a combination of DAS28 and DAS28 with a specified minimum increase in their value, the 
difference between the two arms became more obvious. This criterion might be more 
clinically meaningful. An important lesson from this study is therefore the choice of flare 
definition for future studies. When the ACR/EULAR criteria were applied very few patients 
remained in remission and no difference between groups could be detected. 
At the end of 28 weeks the majority of patients in the MTX monotherapy arm flared, but 3 
patients (20%) had a sustained remission after ADA discontinuation. At the extension visit 
(week 104-156) 3 patients originally allocated to ADA discontinuation had not yet restarted  
ADA, and of these 2 were in remission. 
This suggests that anti-TNF discontinuation might be feasible even in established RA, but 
only for a small group of patients. Identification of these patients is of course of interest. As 
shown in table 2, there was a tendency for lower DAS28 at the time of ADA discontinuation 
as well as shorter time from disease onset to ADA initiation in the subgroup of patients who 
did not flare, suggesting that the ‘’depth’’ of remission according to DAS28 as well as the 
earlier initiation of biologic DMARD might increase the chance of retaining remission after 
discontinuation of the biologic agent.  
Last but not least, all patients experiencing a flare who restarted treatment with ADA again 
achieved DAS28-defined remission without any unexpected safety signals. There was no 
progression of joint damage or deterioration of physical function in either group. 
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The study has limitations, such as the small number of patients, the open label design, and the 
strict definition of flare, as discussed above. A “nocebo” effect (the reverse of the placebo 
effect, where the patient’s expectation of getting worse causes an actual worsening) might 
partly contribute to the higher flare rate in the ADA discontinuation group. On the other hand 
there are important strengths, such as the randomized, controlled character of the trial, the 
homogeneous population of patients and the relevance to the payer perspective on clinical 
practice.  
 
Conclusions  
In this pilot study, remission was rarely maintained in patients who discontinued adalimumab. 
Compared with patients who continued combination therapy, the proportion of patients with 
sustained remission in the discontinuation group was significantly lower for the primary 
endpoint and most secondary endpoints. However, adalimumab discontinuation may be 
feasible in a minority of patients with established RA in stable clinical remission on 
adalimumab plus methotrexate.  
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Tables and figures 
 
 AM Group 
(N=16) 
M Group 
(N=15) 
All 
(N=31) 
Age [years, median (IQR)] 56 (38.8–62) 64 (59–66) 61 (53–65) 
Sex (female) 
10/16 
(62.5%) 
10/15 
(66.7%) 
20/31 
(64.5%) 
Disease duration 
[years, median (IQR)] 
7.6 
(4.0–12.1) 
10.4 
(5.2–19.2) 
8.0 
(4.8–16.2) 
Time (months) on adalimumab at baseline [median 
(IQR)] 
26.5 
(12.5–51.2) 
43.3 
(11.7–51.5) 
29.1 
(12.3–51.2) 
Time from RA diagnosis to adalimumab start [years, 
median (IQR)] 
3.2 
(2.2–9.5) 
6.5 
(4.1–15.1) 
4.8 
(2.8–10.4) 
RF (positive) 
11/16 
(68.8%) 
11/12 
(91.7%) 
22/28 
(78.6%) 
Anti-CCP (positive) 5/10 (50%) 8/9 (88.9%) 
13/19 
(68.4%) 
No. of previous DMARDs [median (IQR)] 2 (1–3) 2 (2–3) 2 (1–3) 
No. of previous biologics [median (IQR)] 0 (0–1) 0 (0–1) 0 (0–1) 
Baseline DAS28 
[median (IQR)] 
2.13 (1.6–
2.4) 
1.69 (1.5–
2.37) 
1.9 (1.55–
2.39) 
Baseline HAQ 
[median (IQR)] 
0.13 (0–0.72) 
0.38 (0.13–
0.63) 
0.38 (0–
0.63) 
Concomitant MTX dose 
[median (IQR)] 
20 (15–20) 20 (10–20) 20 (15–20) 
Table 1. Baseline characteristics in the two treatment arms. 
IQR: interquartile range; RF: rheumatoid factor; anti-CCP: anti-cyclic citrullinated peptide 
antibodies; DMARD: disease modifying antirheumatic drugs; DAS28: disease activity score based 
on 28 joints; HAQ: health assessment questionnaire 
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 AM Group AM Group M Group M group All patients 
 Flare  
(N=8) 
No flare 
(N=8) 
Flare  
(N=12) 
No flare 
(N=3) 
Flare 
(N=20) 
No flare 
(N=11) 
Age [years, median (IQR)] 51.5 
(35-60.5) 
59.5 
(53-62.8) 
63.5 
(59.5-66) 
65 
(33-65) 
61.5 
(53.8-65.5) 
61 
(52-65) 
Disease Duration [years, 
median (IQR)] 
11.2 
(7.0-22.3) 
4.8 
(3.0-8.2) 
10.9 
(5.2-21.9) 
5.5 
(4.8-14.6) 
10.9 
(5.7-21.9) 
5.2 
(3.7-8.2) 
Time from RA diagnosis 
to ADA [years, median 
(IQR)] 
8.5 
(3.4-20.7) 
2.5 
(0.5-3.3) 
7.6 
(4.1-16.2) 
4.8 
(3.8-10.3) 
8.5 
(4.1-16.3) 
3 
(1-4.8) 
Time on ADA treatment 
[years, median (IQR)] 
2.0 
(1.2-4.1) 
2.4 
(0.7-4.7) 
3.8 
(1.5-4.3) 
1.0 
(0.7-1.0) 
3.0 
(1.4-4.2) 
2.3 
(0.7-4.3) 
DAS28 2.4 
(2.1-2.5) 
1.8 
(1.3-2.3) 
1.7 
(1.5-2.5) 
1.7 
(0.5-1.8) 
2.3 
(1.7-2.5) 
1.7 
(1.3-1.9) 
SJC 0 
(0-1.75) 
0 
(0-0) 
0 
(0-1) 
0 
(0-0) 
0 
(0-1) 
0 
(0-0) 
TJC 0.5 
(0-2) 
0.5 
(0-1.8) 
0 
(0-1) 
0 
(0-0) 
0 
(0-1.8) 
0 
(0-1) 
ESR (mmHg) 9 
(5.8-15.5) 
6 
(4.5-10.5) 
8 
(5-10) 
10 
(2-10) 
8 
(5-11) 
6 
(4-10) 
CRP (mg/L) 3 
(1.1-5.0) 
4.5 
(0.6-7.0) 
4.5 
(2.5-6.6) 
2.9 
(1.4-5) 
4 
(1.6-5.2) 
2.9 
(1-7) 
GH 10 
(8-20.5) 
6 
(1.5-7.8) 
5.5 
(0.5-10) 
5 
(1-13) 
8 
(4.3-15.3) 
6 
(1-8) 
HAQ 0.3 
(0-0.9) 
0.13 
(0-0.7) 
0.4 
(0.1-0.7) 
0.4 
(0.3-0.5) 
0.4 
(0-0.7) 
0.3 
(0-0.5) 
Methotrexate dose (mg) 20 
(15-20) 
20 
(15-20) 
18.75 
(10.6-20) 
20 
(10-20) 
20 
(13.1-20) 
20 
(15-20) 
Table 2. Baseline disease characteristics for patients who flared and those who did not flare during the first 
28 weeks (totally and in the two treatment arms). Values in bold differ significantly between flare and no 
flare groups (p<0.05).   
IQR: interquartile range; DAS28: disease activity score based on 28 joints; SJC; swollen joint count; TJC: 
tender joint count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; GH: global health 
assessment (patient’s visual analogue scale); HAQ: health assessment questionnaire;  
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Figure 1. Study design  
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Figure 2. Patients’ disposition.   
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Figure 3. Primary (A) and secondary (B-G) endpoints.    
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Figure 4. Flare-free survival.  

